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ABSTRACT 
Acute myeloid leukaemia (AML) is a biologically and clinically heterogeneous disease. 
Studies investigating heterogeneity in cell cycle status and response to treatment have 
been inconsistent, did not take into account the molecular features of the disease, and 
used blasts derived from aspirates (BMA) or peripheral blood (PB). The work in this 
thesis used the expression of the DNA replication licensing factors MCM2 (positive in 
non-G0 cells) geminin (positive in S/G2/M phase) in combination with MIB-1 (actively 
cycling cells) as assessed by immunohistochemistry and immunocytochemistry to 
define the cell cycle status of the blasts from PB, BMA, and biopsies (BMT). It shows 
that the majority of blasts in PB exist in a G1-arrested state and these blasts cause results 
derived from BMA or PB to significantly underestimate disease proliferation. Further 
experiments using flow cytometry and RNA sequencing support these conclusions and 
demonstrate that accurate assessment of cell cycle status in patients requires the use of 
BMT. A cohort of 181 patients with AML and available BMT for the assessment of 
DNA replication licensing factors was identified and defined for clinical, cytogenetic, 
and molecular features, and clinical outcome. The features of this cohort were 
consistent with those from large clinical trials. Increased expression of geminin and 
higher geminin/MIB-1 ratios (increased speed of cycling) were associated with NPM1 
mutations and improved response to induction therapy in both univariate and 
multivariate analysis. Patients with lower geminin/MIB-1 ratios had increased rates of 
relapse and, in a landmark analysis from the second cycle of treatment, a trend towards 
inferior overall survival. These results suggest a mechanism for the improved response 
and decreased relapse risk seen in patients with NPM1 mutations and the potential 
clinical utility of examining DNA replication licensing factors. 
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COMMONLY USED ABBREVIATIONS 
AML  Acute myeloid leukaemia 
APL  Acute promyelocytic leukaemia 
Ara-C  Cytarabine arabinoside 
ATO  Arsenic Trioxide 
ATRA  All-trans-retinoic acid 
BM  Bone marrow 
BMA  Bone marrow aspirate 
BMT  Bone marrow biopsy (trephine) 
bp  Base pairs 
CBF  Core binding factor 
cDNA  Complementary DNA 
CEBPA  CCAAT-enhancer binding protein α  
CIR  Cumulative incidence of relapse 
CN-AML Cytogenetically normal AML 
CR  Complete remission 
DDW  Double distilled water 
DFS  Disease-free survival 
DNA  Deoxyribonucleic acid 
EFS  Event-free survival 
FAB  French-American-British 
FLT3  Fms-like tyrosine kinase-3 
FLT3ITD FLT3 with an internal tandem duplication 
FLT3WT FLT3 wild-type (no internal tandem duplication) 
FPKM  Fragments Per Kilobase of transcript per Million mapped read 
G-CSF  Granulocyte colony-stimulating factor 
GVHD  Graft-versus-host disease 
GO  Gemtuzumab Ozogamicin 
GVL  Graft-versus-leukaemia 
HR  Hazard ratio 
HSCT  Allogeneic stem cell transplantation 
ID  Induction death 
ITD  Internal tandem duplication 
 17 
MDR-1 Multi-drug resistant protein 
MDS  Myelodysplasia  
MK  Monosomal karytoype 
MLL  Myeloid/lymphoid leukaemia 
MRC  Medical Research Council, UK 
MRD  Minimal Residual Disease 
NK  Normal karyotype 
NPM1  Nucleophosmin 1 
NPM1MUT Nucleophosmin 1 mutation 
NPM1WT  Nucleophosmin 1wild-type 
NRM  Non-relapse mortality 
ORC  Origin recognition complex 
OS  Overall survival 
PB  Peripheral blood 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PI  Propidum Idodide 
Pre-RC Pre-replicative complex 
RFS  Relapse-free survival 
RNA  Ribonucleic acid 
RR  Relapse rate 
TKD  Tyrosine kinase domain 
WCC  White blood cell count 
WHO  World Health Organization 
WT  Wild-type 
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CHAPTER 1. INTRODUCTION 
1.1 Introduction 
Acute myeloid leukaemia (AML) is an aggressive clonal disorder of haematopoietic 
stem or progenitor cells, the defining feature of which is aberrant differentiation and 
excess proliferation leading to the accumulation of immature myeloid cells in the bone 
marrow. This is accompanied by a marked reduction of normal haematopoiesis 
resulting in bone marrow failure.   
AML displays considerable biological heterogeneity such that it may be better 
considered as a collection of malignancies rather than a single disease entity. This 
biological heterogeneity is reflected in significant differences in both presenting 
features and clinical outcome between patients. While some patients are cured, the 
majority who attain remission subsequently relapse. Others are refractory to treatment 
and succumb rapidly to their disease. Despite this heterogeneity, with the exception of 
acute promyelocytic leukaemia (APL), patients who are fit enough receive a similar 
initial induction treatment aimed at achieving complete remission (CR). The 
combination of an anthracycline with cytarabine arabinoside (Ara-C) has been the 
cornerstone of induction treatment for over 30 years. Although there have been 
improvements in outcome over this time, these have largely been the result of advances 
in supportive care. The use of additional drugs has failed to show marked or consistent 
benefit. Those studies that have shown improvements in outcome have tended to 
demonstrate this for those patients who would already be predicted to do better 
(Fernandez et al, 2009; Burnett et al, 2011). Patients with the poorest risk disease have 
seen little benefit. There is a clear need for better understanding of disease biology to 
aid disease stratification and improve treatment. 
The work presented in this thesis examines inter-patient heterogeneity in cell cycle 
status in the context of the demographics of patients with AML and the clinical, 
cytogenetic, and molecular features of their disease. In addition, it examines the 
relationship between cell cycle status, the response to treatment, and survival. This 
introductory chapter will outline the current understanding of diagnosis, prognosis, 
pathogenesis and treatment of AML, and highlight the need and rationale for both 
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improved risk stratification to guide treatment and better understanding of the factors 
associated with response to treatment. It will then outline the rationale for studying the 
cell cycle in patients with AML to assist with these aims. 
 
1.2 Overview of AML 
1.2.1 Clinical presentation 
The accumulation of immature myeloid cells seen within the bone marrow of patients 
with AML occurs as the leukaemic cells outcompete their normal counterparts and 
suppress normal haematopoiesis (Miraki-Moud et al, 2013). Typical clinical features 
of bone marrow failure result and may include fatigue and dyspnoea from anaemia, 
bleeding from thrombocytopenia, and infections from true or functional neutropenia. A 
bleeding diathesis may also result from disseminated intravascular coagulation, which 
is associated with, though not restricted to, patients with APL. Patients may also present 
with leukocytosis and leukostasis. In addition, organs including skin and central 
nervous system may be affected by leukaemic infiltration. 
 
1.2.2 Incidence 
AML is the commonest acute leukaemia in adults, with an annual incidence of 3.4 cases 
per 100,000 adults in the UK and a total of 2,856 new cases diagnosed in the UK in the 
year 2012 (figures from Cancer Research UK). Incidence increases with age, rising 
from 1.8 per 100,000 in young adults up to 17 per 100,000 in individuals ≥60 years of 
age (Deschler & Lubbert, 2006). Almost three quarters of cases are diagnosed in those 
≥60 years of age. 
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1.2.3 Predisposing factors 
Although the majority of new patients with AML have idiopathic (de novo) disease, 
there are recognised predisposing factors and diseases seen in clinical practice, some of 
which represent distinct entities in the World Health Organisation (WHO) classification 
of AML described later in this chapter (Arber et al, 2016). 
 
1.2.3.1 Therapy-related AML 
Two main types of chemotherapy-related acute myeloid leukaemia exist. Drugs that 
target topoisomerase II, such as anthracyclines (e.g. daunorubicin) and 
epidophyllotoxins (e.g. etoposide), can cause patients to develop a rapidly proliferative 
monoblastic disease with cytogenetic abnormalities at the MLL gene locus at 
chromosome 11q23 within 2 years of treatment. More commonly treatment-related 
AML follows the use of alkylating agents (e.g. melphalan and cyclophosphamide), with 
disease occurring 5-6 years after exposure to drug. This is characterised by a 
myelodysplastic prodrome with complex karytoype and typically deletions in 
chromosomes 5 and/or 7. Therapy-related AML may also develop following treatment 
with radiotherapy. 
 
1.2.3.2 Secondary AML 
Transformation to AML may occur following clonal evolution from acquired 
syndromes such as myelodysplasia (MDS), chronic myeloid leukaemia (CML), and the 
myeloproliferative neoplasms polycythaemia vera (PV), essential thrombocythaemia 
(ET) and myelofibrosis (MF).  
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1.2.3.3 Familial AML 
A variety of inherited genetic defects may predispose to the development of AML. 
These include Shwachmann-Diamond syndrome, Fanconi anaemia, and ataxia 
telangiectasia. In addition, a number of germline mutations in families have been 
associated with the development of myeloid disorders and ultimately AML, including 
mutations of RUNX1, CEBPA and GATA2, all genes encoding key transcription factors 
involved in haematopoiesis (Owen et al, 2008; Hahn et al, 2011) 
 
1.2.3.4 AML related to chromosomal disorders 
Many of the congenital disorders of chromosome copy number predispose to the 
development of leukaemia, including AML with trisomy 21 that is classically 
associated with the development of AML with an M7 phenotype (see section 1.3.1 
below). 
 
1.3 Diagnosis and classification 
1.3.1 FAB classification 
The first comprehensive classification of AML was the French-American-British (FAB) 
system (Bennett et al, 1976; Bennett et al, 1985) that required a minimum of 30% blasts 
within the bone marrow compartment and stratified AML according to morphology- 
and cytochemistry-defined lineage type and degree of differentiation. A summary of 
the FAB classification is given in Table 1.1. Some FAB types are associated with 
particular recurrent cytogenetic abnormalities, for example, t(8;21), t(15;17) and 
t(16;16)/inv(16) with subtypes M2, M3 and M4Eo respectively.
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Table 1.1 The French-American-British (FAB) Classification of AML.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: MPO, myeloperoxidase; NSE, non-specific esterase; SB, Sudan Black 
 
FAB subtype Name Cytochemistry Morphological criteria 
  MPO SB NSE  
M0 AML with minimal 
differentiation 
- - - Blasts ≥30% of BM nucleated cells  
Blasts ≥30% of BM non-erythroid cells 
<3% of blasts positive for SB or MPO by light microscopy 
M1 AML without maturation + + - Blasts ≥30% of BM cells 
Blasts ≥90% of BM non-erythroid cells  
≥3% of blasts positive for SB or MPO 
M2 AML with maturation + + - Blasts ≥30% of BM cells 
Blasts 30-89% of BM non-erythroid cells 
Monocytic component <20% of non-erythroid cells 
M3 Acute promyelocytic leukaemia + + - Majority of infiltrate are abnormal promyelocytes 
M4 Acute myelomonocytic 
leukaemia 
+ + + Blasts ≥30% of BM cells 
Blasts ≥30% of BM non-erythroid cells 
Granulocytic component ≥20% of non-erythroid cells 
Significant monocytic component 
M4(Eo) Acute myelomonocytic 
leukaemia with abnormal 
eosinophils 
+ + + Blasts ≥30% of BM cells 
Blasts ≥30% of BM non-erythroid cells 
Granulocytic component ≥20% of non-erythroid cells 
Significant monocytic component 
M5 Acute monocytic leukaemia 
5a: monoblastic 
5b: monocytic 
- - - Blasts ≥30% of BM cells 
Blasts ≥30% of BM non-erythroid cells 
Monocytic component ≥80% of non-erythroid cells 
M6 AML with predominant 
erythroid differentiation 
6a erythroleukaemia 
6b pure erythroid   
      leukaemia 
+ + - Erythroblasts ≥50% of BM nucleated cells  
Blasts ≥30% of BM non-erythroid cells 
M7 Acute megakaryoblastic 
leukaemia 
- - + Blasts ≥30% of BM non-erythroid cells 
Cells express CD41, CD42b, or CD61 
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1.3.2 WHO classification  
The WHO classification (Table 1.2) integrates morphological, cytogenetic, 
immunophenotyping and molecular data into one system and has largely superseded 
the FAB classification (Arber et al, 2016). Some important modifications include the 
lowering of the requisite blast count to 20% except in cases with t(8;21), t(15;17) or 
t(16;16)/inv(16), where the diagnosis may be made irrespective of blast percentage. It 
also introduces AML with mutated NPM1 and AML with biallelic mutations in CEBPA 
as distinct entities, and AML with mutated BCR-ABL1 or RUNX1 as provisional entities. 
The WHO classification also tries to discern events leading to leukaemogenesis by 
including therapy-related AML as a category. Although still developing, such an 
approach has the advantage of trying to focus on the fundamental biology of the disease 
that may guide prognosis and treatment, as well as providing a more robust platform 
for consistent standardised diagnosis. 
 
 
1.4 Molecular basis of AML 
The recurrent cytogenetic and molecular lesions found in AML have also been 
demonstrated to be key events in leukaemogenesis. The classical two-hit model of 
leukaemogenesis required a haematopoietic stem/progenitor cell to have a lesion 
resulting in activated signalling (Class I mutation), e.g. mutations of FLT3, KIT, and 
RAS, in addition to a lesion altering transcription and differentiation (Class II mutation), 
e.g. the in-frame chimeric fusion genes RUNX1/ETO, PML/RARα and CBFB/MYH11 
that result from the balanced chromosomal rearrangements t(8;21), t(15;17) or 
t(16;16)/inv(16) respectively) (Kelly & Gilliland, 2002). However, whole genome-
wide analysis of patient samples, culminating in the Cancer Genome Atlas 
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Table 1.2. The WHO Classification of AML 
 
Acute myeloid leukaemia with recurrent 
genetic abnormalities  
 
AML with t(8;21)(q22;q22); RUNX1-
RUNX1T1  
AML with inv(16)(p13.1;q22) or 
t(16;16)(p13.1;q22); CBFB-MYH11  
APL with t(15;17)(q22;q12); PML-RARA  
AML with t(9;11)(p22;q23); MLLT3-
KMT2A  
AML with t(6;9)(p23;q34); DEK-NUP214  
AML with inv(3)(q21;q26.2) or 
t(3;3)(q21;q26.2); GATA2,MECOM 
AML (megakaryoblastic) with 
t(1;22)(p13;q13); RBM15-MKL1  
AML with BCR-ABL1 (provisional entity) 
AML with mutated NPM1 
AML with mutated CEBPA 
AML with mutated RUNX1 (provisional 
entity) 
 
                  Acute myeloid leukaemia with myelodysplasia-related changes  
 
                                       Therapy-related myeloid neoplasms  
 
 
 
Acute myeloid leukaemia, not otherwise 
specified  
 
AML with minimal differentiation  
AML without maturation  
AML with maturation  
Acute myelomonocytic leukaemia  
Acute monoblastic/monocytic leukaemia  
Acute erythroid leukaemia  
Acute megakaryoblastic leukaemia  
Acute basophilic leukaemia  
Acute panmyelosis with myelofibrosis  
                                                                   Myeloid sarcoma  
Myeloid proliferations related to Down’s 
syndrome 
 
Transient abnormal myelopoiesis  
Myeloid Leukaemia associated with Down’s 
syndrome 
Data from (Arber et al, 2016) 
 
project which reported 200 AML genome sequences, has resulted in a rapid expansion 
in the list of genes recurrently mutated in AML and shows that this two-hit model is 
now too simple (Cancer Genome Atlas Research, 2013). Genetic lesions can now be 
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broadly characterised into 9 groups (Table 1.3), although even here there is further 
complexity, for example WT1 at least partially exerts its effect through alteration in 
TET2 activity, thus potentially fulfilling criteria for a Class 3 and a Class 4 mutation 
(Rampal et al, 2014). It is worth noting that within this proposed system, AML with 
mutations in NPM1 are still regarded as distinct class.  
 
The genetic landscape changes markedly with age (Rubnitz & Inaba, 2012) and also 
with disease ontogeny. For example, the alterations found in secondary AML are 
distinctly different to those found in de novo disease (Lindsley et al, 2015), with a bias 
towards splicing factor mutations and a negative association with mutations of NPM1. 
 
This co-occurrence of genetic alterations with different functional effects on 
haematopoietic progenitors is a multi-step process and gives rise to clonal heterogeneity 
with a subclonal architecture (Walter et al, 2012; Welch et al, 2012; Bochtler et al, 
2013; Klco et al, 2014). The order of acquisition of the genetic lesions can be inferred 
from assessing the variant allele frequency/fraction (VAF), and genome-wide analysis 
can reveal some of the overall clonal architecture by assessing VAF in multiple genes. 
Whilst the order of mutations can vary between patients, a number of mutations have 
been well established as recurrent founder mutations. Furthermore, some of the earliest 
pre-leukaemic lesions, e.g. DNMT3A mutations, may persist in remission and yet 
remain compatible with long-term disease-free survival (Ploen et al, 2014). In addition, 
early lesions, e.g. NPM1, are in general stable in the event of relapse, suggesting that 
AML relapse emerges from incompletely eradicated founder clones rather than from 
the development of new malignant clones (Kronke et al, 2013). 
 
The earliest lesions are typically involved in epigenetic modification, e.g. DNMT3A 
and TET2, and are also among the most frequent genetic lesions in the recently defined 
entity clonal haematopoiesis of indeterminate potential (CHIP) (Genovese et al, 2014; 
Jaiswal et al, 2014). Although clonal haematopoiesis with increasing age had been 
described previously by analysis of X-inactivation (Busque et al, 1996; Gale et al, 
1997), recent studies show that mutations such as DNMT3A and TET2 are common in 
the general population, increase in frequency with age, and confer an increased risk of 
AML (Jaiswal et al, 2014). Although the majority of people with CHIP never develop 
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a myeloid disorder, they do have an increase in all-cause mortality, with the greatest 
increase in death resulting from cardiovascular disease (Jaiswal et al, 2014). 
 
 
Table 1.3 Recurrent mutations in AML according to functional group 
 
Class Functional Group Examples Approximate 
frequency in AML 
1 Transcription factor resulting from gene 
fusions 
t(8;21) 
t(16;16) 
t(15;17) 
 
18% 
2 Nucleophosmin 1 NPM1 27% 
3 Tumour suppressor genes TP53 
WT1 
PHF6 
 
16% 
4 DNA methylation-related genes DNMT3A 
IDH1 
IDH2 
TET2 
 
44% 
5 Activated signalling genes FLT3 
KIT 
N-RAS 
K-RAS 
 
59% 
6 Chromatin modifiers ASXL1 
EZH2 
30% 
7 Myeloid transcription factor genes CEBPA 
RUNX1 
22% 
8 Cohesin complex SMC1A 
SMC3 
RAD21 
STAG1 
STAG2 
 
 
13% 
9 Spliceosome complex SRSF2 
SF3B1 
U2AF1 
ZRSR2 
 
14% 
Data taken from (Meyer & Levine, 2014) 
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1.5 Prognostic factors in AML 
Given the heterogeneity in both patient factors and disease-related factors, a key goal 
is to integrate this information to develop prognostic models that can predict outcome. 
This may allow the development of improved risk-adapted approaches to treatment, e.g. 
who should be recommended to receive an allogeneic stem cell transplant in first 
remission and who may be eligible for or better served by novel treatments. 
Furthermore, there are a variety of reasons for treatment failure including co-
morbidities precluding optimal induction therapy, treatment-related early death, failure 
to achieve remission (primary refractory disease), and relapsed disease.  
 
1.5.1 Patient-related factors 
Increasing age is an adverse prognostic factor in AML leading to a decrease in overall 
survival (OS) (Appelbaum et al, 2006; Juliusson et al, 2009) and notably retains its 
poor prognostic impact in multivariate analysis. The large United Kingdom Medical 
Research Council (MRC) trials demonstrated that for patients >60 years of age who 
were deemed fit enough for intensive chemotherapy, the 5-year OS was only 14% 
(Smith et al, 2011). There are several high-risk features that increase with age including 
adverse cytogenetics, higher rates of secondary AML, and intrinsic chemoresistance 
including the expression of the multidrug resistance protein (MDR-1) (Slovak et al, 
2000; Appelbaum et al, 2006; Erba, 2007; Smith et al, 2011). In addition, performance 
status, although associated with increasing age, is independently associated with poorer 
outcomes and is also a predictor of early treatment-related death (Walter et al, 2011). 
 
1.5.2 Disease-related factors 
1.5.2.1 Clinical factors 
Analysis of the MRC AML 10 and 12 trials revealed a number of simple measurable 
clinical parameters with prognostic relevance. In addition to age, factors at diagnosis 
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predicting for inferior outcome include secondary AML and a high peripheral blood 
white cell count. The response to initial treatment also predicts outcome. In the AML 
12 trial, >15% blasts in the marrow after first cycle of induction treatment was 
indicative of a poor prognosis compared to patients with 5-15% blasts or <5% blasts 
(5-year OS, 26%, 44% and 56%, respectively). This is consistent with the results of the 
earlier MRC AML 10 trial where patients with >15% blasts had 5-year OS of 23% 
compared with 53% for patients with <5% blasts.  
In time, greater stratification may be possible with the use of minimal residual disease 
(MRD) assessment by flow or molecular analysis to more accurately assess the burden 
of residual disease and with greater sensitivity (Freeman et al, 2013; Grimwade & 
Freeman, 2014; Chen et al, 2015). Suitable examples that have been studied include 
assessment of fusion transcript levels in patients with core-binding factor leukaemias 
[t(8;21) or t(16;16)/inv(16)] and APML [t(15;17)] (Yin et al, 2012). NPM1 also has the 
potential to be a clinically useful MRD marker in that it should be essentially 
undetectable in remission but is rarely absent at relapse (Kronke et al, 2013; Ivey et al, 
2016). However, clonal evolution of the disease limits the number of molecular markers 
that can be usefully employed for this purpose. Internal tandem duplications of the 
FLT3 gene (FLT3-ITDs) are too unstable at relapse (Kottaridis et al, 2002) and 
DNMT3A mutations persist in remission (Ploen et al, 2014). 
 
1.5.2.2 Cytogenetic factors 
Data from the MRC AML 10 trial that recruited over 1600 children and adults up to 
age 55 and for whom karyotype data was available in 83%, revealed clear prognostic 
differences for different cytogenetic lesions. Patients could be defined into 3 broad 
groups with favourable risk cytogenetics (5-year OS, 72%), intermediate risk 
cytogenetics (44%), or adverse risk cytogenetics (17%) (Grimwade et al, 1998). This 
study has been updated to include patients from MRC AML 12 and MRC AML 15 and 
includes 5876 patients with AML aged 16-59 years (Grimwade et al, 2010). This study 
confirmed the major findings of the original study whilst refining some risk- groups 
(e.g. changed definition of complex karyotype from ≥5 to ≥4 cytogenetic abnormalities), 
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and being able to include prognostic information for some of the less frequent recurrent 
lesions that were present in too few numbers in the original study 
 
Table 1.4. The MRC Classification of Cytogenetic Risk Groups 
Risk group  
 
Proportion of 
patients 
 
Original MRC 
classification1 
 
Refined MRC classification2  
 
Favourable  
 
12%  
 
8% 
 
3% 
t(15;17) 
 
t(8;21) 
 
inv(16) or t(16;16) 
t(15;17) 
 
t(8;21) 
 
inv(16) or t(16;16) 
Intermediate 42% 
 
25% 
Normal Karyotype 
 
Other non-complex 
Normal Karyotype 
 
Other non-complex 
Adverse 10% abn(3q) 
 
 
-5 or del(5q) 
-7 
 
 
 
 
 
 
Complex (≥ 5 unrelated 
abnormalities)  
 
abn(3q) excluding t(3;5) 
inv(3) or t(3;3) 
 
add(5q), del(5q) or -5  
7, add(7q) or del(7q)  
t(6;11) 
t(10;11) 
t(11q23) excluding t(9;11) 
and t(11;19)  
t(9;22) 
-17 or abn(17p)  
Complex (≥ 4 unrelated 
abnormalities)  
 
  
1  (Grimwade et al, 1998); 2  (Grimwade et al, 2010) 
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to allow for definitive statements on outcome. The original and refined MRC 
cytogenetic classifications are shown in Table 1.4. Within each broad group there is 
also variation in outcome depending on the individual cytogenetic lesion. For example, 
patients with APL t(15;17) do better than other favourable risk patients, and patients 
with inv(3) do worse within the adverse risk group. Examples of 10-year OS figures for 
some of the most frequent recurrent cytogenetic abnormalities (or those incorporated 
into the WHO classification) are shown in Table 1.5. 
 
Table 1.5 10-year overall survival according to cytogenetic lesion 
 
Cytogenetic abnormality  10-year overall 
survival (%)  
t(15;17) 81 
t(8;21) 61 
inv(16) 55 
t(9;11) 
 
 
39 
t(6;9) 27 
Other t(11q23) 22 
-7/del(7q) 10 
-5/del(5q) 6 
inv(3) 3 
Data from (Grimwade et al, 2010) 
 
The combination of cytogenetic lesions may also be important for prognosis. For 
example, in the MRC data, favourable risk lesions maintain their favourable status 
irrespective of additional cytogenetic lesions. It has also been demonstrated outwith the 
MRC trials that the ‘monosomal karyotype’ (one monosomy with at least one additional 
autosomal monosomy, or with one additional chromosomal structural abnormality, 
excluding favourable risk lesions) has a particularly poor prognosis within the adverse 
risk group (4-year OS, 4%) (Breems et al, 2008).  
Beyond the level of conventional metaphase banding analysis, cryptic chromosomal 
changes may be demonstrated by single-nucleotide polymorphism (SNP) arrays or by 
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whole genome sequencing. Although SNP arrays do not replace banding analysis or 
fluorescence in situ hybridisation (FISH) as they cannot demonstrate balanced 
translocations, they can show cryptic changes in large numbers of patients who had 
been labelled as normal karyotype. This is exemplified by the Cancer Genome Atlas 
project which detected a number of cryptic fusion genes by sequencing (Cancer 
Genome Atlas Research, 2013). 
 
1.5.2.3 Integrating cytogenetic and clinical prognostic features 
Data on response to first treatment and cytogenetics from the MRC AML trials was 
used to derive the “Wheatley score” with the aim of aiding risk stratification in future 
trials (Wheatley et al, 1999). Table 1.6 outlines this prognostic scoring system and the 
5-year OS and relapse risk for patients in the different prognostic groups treated on the 
MRC AML 12 trial. Based on the outcome of the AML 12 and AML 15 trials this risk 
scoring system has been refined and updated to include the additional clinical features 
of patient age, sex, whether the AML is de novo or secondary, and the peripheral blood 
white cell count at diagnosis. This scoring system (Table 1.7) was used for risk 
stratification in the MRC AML 17 trial and to define 3 risk groups with 5-year OS of 
63%, 47%, and 24% respectively.  
Table 1.6 The MRC derived Wheatley score 
Prognostic Risk 
Group 
Patients included 5-year 
OS 
5-year 
RR 
Good Any patient with t(8;21), t(16;16)/inv(16), or t(15;17) 
irrespective of other genetic abnormalities or bone 
marrow status following course 1. 
76% 25% 
Standard Any patient not in good or poor risk groups 48% 52% 
Poor >15% blasts in bone marrow following course 1 or 
adverse cytogenetic lesion [-5, -7, del(5q), abn3(q), 
t(9;22)]  
or 
complex cytogenetics (≥5 abnormalities without a 
favourable genetic abnormality) 
21% 73% 
Abbreviations: OS; overall survival, RR; relapse risk 
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 Table 1.7 The AML17 risk stratification formula 
 
 
 
 
 
Abbreviations: CR; complete remission, PR; partial response 
 
1.5.2.4 Molecular markers in AML 
Recurrent molecular lesions, and their clinical impact, have led to further refinement of 
prognostic models of AML. For example, TP53 mutations are associated with AML 
with complex karyotype and have a particularly poor prognosis (Haferlach et al, 2008; 
Rucker et al, 2012). In the favourable prognosis cohort, mutations in KIT confer an 
adverse prognosis (Allen et al, 2013). However, the context in which molecular 
mutations have had the greatest impact is in the approximately 50% of patients with 
normal karyotype AML that do not have a demonstrable cytogenetic lesion using 
metaphase or FISH analysis. 
There are numerous recurrent molecular lesions in cytogenetically normal AML (CN-
AML) and some of the most frequent of these and their general prognostic implications 
are shown in Table 1.8. The exact prognostic impact of a mutation can relate to the 
mutation level (measured by allelic burden or VAF) and the presence of co-existent 
mutations. The prognostic implication of combinations of lesions has recently been 
explored in a large international study of over 1500 patients treated in 
0.01325 x age (in years) 
+ 
0.16994 x sex (1 = male, 0 = female) 
+ 
0.2231 x diagnosis (0 = de novo, 1 = secondary) 
+ 
0.65082 x cytogenetics (1 = favourable, 2 = intermediate, 3 = adverse) 
+ 
0.19529 x status post course 1 (1 = CR, 2 = PR, 3 = no response) 
+ 
0.00169 x WCC (x109/l) 
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Table 1.8 Recurrent genetic mutations with prognostic significance in intermediate karyotype and cytogenetically normal AML 
(CN-AML) 
Mutation Frequency in 
CN-AML 
Positive 
association 
Negative 
association 
Prognosis in CN-AML Selected References 
NPM1 42-62% FLT3-
ITD/TKD 
DNMT3A 
IDH1/2 
CEBPA 
biallelic 
Favourable, particularly in 
the absence of FLT3-ITD or 
DNMT3A mutation 
(Schnittger et al, 2005; Gale et al, 
2008; Gale et al, 2015) 
FLT3-ITD 30-35% NPM1  Adverse, particularly in the 
absence of NPM1 mutation. 
Increasing adverse impact 
with increasing allelic burden 
(Kottaridis et al, 2001; Gale et al, 
2008; Schlenk et al, 2008; Linch et 
al, 2014) 
DNMT3A 20-25% NPM1 
FLT3-ITD 
CEBPA 
biallelic 
Adverse, particularly in the 
absence of NPM1 mutation 
(Ley et al, 2010; Thol et al, 2011; 
Gale et al, 2015) 
IDH1/IDH2 30% NPM1 
FLT3-ITD 
TET2 
WT1 
Controversial, likely 
dependent on the specific 
mutation and the context of 
co-existing mutations 
(Abbas et al, 2010; Boissel et al, 
2010; Green et al, 2010a; Marcucci 
et al, 2010; Paschka et al, 2010; Thol 
et al, 2010; Green et al, 2011) 
TET2 23-27%  IDH1/IDH2 Controversial but may confer 
an adverse prognosis 
(Chou et al, 2011; Gaidzik et al, 
2012) 
FLT3-TKD 14% NPM1  Controversial, possibly 
favourable  
(Mead et al, 2007; Bacher et al, 
2008; Whitman et al, 2008) 
CEBPA 8-19% FLT3-ITD  
(for monoallelic 
CEBPA) 
NPM1 
(for biallelic 
CEBPA) 
Favourable if biallelic (Pabst et al, 2009; Wouters et al, 
2009; Dufour et al, 2010; Green et 
al, 2010b) 
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prospective clinical trials (Papaemmanuil et al, 2016). Amongst the most frequent and 
prognostically significant mutations, particularly in patients with normal karyotype, is 
NPM1, and the impact of this mutation further depends on the presence or absence of 
cooperating lesions, most notably a FLT3-ITD. The biological and prognostic impact 
of these mutations is discussed briefly here before being returned to in Chapter 4. 
 
1.5.2.4.1 NPM1 mutations 
Mutations in the gene encoding nucleophosmin 1 protein (NPM1) disrupt the nucleolar 
localisation signal and encode a novel nuclear export signal, which leads to aberrant 
localisation of the protein in the cytosol. This is thought to disrupt the usual protein 
function that includes diverse cellular processes such as ribosome biogenesis, 
regulation of apoptosis, and DNA repair. Information from mutation levels suggests 
that NPM1 mutations are usually heterozygous and found in all leukaemic cells of 
NPM1-mutant AML (Gale et al, 2008). This implies that these mutations are early 
events in leukaemogenesis. Although one of the commonest mutations in AML, being 
found in between a third and a quarter of patients, it is particularly common in CN-
AML. As well as being ascribed as a distinct entity in the WHO classification system, 
it is a cornerstone of the European LeukemiaNet guide for prognosis in AML (Table 
1.9). Although generally conferring a favourable prognosis, the impact of NPM1 
mutations may be dependent on the context of other co-existent recurrent mutations 
with which they are positively correlated, e.g. DNMT3A, IDH1 and IDH2 mutations 
and FLT3-ITD. The presence of a FLT3-ITD (described below), abrogates the positive 
impact of NPM1 mutation.  
 
1.5.2.4.2 FLT3-ITD 
FLT3 is a cytokine receptor belonging to the class III family of receptor tyrosine kinases. 
FLT3-ITDs are found in approximately 25% of younger adults with AML and are more 
frequent in patients with a normal karyotype and patients with APL. These duplications 
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are always multiples of 3 base pairs (bp) and remain in-frame. The consequence of the 
duplication is to disrupt the negative regulatory activity of the juxtamembrane domain, 
cause constitutive activation of the receptor, and enhanced signalling through the 
downstream RAS, MAPK, and STAT5 pathways This alters the normal role of FLT3 
in cell proliferation, differentiation and survival. Except in patients with APL, FLT3-
ITD mutations are associated with poor prognosis, including lower CR rates, higher 
rates of relapse and decreased OS (Small, 2006), although the majority of studies have 
not shown decreased CR rates. There is large variation between the mutant level seen 
in patients. Some have mutation levels <25% of total FLT3 alleles suggesting that not 
all cells carry a heterozygous mutation. Conversely, other patients have a mutational 
level greater than 50%, suggesting loss of the wild-type FLT3 allele. This loss occurs 
by uniparental disomy and is associated with a particularly poor outcome (Gale et al, 
2008). 
 
Table 1.9 The European LeukemiaNet prognostic stratification of AML 
 
 
Risk profile Subsets 
Favourable t(8;21)(q22;q22); RUNX1-RUNX1T1 
inv(16)(p13.1q22)or t(16;16)(p13.1;q22); CBFB-MYH11 
Mutated NPM1 without FLT3-ITD (normal karyotype) 
Biallelic mutated CEBPA (normal karyotype) 
 
Intermediate-I Mutated NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 and FLT3-ITD (normal karyotype) 
Wild-type NPM1 without FLT3-ITD (normal karyotype) 
 
Intermediate-II t(9;11) (p22;q23); MLLT3-KMT2A 
Cytogenetic abnormalities not classified as favourable or adverse 
 
Adverse inv(3)(q21q26.2) or t(3;3)(q21;q26.2); GATA2-MECOM (EVI1) 
t(6;9) (p23;q34); DEK-NUP214 
t(v;11) (v;q23); KMT2A rearranged 
-5 or del(5q); -7; abnl(17p); complex karyotype 
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1.6 Treatment of AML 
Despite the advances in the genetic characterisation of AML and the identification of 
novel potential treatment targets, the mainstay of treatment for patients without APL 
remains induction therapy with an anthracycline, normally daunorubicin, for 3 days 
combined with daily Ara-C, often as a continuous infusion; the so called “3+7” 
approach. The aim of induction is to achieve a CR, which is commonly defined as <5% 
blasts in a normocellular bone marrow with normal trilineage haematopoiesis in the 
absence of extramedullary disease in a patient who is transfusion-independent and with 
a peripheral blood neutrophil count >1 x109/l and platelet count >100 x109/l. Without 
further treatment, disease-free survival is limited, and so patients normally proceed to 
consolidation treatment aimed at eliminating residual leukaemia and reducing the risk 
of relapse. However, despite the extensive experience with this approach, many 
questions about standard induction therapy remain. 
 
1.6.1 What dose of anthracycline should be used for induction therapy? 
Following evidence that higher doses of daunorubicin up to 90mg/m2 may be beneficial, 
this question has been explored in several studies (Fernandez et al, 2009; Lowenberg 
et al, 2009). Such investigations have generally shown that this higher dose is superior 
to a daily dose of 45mg/m2 for patients up to the age of 65 years. The higher dose of 
90mg/m2 in these studies was associated with improved CR rates without demonstrable 
delayed recovery or jeopardising of other post-remission treatments. Particular benefit 
was seen for patients with NPM1, and the results of an updated reports suggests this 
benefit extends to patients with DNMT3A or FLT3-ITD mutations (Luskin et al, 2016). 
However, in the UK NCRI AML 17 trial patients were randomised to receive either 
60mg/m2 or 90mg/m2 and, following a significant increase in mortality at 60 days in the 
90mg/m2 cohort, this randomisation was terminated (Burnett et al, 2015a). To date no 
differences in OS have been reported between the two cohorts, although the report of a 
subgroup analysis suggests a beneficial effect of the higher dose of anthracycline on 
the rates of relapse and OS in patients with FLT3-ITD (Burnett et al, 2016). In a 
systematic review there was some evidence that idarubicin may give superior OS to 
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daunorubicin although the studies included predate the use of at least 60mg/m2 in 
induction and one third of the studies had no survival data available to contribute to a 
meta-analysis (Li et al, 2015). 
 
1.6.2 Should additional cytotoxics be given during induction? 
Studies investigating use of additional chemotherapy agents to the standard “3+7” 
backbone have been generally disappointing, although occasional improvements have 
been reported. A trial from the Polish Adult Leukaemia Group showed improved CR 
rates and potentially improved OS with the addition of cladribine, with particular 
benefit in older patients and those with adverse risk cytogenetics (Holowiecki et al, 
2012). Another purine analogue, fludarabine, in combination with cytarabine, G-CSF, 
and idarubicin (FLAG-Ida) showed no difference in OS compared with DA in the UK 
MRC AML 15 trial. Remissions were more frequent with FLAG-Ida, with a 
concomitant reduced risk or relapse, but toxicity resulted in fewer patients completing 
a full number of consolidation chemotherapy cycles (Burnett et al, 2013). The addition 
of other purine analogues such as clofarabine have so far failed to show benefit in trials 
when used as initial therapy. 
 
1.6.3 Is there a role for Monoclonal antibodies? 
Gemtuzumab ozogamicin (Mylotarg) is an anti-CD33 monoclonal antibody conjugated 
to the calicheamicin toxin. There are six published studies investigating the addition of 
this agent to induction therapy for AML. Unfortunately, the first of these trials (SWOG 
S0106) closed prematurely because of an increased early mortality in the GO arm (5.5% 
v 1.4%, P=0.01) (Petersdorf et al, 2013). In addition, the United States Food and Drug 
Administration withdrew the drug. However, subsequent studies have tended to show 
a benefit when GO was used as part of induction treatment, and the findings of these 
individual studies have been mirrored in a meta-analysis (Hills et al, 2014). The optimal 
dosing strategy has yet to be confirmed. Furthermore, benefits appear to be restricted 
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to patients with favourable risk disease and a proportion with intermediate risk disease. 
There was no benefit seen in patients with adverse risk cytogenetics.  
 
1.6.4 Is there a role for small molecule inhibitors? 
The improved understanding of the molecular lesions underlying AML have led to the 
development of a wealth of small molecule inhibitors. However, despite novel trial 
design to rapidly assess new agents such as the AML MRC “pick-a-winner” approach, 
progress has been limited (Hills & Burnett, 2011). Part of this may reflect the choice of 
target, an inability to target effectively, or selection for resistance. One of the main 
therapies investigated has been FLT3 inhibitors and collectively the trials and studies 
have been disappointing. Even studies that have shown good initial responses and blast 
clearance have ultimately failed. This may reflect the fact that FLT3 mutations are 
generally late events and these inhibitors will have less effect on subclones lacking the 
mutation. Furthermore, a recurring theme from studies is the outgrowth of FLT3 
mutants with point mutations that confer resistance to inhibitors (Daver et al, 2015). 
Other problems have included pharmacokinetic problems and incomplete inhibition of 
the target. Despite these issues, recent reports have shown for the first time that the 
addition of a FLT3 inhibitor to standard induction therapy can improve OS for patients 
with mutated FLT3 (Stone et al, 2015; Knapper et al, 2016). 
 
1.6.5 Post-remission therapy 
One of the major considerations for the treatment of a patient with AML is the optimal 
post-remission therapy. The broad choice is between consolidation chemotherapy with 
further cycles of intensive chemotherapy or allogeneic stem cell transplantation 
(HCST). The factors taken into consideration when deciding which approach to use, 
and if HSCT the conditioning to be used, include the age of the patient, the risk of 
relapse according to the discussed prognostic factors, and the availability of a suitable 
donor. In effect, this is a summation of the risks of the transplant itself in terms of 
 39 
toxicity, infection and graft-versus-host disease (GVHD), and the decreased risk of 
relapse in terms of further anti-leukaemia treatment and the graft-versus-leukaemia 
(GVL) effect. 
In general, an HSCT is the preferred option for younger patients with poor risk disease 
or intermediate risk disease without an isolated NPM1 mutation who have a sibling 
donor. For patients with favourable risk disease or with intermediate risk disease and 
an unrelated donor only, there are arguments for using consolidation chemotherapy 
rather than HSCT. However, the improving survival with alternative stem cell sources 
other than siblings, and the increased risk of relapse seen with isolated FLT3-ITD (in 
intermediate risk disease) may persuade some clinicians towards transplant in these 
settings. 
 
1.6.6 Non-intensive therapy 
For patients thought unable to tolerate standard intensive treatment, either because of 
age or comorbidity, attenuated treatment or supportive care may be offered. Low-dose 
Ara-C (20mg b.d. by subcutaneous injection) is the standard attenuated treatment, 
though not without haematological toxicity. Furthermore, there are no clear algorithms 
in this patient population. Although low-dose Ara-C may induce responses in up to 20% 
of patients, the median OS is only 6 months, and outcome for patients is highly 
dependent on cytogenetic risk factors. In an MRC trial where 217 patients were 
randomised to receive low-dose Ara-C or best supportive care with hydroxyurea, 
although overall there was a survival advantage for treatment with low-dose Ara-C, this 
advantage was not seen in those patients with adverse risk karyotype, none of whom 
achieved CR (Burnett et al, 2007). 
Hypomethylating agents such as azacitidine and decitabine have also shown promise 
in this setting. CR rates of 15-20% have been seen, and there is a suggestion of survival 
advantage over other treatment including low-dose Ara-C, albeit modest. Crucially, 
even in the absence of CR, both drugs may induce substantial haematological 
improvement (Kantarjian et al, 2012; Lubbert et al, 2012). 
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1.6.7 APL 
The clinically and biologically distinct features of APL translate into a distinct 
treatment approach. In addition to sensitivity to anthracyclines, APL is a paradigm for 
therapies that induce differentiation of cells, and this can be achieved using either all-
trans retinoic acid (ATRA) or arsenic trioxide (ATO). The combination of an 
anthracycline with ATRA achieves CR rates of >90% and translates to cure rates of 
approximately 80% (Sanz & Lo-Coco, 2011).  More recently, a randomised phase 3 
trial that formed part of the MRC AML17 trial showed that treating with the 
combination of ATRA + ATO without standard cytotoxics was feasible in both high 
and low risk APL patients, with CR rate of 94% and a 4-year event free survival (EFS) 
and OS of 91% and 93%, respectively. Interestingly, although the OS was not 
statistically superior to that seen with the combination of idarubicin and ATRA, the 
EFS was superior, which was due to a significantly decreased risk of relapse (Burnett 
et al, 2015b). 
 
1.6.8 Treatment of relapse 
Unfortunately, the majority of patients with non-APL disease relapse, and there is little 
data from prospective clinical trials to guide treatment post-relapse. However, the 
general approach is to offer reinduction chemotherapy with the aim of achieving a 
second remission (CR2) followed by an HSCT.  There are well-established risk-factors 
for prognosis following relapse including older age, adverse cytogenetics at initial 
diagnosis, a shorter duration of first remission (<12-18 months), and previous 
allogeneic transplantation. Such features are associated with lower rates of achieving 
CR2 and of OS (Breems et al, 2005), and patients with unfavourable prognostic features, 
particularly if more than one are present, may be better served by investigational 
treatments or palliation. 
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1.7 Unresolved issues in the biology and prognosis of AML 
Despite the wealth of understanding of biological and prognostic markers and available 
treatments, there are still innumerable outstanding questions with direct importance to 
the treatment of patients with AML. Many of these challenges relate to how specific 
genetic lesions translate to clinical features and response to treatment, and despite large 
studies exploring the prognostic impact of mutations and groups of mutations, it is still 
not clear how this is related to disease biology. For example, it is unclear why patients 
with NPM1 mutations are associated with such high rates of remission, and why FLT3-
ITD mutations are associated with such high rates of disease recurrence. Nor is it clear 
why some combinations of mutations are more prevalent than others, although 
presumably lesions that are mutually exclusive have either functional overlap or are 
disadvantageous to the cell in combination. 
 
1.8 The cell cycle  
The decision of a cell to divide and the ability of a cell to divide are fundamental 
biological processes. The cell cycle also serves as an integration point that incorporates 
and translates multiple upstream signals, and it is highly regulated during the execution 
of division. The normal cell cycle may therefore go awry in the context of genetic 
lesions. 
Precise duplication of DNA during each cell division is essential for genomic stability. 
This is achieved through the division of each cell cycle into discrete steps that are tightly 
regulated. During the synthesis or S phase, the chromosomal DNA of the cell is 
duplicated. Under normal circumstances, these duplicated chromosomes are divided 
equally between daughter cells in the mitotic or M phase. Prior to the S phase, there is 
a first gap phase (G1), and between the S phase and the M phase there is a second gap 
phase (G2). These gap phases are pauses that allow for checks of integrity and repair of 
genetic damage to occur prior to the next stage of the cell cycle. In addition, cells may 
exit the cell cycle and enter G0 during quiescence, senescence, or differentiation (Figure 
1.1). 
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1.8.1 The G1-S phase checkpoint 
The control of entry into the cell cycle is achieved through tightly regulated initiation 
events at multiple origins of replication throughout the genome. In late mitosis and 
early G1, pre-replicative complexes (pre-RC) are assembled at origins of replication, 
which involves sequential binding of the origin of recognition complex (ORC, made up 
of proteins ORC1-6) and the proteins CDC6 and CDT1 (Blow & Dutta, 2005) (Figure 
1.2). These then recruit and load MCM2-7, a heterohexameric complex of proteins with 
helicase activity, to origins of replication (Perkins & Diffley, 1998), creating the pre-
RC. The chromatin at this ORC is now ‘licensed’ for DNA synthesis during S phase. 
Once MCM2-7 is loaded onto the DNA, CDC6 and CDT1 dissociate and are no longer 
required for MCM2-7 to remain bound to the DNA and for the origin to remain licensed 
(Blow & Dutta, 2005). On subsequent activation of MCM2-7 through phosphorylation 
by CDC7 kinase, a conformational change leads to the recruitment of DNA polymerase 
alpha and other members of the replication machinery to the complex and the initiation 
of DNA synthesis (Machida et al, 2005). This activation by CDC7 is believed to be 
non-redundant. After the initiation of replication, the MCM2-7 complex travels along 
the DNA in a 3’ direction from the origin, with the consequence that the origins are left 
in an unlicensed state.  
It is important to prevent reloading of MCM2-7 and re-replication of the same section 
of DNA in a single cell cycle. Thus the ORC, CDC6, and CDT1 are regulated in a cell 
cycle-dependent manner. One of the most important mechanisms to prevent MCM2-7 
re-loading, and hence re-licensing, is the binding of CDT1 by the regulatory protein 
geminin (McGarry & Kirschner, 1998; Wohlschlegel et al, 2000). Geminin is itself 
subject to cell cycle-dependent regulation such that it is expressed at high levels and 
can only bind to CDT1 during S, G2, and M phases (McGarry & Kirschner, 1998). 
Geminin is ubiquitinated at the metaphase to anaphase transition leading to its 
inactivation. Thus, in late M phase and early G1, geminin is no longer available to bind 
CDT1, which is once again free to load MCM2-7 onto DNA and license origins at the 
beginning of the next cell cycle. 
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Figure 1.1 The Cell Cycle. The cell cycle can be divided into the synthesis (S) phase in which DNA is duplicated and the mitosis (M) 
phase in which cells divide into two daughter cells. These phases are separated by two gap phases (G1 and G2) in which growth and repair 
occur. G0 is another gap phase denoting an out-of-cycle state, e.g. quiescence or senescence.  (Figure adapted from Rodriguez-Acebes et 
al, 2010). 
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Figure 1.2 The G1-S phase checkpoint.  There are up to 100,000 origins of replication throughout the genome in each cell (A). The origin recognition 
complex (ORC) binds to an origin of replication (B) and recruits CDT1 and CDC6 (C). This complex then recruits MCM2-7 to the origin (D). After 
phosphorylation of MCM2, MCM4 and MCM6 by the kinase CDC7, CDC6 and CDT1 dissociate and new components are recruited to the DNA 
synthesis/sliding clamp complex (E). In addition to Polymerases α, δ and ε, the other components of the replication machinery are the GINS complex 
(consisting of the four proteins SLD5, PSF1, PSF2 and PSF3), MCM10, CDC/SLD2 and DPB11/SLD2. Once all components are recruited, the sliding 
clamp moves in a 3’ direction replicating DNA (direction of travel indicated by green arrows).
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1.8.2 The G1-S phase checkpoint in disease 
Downregulation of CDT1 at the G1-S transition is a key event in preventing re-licensing 
of replicated origins. In addition to the binding of CDT1 by geminin, downregulation 
is also achieved by cell cycle-dependent proteolysis. The inhibition of either system of 
control appears sufficient to allow re-licensing and re-replication of DNA. Both 
insufficient licensing and re-replication may contribute to disease. 
 
1.8.2.1 Insufficient origin licensing 
As MCM2-7 proteins are essential for DNA replication, the prevention of their loading 
onto DNA completely prevents replication (Chong et al, 1995; Kubota et al, 1995; 
Madine et al, 1995; Ekholm-Reed et al, 2004a; Tsuji et al, 2006; Stuermer et al, 2007). 
However, a reduction rather than an absence of MCM2-7 loaded onto DNA may have 
unpredictable or detrimental consequences by reducing the number of replication 
origins available for use. 
There is a considerable amount of redundancy in the system, both in terms of replication 
origins and also the number of MCM2-7 heterohexamers. For example, the replication 
forks initiated from a single origin of replication have the potential to replicate 
approximately 1.5 Mb of DNA, but in a mammalian cell, replication origins are spaced 
on average 30-150 kb apart. Furthermore, there are up to 20 times more MCM2-7 
molecules loaded onto DNA in G1 than there are active replication origins, and cells are 
able to synthesise DNA at normal rates when the level of MCM2-7 is reduced (Cortez 
et al, 2004; Tsao et al, 2004; Ge et al, 2007). This redundancy may allow cells to deal 
with problems arising during S phase. Replication forks that encounter DNA damage 
have the potential to stall irreversibly (Lambert & Carr, 2005). If such stalling happens 
in the context of two converging forks, replication of the intervening DNA is potentially 
difficult. As there is currently no known system that identifies the unreplicated portion 
of DNA, further licensing of DNA by loading more MCM2-7 at this stage could 
potentially lead to re-replication of DNA. The normal system of control therefore 
 47 
dictates that all origins need to be licensed prior to entry into S phase, and as such it 
should not be possible to license a new origin between the two stalled forks.   
However, inhibition of replication forks promotes the activation of dormant origins that 
do not fire in unperturbed phases (Anglana et al, 2003; Woodward et al, 2006; Ge et al, 
2007; Gilbert, 2007; Ibarra et al, 2008). The activity of these dormant origins is 
dependent on the full complement of MCM2-7 being loaded onto DNA. In the absence 
of replicative stress, dormant origins are passively replicated by forks from 
neighbouring origins and therefore do not normally fire. Under conditions of replicative 
stress however, they become essential for complete replication and cell survival and, if 
MCM2-7 loading is reduced, fewer replication origins are used which results in DNA 
strand breaks, checkpoint activation, genetic instability, and cell death (Shreeram et al, 
2002; Tanaka & Diffley, 2002; Feng et al, 2003; Teer et al, 2006; Bailis et al, 2008). 
 
1.8.2.1.1 Animal models of insufficient origin licensing 
Murine models have produced data that is consistent with these ideas. Mice 
heterozygous for an hypomorphic Mcm4 allele produce a destabilised protein that leads 
to a reduction to approximately 50% of functional MCM2-7 heterohexamers being 
loaded onto DNA (Shima et al, 2007). A different mutant Mcm4 has also been described 
that is able to generate a non-functional helicase whilst not affecting the stability of the 
mutant protein itself, thus locking other MCM proteins into a functionally dead 
complex equating to a functional loss of all members of the MCM2-7 complex (Bagley 
et al, 2012). A further model, this time assessing a hypomorphic MCM2 protein, 
exhibited similar defects in dormant origin usage (Pruitt et al, 2007; Kunnev et al, 2010). 
In all three models, there was evidence of increased DNA damage and genome 
instability. There was also some evidence of a stem cell deficiency, with an overall 
decrease in cellular proliferation and a possible depletion of the stem cell population. 
Perhaps unsurprisingly, mice in these models develop malignancies; 80% of female 
mice with hypomorphic MCM4 died of mammary adenocarcinoma (Shima et al, 2007), 
and MCM2 mutant mice developed T and B cell lymphomas (Pruitt et al, 2007). 
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1.8.2.1.2 Insufficient licensing in human disease 
Mutations leading to a truncated form of MCM4 have also been shown to be responsible 
for human disease in which patients present with natural killer cell deficiency, adrenal 
insufficiency and growth retardation, in addition to genome instability (Casey et al, 
2012; Gineau et al, 2012; Hughes et al, 2012). This truncated form of MCM4, although 
apparently incorporated into the helicase and loaded onto DNA, leads to increased 
levels of chromosome breakage and impaired cell cycle progression.  
Other members of the pre-RC have also been implicated in human disease. Meier-
Gorlin syndrome (MGS) is a rare disorder linked to mutations leading to defective non-
MCM pre-RC proteins (ORC1, ORC4, ORC6, CDT1 and CDC6) and is characterised 
by primordial dwarfism, mild to severe microcephaly, and hypoplasia of the ear and 
patella (Bicknell et al, 2011a; Bicknell et al, 2011b; Guernsey et al, 2011). However, 
it is noteworthy that although some features of MCM-deficient mice are present in cells 
from affected individuals, including impaired licensing and altered S-phase progression, 
the patients do not display chromosomal instability or have a demonstrably increased 
risk of cancer.  It is possible that the reduction in licensing seen in MGS is only critical 
to certain cells during development. It is also possible that the phenotype of MGS may 
reflect other functions of the pre-RC unrelated to their role in origin licensing. For 
example, ORC1 has a role in the regulation of centrosome duplication and the ORC1 
mutations found in MGS promote centrosome reduplication (Hemerly et al, 2009; 
Hossain & Stillman, 2012; Kuo et al, 2012). In addition, ORC6 has a role in cytokinesis 
(Prasanth et al, 2002), CDT1 is important for microtubule attachment to kinetochores 
(Varma et al, 2012), and CDC6 has a role in regulating the checkpoint kinase ATR 
(Clay-Farrace et al, 2003; Oehlmann et al, 2004). It is also noteworthy that all of the 
proteins mutated in MGS have been implicated in cilia formation that in turn are 
important for a number of signalling pathways, including Hedgehog signalling (Stiff et 
al, 2013).  
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1.8.2.2 Re-licensing in S and G2 and re-replication 
Proteolysis or inhibition of CDT1 is the predominant mechanism by which human cells 
downregulate the licensing system in S phase in order to prevent the potentially 
catastrophic re-licensing and re-replication that would otherwise occur. Proteolysis of 
CDT1 is coupled to DNA synthesis and cell cycle progression in at least two ways, both 
of which act by ubiquitination (Nishitani et al, 2006). CDT1 is a substrate of the CUL4-
DDB1-CDT2 ubiquitin ligase and its activation requires that it is recruited to PCNA 
(proliferating cell nuclear antigen), a DNA polymerase factor, and thus links the 
degradation of CDT1 to ongoing DNA synthesis (Hu et al, 2004; Arias & Walter, 2006; 
Hu & Xiong, 2006; Senga et al, 2006). Another mechanism of ubiquitination requires 
the phosphorylation of CDT1 by CDK2-cyclin A kinase and its recognition by the 
SCFSKP2 complex. As CDK2-cyclin A kinase is active during S and G2 phase, this 
system also couples the degradation of CDT1 to DNA replication and S-phase 
progression (Li et al, 2003; Liu et al, 2004; Sugimoto et al, 2004; Takeda et al, 2005). 
However, the main route to CDT1 proteolysis is likely to be the CUL4-DDB1-CDT2 
ubiquitin ligase, as loss of any of these components leads to re-replication whereas the 
loss of SKP2 does not.  
As described above, geminin is active during the S-G2-M phases and binds to CDT1, 
thus preventing the loading of MCM2-7 onto DNA during these phases (McGarry & 
Kirschner, 1998; Wohlschlegel et al, 2000; Tada et al, 2001). The loss of geminin 
results in re-licensing and re-replication (Melixetian et al, 2004; Zhu et al, 2004). The 
activity of geminin is halted at the metaphase to anaphase transition following 
ubiquitination by APC/C, thus freeing CDT1 to license DNA in preparation for the next 
round of DNA replication. APC/C is in turn regulated by EMI1 (Machida & Dutta, 
2007). The main role of EMI1 appears to be the inhibition of APC/C in G1 in order that 
there is sufficient CDK activity to allow entry into S phase. However, loss of EMI1 
leads to a failure to regulate APC/C, which destabilises geminin during S phase and 
promotes re-replication. 
Although the deregulation of CDC6 plays a minor role in preventing re-licensing, it 
may allow limited re-replication. Part of the control mechanism appears to be through 
the export of CDC6 from the nucleus during S-G2 phase, and overexpression of CDC6, 
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which results in higher nuclear levels during these stages of the cell cycle, increases the 
severity of re-replication seen following dysregulation of CDT1 (Saha et al, 1998; 
Petersen et al, 1999). More recently, an alternative mode of regulation by SCF-
dependent degradation of CDC6 has been shown to prevent re-replication (Walter et al, 
2016).  
CDC6 overexpression also causes heterochromatinisation and repression of the 
INK4A/ARF tumour suppressor locus (CDKN2A) (Gonzalez et al, 2006b). In addition, 
CDC6 has been shown to be involved in the activation of checkpoint kinases in 
response to the inhibition of replication (Clay-Farrace et al, 2003; Oehlmann et al, 
2004). Finally, CDC6 may stimulate inappropriate recovery from cell cycle arrest 
mediated by p21 in response to DNA damage by releasing p21 from CDK (Kan et al, 
2008). All of these effects could lead to genetic instability. There is also recent evidence 
that CDC6 regulates the initiation of ribosomal DNA transcription providing a link 
beyond DNA replication to protein expression (Huang et al, 2016). 
 
1.8.2.2.1 Animal models of re-licensing in S and G2 and re-replication 
Overexpression of CDT1 in a mouse model results in tumour formation (Arentson et 
al, 2002). In addition, mice that specifically overexpress CDT1 in T-cells develop 
thymic lymphoblastic lymphoma in a p53-null background (Seo et al, 2005). Crucially 
however, it is not known whether replication licensing is the key rate-limiting step for 
progression through G1 and hence whether increasing the rate of loading of MCM2-7 
onto DNA may significantly alter the rate of cell division. It may be therefore, that the 
apparent malignant potential of CDT1 is a consequence of the genetic instability it 
induces. Indeed, malignant cells overexpressing CDT1 in this same mouse model 
displayed severe chromosomal aberrations and genetic instability. 
The downregulation of geminin following the transduction of Hoxb4 into murine foetal 
liver cells resulted in increased proliferation potential in murine haematopoietic stem 
and progenitor cells, which was postulated to be through the increased loading of pre-
RC onto DNA (Ohno et al, 2010). Gmnn null mouse embryos stop dividing at the early 
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blastula stage with greater DNA content than normal, premature differentiation as 
trophoblast cells, and no markers of embryonic stem cells (Gonzalez et al, 2006a; Hara 
et al, 2006). In a subsequent inducible model, deletion of geminin from haematopoietic 
cells using a conditional floxed geminin allele, with loxP sites flanking exons 5, 6, and 
7 (encoding the binding site for CDT1) and a Cre recombinase under an Mx1 promoter 
led to anaemia and thrombocytosis in mice (Shinnick et al, 2010). Intriguingly, 
although there was some evidence of over-replication of DNA in methylcellulose 
colonies of CD34+ cells from these mice, and there was a dramatic decrease in colony 
forming ability including a complete absence of erythroid colonies, the stem and 
progenitor cell compartment in the mice was preserved. The geminin null cells were 
able to successfully reconstitute haematopoiesis in lethally irradiated mice (although 
there was an engraftment defect on secondary transplantation), and the megakaryocytes 
and erythroblasts had normal DNA content. In ex vivo culture there was, however, clear 
evidence of overreplication of DNA in isolated CD34+ cells, with a significant 
population of cells with DNA content greater than 4n.  
In addition to its role in cell cycle regulation, models have also revealed interactions of 
geminin with other protein targets including other homeobox members, members of the 
polycomb group 1 complex, and members of the SWI/SNF chromatin remodelling 
complex (Seo & Kroll, 2006). Through these interactions, geminin has been shown to 
influence transcriptional programmes and have a key role in neural development, 
organogenesis, and axis patterning (Kushwaha et al, 2016). It has no clear role in 
haematopoietic transcriptional programmes, although there is some evidence from in 
vitro siRNA experiments in mouse bone marrow that HOXA9 may induce the activity 
of haematopoietic progenitors in part through down regulation of geminin (Ohno et al, 
2013). 
 
1.8.2.2.2 Mutations in the replication licensing system in cancer 
A review of the COSMIC (catalogue of somatic mutations in cancer) database 
(http://cancer.sanger.ac.uk/cosmic) shows that, with the exception of APC, mutations 
in the genes encoding the pre-RC and the main proteins controlling the pre-RC are 
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infrequent in human cancer (Table 1.10), particularly when compared with the mutation 
rates of some of the more frequently mutated genes found in various cancer types 
including TP53, KRAS and BRAF (Alexandrov et al, 2013). However, the apparently 
high levels of non-redundancy in the system, particularly with the central role of CDT1 
for preventing re-replication, may mean that mutations that result in, for example, loss 
of functional geminin or failure of CDT1 to be lysed or bound by geminin, may lead to 
lethal levels of re-replication and therefore cells acquiring such a mutation do not 
survive sufficiently long to gain a potential competitive advantage from genomic 
instability. 
However, there is some evidence that dysregulation of this crucial pathway does exist 
in cancer, and it is unclear whether this dysregulation is a consequence or a cause of 
the oncogenic process, or indeed both. For example, it is possible that malignant cells 
lose the ability to differentiate and therefore continue to divide and express MCM 
proteins. In this scenario, the MCM proteins are not directly oncogenic but simply a 
marker of active proliferation. An alternative explanation is that the deregulation of 
replication licensing actively promotes the development of cancer by inducing re-
replication and chromosomal instability. 
Of note, some of the genes that are frequently mutated in cancer have been shown to 
be involved in abnormalities of G1-S phase control and DNA replication, indicating that 
there are likely to be other routes to dysregulation of cell cycle progression through G1-
S phase. For example, overexpression of cyclin D1, an oncogene that is frequently 
mutated in cancer, can result in origin re-licensing and re-replication (Aggarwal et al, 
2007), presumably at levels that are sufficient to result in genetic instability without 
resulting in cell death.  Again, the crux of the mechanism appears to involve CDT1 
stabilisation in S phase as a result of the loss of CUL4 expression.  
Cyclins may also be linked to insufficient licensing. For example, the overexpression 
of cyclin E is associated with a reduction in the loading of MCM2-7 onto DNA during 
late M and G1 phases of the cell cycle (Ekholm-Reed et al, 2004a). Consistent with this 
reduction is a decreased rate of S phase progression, as well as genetic instability, and 
accelerated tumour formation in mouse models of cyclin E abnormalities (Spruck et al, 
1999; Ekholm-Reed et al, 2004b; Loeb et al, 2005). 
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Table 1.10. The frequency of mutations in replication licensing proteins and 
selected frequently mutated genes 
 
 
 Gene 
 
Number of 
samples assessed 
 
Number of coding 
mutations detected 
 
Coding mutations 
(%) 
 
Replication 
licensing 
proteins 
ORC1 35730 151 0.42% 
ORC2 35732 108 0.30% 
ORC3 35731 117 0.33% 
ORC4 35731 72 0.20% 
ORC5 35731 85 0.24% 
ORC6 35731 35 0.10% 
MCM2 36824 6 0.02% 
MCM3 35752 129 0.36% 
MCM4 35824 174 0.49% 
MCM5 35753 119 0.33% 
MCM6 35752 126 0.35% 
MCM7 35752 118 0.33% 
CDT1 35752 72 0.20% 
CDC6 36220 84 0.23% 
GMNN 35752 36 0.10% 
CDC7 36633 122 0.33% 
EMI1 36814 67 0.19% 
APC 54158 4700 11.52% 
Selected 
frequently 
mutated genes 
TP53 121490 30125 24.80% 
KRAS 204218 38301 18.75% 
NRAS 102740 4888 4.76% 
BRAF 238724 43242 18.11% 
PTEN 66367 3583 5.40% 
CDKN2A 69867 5027 7.20% 
 
Data extracted from the COSMIC (catalogue of somatic mutations in cancer) database 
October 2016 (http://cancer.sanger.ac.uk/cosmic) 
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1.9 Cell cycle markers in oncology 
The well-defined biology of the G1-S phase transition means that analysis of the 
expression of relevant proteins may enable the definition of the stage of the cell cycle 
of a particular cell. Many of these cell cycle proteins can now be detected by 
immunohistochemistry of fixed tissue sections (Williams & Stoeber, 2007; Rodriguez-
Acebes et al, 2010), allowing for direct analysis as well as assessment of archived 
samples. MIB-1, the antibody that recognises the MKI67 protein (a protein associated 
with ribososmal RNA transcription and the perichromosomal layer and that is nuclear 
only in proliferating cells (Booth et al, 2014)) is the gold standard 
immunohistochemical marker for proliferation used in routine clinical practice. It 
identifies actively proliferating cells as opposed to cells that are in G1 and licensed for 
replication only and, in addition, may not be positive at the very earliest stages of G1 
(Figure 1.3). However, from the known expression of other proteins, as outlined in 
Figure 1.2, additional markers can be added in an attempt to better define the stages of 
the cell cycle. For example, antibodies to MCM2 label cells that are actively in cycle 
(G1-S- G2-M phases). Expression of MCM2 is lost when cells enter a quiescent non-
proliferating state (G0) and this is readily demonstrable on fixed tissue sections (Figure 
1.4). Although there is a correlation between MCM2 and MIB-1 expression in tissue 
sections, they are not surrogates for one another. For example, in some tumour types 
MCM2 may be expressed in the majority of cells, whilst MIB-1 is expressed by <10% 
of cells in the same tissue section (Dudderidge et al, 2005a). The presence of a weaker 
correlation suggests a tumour phenotype with a low proliferation rate and/or cells 
arrested in early G1. The origin licensing inhibitor geminin is only detectable once cells 
have passed the G1-S phase checkpoint into S/G2/M phases (Figure 1.3), thus 
preventing re-replication. 
  
These three markers, MCM2, MIB-1, and geminin, may thus be used on archived 
histological sections to define populations of cells at various stages of the cell cycle 
(Table 1.11). They may also be used to derive features of cell cycle kinetics such as the 
number of cells out of cycle (MCM2 negative), cells in cycle without actively cycling 
(MCM2 positive, MIB-1 negative), and the number of cells that have progressed 
through G1 into the S-G2-M phases (MCM2 positive, MIB-1 positive, and geminin 
positive) (Table 1.12). 
 55 
 
 
Table 1.11 Cell cycle markers that define cells at different stages of the cell cycle 
 Antibody 
 
Cells stained 
 
Biomarker MCM2 
 
 
 
MIB-1 
(MKI67) 
 
 
Geminin 
Cells with origin of replication licensed for DNA 
synthesis and cell division 
Positive in G1/S/G2/M, not in G0 
 
Actively proliferating cells 
Positive in G1/S/G2/M, not in G0 
 
Cycling cells that have progressed beyond G1 
Positive in S/G2/M, not in G1 or G0 
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Figure 1.3 Expression of cell cycle markers in relation to the phases of the cell cycle. Mcm2 is expressed in all cells in all of the cell 
cycle phases except G0, MIB-1 detects the protein MKI67 and is expressed in all actively proliferating cells but not those cells in the earliest 
stages of G1 or arrested in G1. Geminin is expressed only in cells that have progressed beyond G1. (Figure adapted from Rodriguez-Acebes 
et al, 2010). 
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Figure 1.4. Expression of MCM2 in normal epithelial and glandular tissue. MCM2 expression using immunohistochemistry in normal human 
tonsil showing the expression (darkly stained cells) in (A) epithelium (x40) and (B) glandular tissue (x20).  In epithelium it is expressed in the 
basal proliferating layer but lost as cells differentiate (enter G0) and migrate towards the epithelial surface. Expression in glandular tissue is 
generally restricted to the follicles, the region in which cells are proliferating. 
A B 
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Table 1.12 Derived values from cell cycle marker LIs that define cell cycle kinetics 
 
 
Relationship of 
biomarker 
 
 
Significance of relationship 
MIB-1 LI/MCM2 LI 
 
 
Geminin LI/MIB-1 LI 
 
 
MIB-1 LI – Geminin LI 
The proportion of non-quiescent cells that are actively 
proliferating 
 
Indicates the relative length of G1 phase as a surrogate 
for speed of proliferation 
 
Represents the proportion of cells that are transiting G1 
 
 
1.9.1 Expression of licensing proteins in cancer  
Many studies have shown that there is an inappropriate expression of MCM2-7 and 
other pre-RC proteins in a wide variety of premalignant dysplasias and cancers, and 
these have been used to try and improve both diagnostic tests and predicted response to 
treatment. For example, it has been shown that the detection of an elevated level of 
MCM5 in urine sediments is predictive of bladder cancer (Stoeber et al, 1999; Stoeber 
et al, 2002), and this principle can be extended to gastric aspirates, biliary secretions, 
and stool samples (Davies et al, 2002; Williams et al, 2004; Ayaru et al, 2008). Such 
markers can also be combined with morphology to improve the accuracy of screening 
tests of, for example, cervical smears (Williams et al, 1998).  
There have been numerous studies associating the aberrant expression of proteins 
linked to G1-S phase with the aggressiveness of a malignancy.  For example, expression 
levels of MCM2 and geminin predict for adverse prognosis in breast cancer (Gonzalez 
et al, 2003; Gonzalez et al, 2004), as does CDC6 in ovarian cancer (Deng et al, 2016). 
Although normally predicting for poorer outcome, this is not the case in all tumour 
types studied. For example, higher expression of geminin correlates with improved 
survival in high-grade astrocytomas (Shrestha et al, 2007).  
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This principle has been extended to study the association between combinations of 
markers of cell cycle status/progression and clinical outcome. The larger studies 
containing >100 patients are summarised in Table 1.13. The biological features seen 
and the prognostic impact are partially dependent on the exact markers studied, the cut-
off for significance, the tumour type studied, and the type of analysis done including, 
for example, whether multivariate analysis was performed. In one study of penile 
cancer, the markers MCM2, geminin and Ki-67 (MIB-1) were associated with features 
of aggressive disease (Kayes et al, 2009), a finding confirmed by others (May et al, 
2013). However, the results of two studies assessing the impact of cell cycle status in 
NSCLC, which included MCM2, were contradictory. The larger of the two studies 
concluded that patients with lower levels of MCM2 had longer median survival 
(Ramnath et al, 2001). In contrast, a later study using the same cut-off for high MCM2 
(25%) that had fewer patients but examined a greater number of other cell cycle 
biomarkers found a non-significant effect of MCM2 on survival except when 
considered in conjunction with the marker gelsolin, an actin binding protein that 
regulates actin filament assembly and disassembly (Yang et al, 2006). Such differences 
may relate to the smaller numbers in the study, positive or negative associations 
between markers, or the need to combine markers to gain more complete information 
of cell cycle dynamics in tumour samples. In general, the larger studies using combined 
cell cycle markers have shown a correlation of the expression of DNA replication 
licensing proteins with more aggressive disease that in some cases is independent of 
other known prognostic factors. 
 
1.9.2 Expression of DNA replication licensing proteins in haematological malignancies 
In a study of various B-cell malignancies, the patterns of expression of cell cycle 
licensing proteins were associated with disease phenotype. In samples from patients 
with CLL, most cells were arrested in G1 (Obermann et al, 2005a). In contrast, in 
samples from patients with DLBCL or Burkitt’s lymphoma, the majority of cells were 
actively cycling as defined by a higher geminin to Ki-67 (MIB-1) ratio. Crucially, 
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Table 1.13 Key findings from larger studies (>100 patients) of cell cycle analysis using immunohistochemistry in various tumour 
types 
Tumour Type Number of Patients Markers studied Outcome  Reference 
NSCLC 221 MCM2 
Ki-67(MIB-1) 
MCM2 was an independent prognostic marker for survival. 
Patients with LI<25% had longer median survival 
(Ramnath et al, 2001) 
Renal 176 MCM2 
Ki-67 (MIB-1) 
Geminin 
Increased expression of all markers associated with DFS. Only 
Ki-67 LI>12% was independent of clinical variables such as 
grade and capsular invasion 
(Dudderidge et al, 2005b) 
Lung adenocarcinoma 145 MCM2 
Ki-67 (MIB-1) 
High MCM2 and Ki-67 LIs were independent prognostic 
factors for poor outcome 
(Hashimoto et al, 2004) 
GIST 277 MCM2 
Ki-67 (MIB-1) 
p16 (INK4A) 
Increased LIs for MCM2 and Ki-67 associated with decreased 
DFS. Ki-67 but not MCM2 was independent on multivariate 
analysis 
(Huang et al, 2006) 
NSCLC 128 MCM2 
Ki-67 (MIB-1) 
Increased levels of MCM2 associated with non-significant 
inferior survival. No impact of Ki-67 on outcome 
(Yang et al, 2006) 
Ovarian Epithelial 143 MCM2 
Ki-67 (MIB-1) 
Geminin 
Markers were associated with tumour stage and ploidy (Kulkarni et al, 2007) 
Penile 141 MCM2  
Ki-67 (MIB-1) 
Geminin 
Markers associated with arrested tumour differentiation and 
aneuploidy 
Accelerated cell cycle progression was linked to increasing 
tumour size, stage, and depth of invasion 
(Kayes et al, 2009) 
Breast 182 MCM2 
Ki-67 (MIB-1) 
Geminin 
Higher rates of relapse in patients with both high MCM2 
(>30%) and high geminin (>7%) 
(Loddo et al, 2009) 
Gastric  128 MCM2 
Ki-67 (MIB-1) 
Geminin 
Higher geminin LI (>25%) associated with worse prognosis (Shomori et al, 2010) 
Salivary 170 Ki-67 (MIB-1) 
Geminin 
Geminin associated with tumour invasion and metastasis 
Higher geminin associated with decreased OS and 
independently predictive of survival and relapse 
(Yamazaki et al, 2010) 
Penile 158 MCM2 
Ki-67 (MIB-1) 
Geminin 
Markers associated with more aggressive disease but were not 
independent factors 
 
(May et al, 2013) 
DFS, disease-free survival; GIST, gastrointestinal stromal tumour; NSCLC, non-small cell lung cancer 
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these phenotypes were also associated with the response and curability of these diseases 
following treatment by standard chemotherapy.  
In myeloid malignancies, MCM2 expression has been assessed in MDS, and MCM2 
expression was associated with bone marrow cell apoptosis and peripheral blood 
cytopaenias (Suzuki et al, 2012). However, there have been no studies assessing the 
patterns of expression of cell cycle licensing proteins to analyse the cell cycle status of 
samples from patients with either MDS or AML.  
 
1.10 The Cell Cycle in AML 
In the normal haematopoietic system, proliferation is tightly linked to differentiation. 
In an asymmetrical cell division, one daughter cell retains stem cell properties while 
the other undergoes differentiation. It is also possible to have symmetrical division 
where both daughter cells are stem/progenitor cells or both differentiate, with the 
choices made being influenced by cytokines and the subset of stem cells (Rieger et al, 
2009; Ito et al, 2016). In the context of AML, the balance between differentiation and 
cell cycle progression is grossly abnormal, with a drive away from differentiation 
towards proliferation.  
There are also numerous interdependent mechanisms of cell cycle dysregulation in 
AML. These include abnormal signalling drives to enter or progress through the cell 
cycle, as well as impairment of crucial inhibitors of cell cycle progression (Table 1.14). 
Many of these have been targets for drug development, and some of the drugs currently 
in the most advanced phases of clinical development are outlined in Table 1.15. 
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Table 1.14 Examples of key mechanisms implicated in cell cycle dysregulation in AML 
General mechanism 
of dysregulation 
 
Affected 
gene 
Normal protein function Defect in AML Implication for cell 
cycle 
Reference 
Signal Transduction FLT3 
 
 
c-KIT 
 
 
 
 
RAS 
 
 
Expansion and survival of early 
haematopoietic progenitor cells 
 
The tyrosine kinase receptor for 
stem cell factor. Expansion and 
survival of early haematopoietic 
progenitor cells 
 
Activates downstream effector 
pathways including PI3K and 
MAPK 
Activating mutations 
Overexpression 
 
Activating mutations 
 
 
 
 
Activating mutations in both 
N-RAS and K-RAS 
Possible drive to 
excess proliferation 
(Kelly & 
Gilliland, 
2002) 
Cyclins Cyclin A 
 
 
 
Cyclin B 
 
 
Cyclin D 
 
 
 
Cyclin E 
 
Activation of Cdk2 in the 
regulation of S phase 
progression 
 
Activation of Cdk1 at the G2-M 
phase transition 
 
Activation of Cdk4/6 that is 
required for cell cycle 
progression 
 
Activation of Cdk2 in the 
regulation of the G1-S phase 
transition 
 
Upregulated/overexpressed 
 
 
 
Upregulated/overexpressed 
 
 
Upregulated/overexpressed 
 
 
 
Upregulated/overexpressed 
Increased cell cycle 
progression 
(Yang et al, 
1999) 
 
 
 
(Nakamura et 
al, 2010) 
 
(Argiropoulos 
et al, 2010) 
 
 
(Iida et al, 
1997) 
Cyclin-dependent 
kinase (Cdk) inhibitors 
p15 
 
p16 
Inhibitor of Cdk4 
 
Inhibitor of Cdk4 
Downregulated 
 
Downregulated 
Increased rate of 
progression into S 
phase 
(Paul et al, 
2010) 
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p21 
 
 
p27 
 
 
Inhibitor of Cdk2 and  
Cdk4 
 
Inhibitor of Cdk2 and  
Cdk4 
 
 
Downregulated 
 
 
Downregulated 
 (Taniguchi et 
al, 1999) 
 
(Peterson et al, 
2007) 
 
 
(Yokozawa et 
al, 2000) 
Mitotic kinase Aurora A 
 
 
 
 
Aurora B 
 
 
 
PLK1 
 
Involved in function of the 
mitotic spindle including 
chromosome alignment and 
cytokinesis 
 
Chromosome attachment to 
microtubules 
 
 
Regulation of numerous facets 
of mitosis including mitotic 
entry and chromosome 
separation 
 
Overexpressed 
 
 
 
 
Overexpressed 
 
 
 
Overexpressed 
Mitotic checkpoints 
over-ridden 
 
 
 
Chromosomal 
missegregation 
 
 
Aberrant entry into 
mitosis. Potential 
contribution to 
aneuploidy 
(Yang et al, 
2013) 
 
 
 
 
(Yang et al, 
2007) 
 
 
 
(Renner et al, 
2009) 
DNA damage response TP53 
 
Inhibition of cell cycle 
progression in the event of 
DNA damage 
Mutated and/or deleted Reduced checkpoint 
activity and 
inappropriate cell 
cycle progression in 
the context of DNA 
damage 
 
(Zhang et al, 
2016) 
Table   1.14 continued 
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Table 1.15 Examples of novel drugs targeting cell cycle proteins currently in trials of AML patients 
 
 
 
Protein(s) 
targetted 
Normal Function Abnormality in AML Drug Mechanism of action Trial 
Phase  
Trial 
Mdm2 E3 ubiquitin ligase that 
negatively regulates 
p53 
Overexpressed in some 
subsets of AML  
Idasanutlin Small molecule antagonist of 
Mdm2 
Phase 1 NCT01773408 
Cyclin-
dependent 
kinases 
Serine/threonine 
kinases that are 
activated by Cyclins, 
e.g. Cdk4/6 activated 
by Cyclin D, and Cdk2 
activated by Cyclin E 
Downstream targets of 
activating kinase 
mutations and 
deregulated signalling 
cascades 
Alvocidib Flavinoid alkaloid inhibitor of 
Cdk9 and Cdk4/6 
Phase 2 NCT01413880 
Plk1 (polo-
like kinase 
1) 
Regulator of mitotic 
entry, centrosome 
kinetics, and 
cytokinesis 
Overexpressed in some 
subsets of AML 
Volasertib Small molecule 
dihydropteridinone derivative 
inhibitor of Plk1 
Phase 3 NCT01721876 
Aurora 
kinases 
Aurora kinase A 
required for proper 
function of mitotic 
spindle, chromosome  
alignment, and 
cytokinesis 
 
Aurora kinase B 
required for 
chromosome 
attachment to 
microtubules 
Both are overexpressed 
in AML 
Alisertib 
 
 
 
Barasetib 
 
 
 
Selective inhibitor of Aurora 
kinase A 
 
 
Selective inhibitor of Aurora 
kinase B 
Phase 1 
 
 
 
Phase 
2/3 
NCT01779843 
 
 
 
NCT00952588 
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1.10.1 The rationale for studying DNA replication licensing proteins in AML 
The cell decision to traverse from G1 to S phase lies at the crossroads of proliferation 
and differentiation. The cell cycle machinery acts as an integration pathway for the 
information transduced through upstream signalling pathways that determines whether 
a cell undergoes cell division or differentiates (Williams & Stoeber, 2007). In addition 
to the wide array of cell cycle abnormalities outlined above, the effects on this point of 
integration may reflect the combined influence of cytogenetic and molecular lesions 
found within a cell. Thus, analysing the cell cycle licensing proteins in the context of 
well-defined cytogenetic and molecular lesions may inform our understanding of 
disease biology. Defining the cell cycle according to cell cycle licensing proteins may 
also inform on the response to therapy. The intensive induction chemotherapy regimens 
described earlier are to some extent dependent on cells being in a state of actively 
cycling in order to be effective. This can be appreciated by considering the mechanism 
of the two main drugs used for induction chemotherapy in AML: daunorubicin and Ara-
C. 
Daunorubicin is an anthracycline, a class of drugs that act by inhibiting topoisomerase 
II. The action of this enzyme under normal physiological conditions is to relax 
supercoils in DNA, thus allowing for transcription or replication to occur. The drug 
stabilises the topoisomerase complex, preventing the double helix resealing correctly 
and restricting replication. In addition, anthracyclines bind to and intercalate DNA, and 
on intercalation may also displace histones from chromatin (Pang et al, 2013). 
Ara-C is converted to cytosine arabinoside triphosphate by the enzyme deoxycytidine 
kinase. The triphosphate is then competitively incorporated into the DNA strand during 
chain elongation, which results in chain termination and a block in DNA synthesis 
(Kufe et al, 1980; Major et al, 1981; Major et al, 1982). Sustained high cellular 
concentrations of Ara-C triphosphate relative to the deoxycytidine form are thought to 
favour drug incorporation into replicating DNA, thereby initiating the leukemic cell 
death associated with therapeutic response (Gunji et al, 1991). A further method of Ara-
C action is by inhibition of DNA polymerase, in particular polymerase α (Yoshida et 
al, 1977; Allaudeen et al, 1982). The marked differences in response to these two drugs 
according to clinical and biological features may reflect resistance to apoptosis, for 
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example through inadequate TP53 response to DNA damage, intrinsic mechanisms of 
drug resistance such as MDR-1 expression or, in the case of Ara-C, possibilities also 
include lower levels of deoxycytidine kinase leading to decreased levels of the active 
triphosphate form, higher levels of cytidine deaminase that may inactivate Ara-C, or 
higher levels of deoxycytidine triphosphate that results in more resistance to  
competition from the Ara-C triphosphate form.   
 
However, as with the response described above for patients with lymphoproliferative 
disorders, the differences may also reflect varying vulnerabilities based upon the 
relative amount of time spent in a particular phase of the cell cycle compared to normal 
cells, whether because of the rapidity of cell cycling and the resulting levels of drug 
incorporation, or due to spending more time in a phase of the cell cycle where the cell 
is more vulnerable to damage. Numerous studies have sought to relate the cell cycle 
status in patients with AML with response to treatment and clinical outcome, and these 
will be presented in detail in chapter 3. However, the results have been inconsistent 
and, for some features, directly contradictory. Furthermore, none have sought to define 
cell cycle status according to well-defined cell cycle licensing markers, nor have they 
been performed with knowledge of cytogenetic data and the major molecular 
prognostic markers FLT3-ITD and NPM1.  
 
 
1.11 Summary and aims of thesis 
The aim of the studies presented in this thesis was therefore to explore the relationship 
between the cell cycle dynamics of leukaemic blast cells from patients with AML, in 
terms of the expression of DNA replication licensing proteins, with clinical, cytogenetic 
and molecular features of the patients’ disease, and further to assess this information in 
relation to response to induction therapy and overall clinical outcome. 
Chapter 3 examines the current body of knowledge of clinical studies of the cell cycle 
in AML, and discusses possible reasons for inconsistencies between the results and how 
the previous methods used are open to inaccuracies. Results are then presented on 
studies assessing expression of cell cycle licensing proteins for defining the cell cycle 
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state in patients with AML. Chapter 4 describes a cohort of patients with a new 
diagnosis of AML treated at UCLH and known to have pre-treatment biopsies available 
for further analysis, and defines this population in terms of clinical and molecular 
features, response to treatment and outcome. Chapter 5 then presents the results of 
studies determining the expression of cell cycle licensing proteins in these patients and 
their correlation with the clinical features, major molecular mutations, and clinical 
outcome. Areas of further study suggested by the work in this thesis are then explored 
in chapter 6. 
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CHAPTER 2. MATERIALS AND METHODS 
 
Specific materials and methods are described in the relevant results chapters. 
 
 
2.1 Immunohistochemistry and immunocytochemistry 
 
2.1.1. Reagents 
 
Agarose (Bioline, London, UK) 
Ammonium chloride (VWR International Ltd., Lutterworth, UK). 
BondTM Polymer Refine Detection kit (Leica Biosystems, Newcastle, UK). 
BondTM Primary Antibody Diluent (Leica Biosystems, Newcastle, UK). 
Dulbecco’s Phosphate Buffered Solution (PBS) without calcium/magnesium (PAA 
Laboratories Ltd., Somerset, UK) 
EDTA (ethylenediaminetetraacetic acid, disodium salt) (Sigma Aldrich, Poole, UK) 
Ethanol 100% (VWR International Ltd., Lutterworth, UK) 
Formalin (37-40%) (VWR International Ltd., Lutterworth, UK) 
Sodium phosphate (monobasic) (VWR International Ltd., Lutterworth, UK) 
Sodium phosphate (dibasic/anhydrous) (VWR International Ltd., Lutterworth, UK) 
Trypan Blue (0.4%) (Sigma Aldrich, Poole, UK)  
Xylene (VWR International Ltd., Lutterworth, UK) 
 
 
2.1.2 Antibodies 
 
Cleaved Caspase-3 (Asp175) (Cell Signalling Technology, Hitchin, UK) 
Geminin (Leica Biosystems, Newcastle, UK). 
MCM2 (BD Biosciences, Oxford, UK) 
MIB-1 (Dako UK Ltd., Ely, UK) 
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2.1.3 Buffers 
 
Ammonium chloride red cell lysis buffer (10x): 8.02g ammonium chloride, 0.84g 
sodium bicarbonate, 0.37g EDTA (disodium) in 100ml DDW. Stored at 4°C. 
 
Neutral buffered formalin (10%): 100ml of formalin (37-40% stock solution) in 900ml 
DDW, 4g sodium phosphate (monobasic), 6.5g sodium phosphate (dibasic/anhydrous). 
Stored at room temperature. 
 
 
 
2.2 Molecular biology 
 
2.2.1 Reagents 
 
Agarose (Bioline, London, UK) 
Bioline buffer and magnesium chloride (Bioline, London, UK) 
BIOTAQTM polymerase (Bioline, London, UK) 
Boric acid (VWR International Ltd., Lutterworth, UK) 
Bromophenol blue (VWR International Ltd., Lutterworth, UK) 
Chloroform (VWR International Ltd.., Lutterworth, UK) 
DNA size standard kit – 400bp or 600bp (Beckman Coulter UK Ltd., Buckinghamshire, 
UK) 
Diethylpyrocarbonate (DEPC) treated water (Invitrogen, Paisley, UK) 
dNTPs (Bioline, London, UK) 
DTAB (dodecyl-trimethyl ammonium bromide) (Sigma Aldrich, Poole, UK) 
EDTA (ethylenediaminetetraacetic acid, disodium salt) (Sigma Aldrich, Poole, UK) 
Glycerol (VWR International Ltd., Lutterworth, UK) 
Ethanol 100% (VWR International Ltd., Lutterworth, UK) 
Ethidium bromide (Invitrogen, Paisley, UK) 
Hyperladder IV (Bioline, London, UK) 
Primers (IDT, Leuven, Belgium) 
PurelinkTM RNA Micro Kit (Life Technologies Ltd., Paisley, UK) 
PurelinkTM DNase/Carrier RNA (Life Technologies Ltd., Paisley, UK) 
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Qiagen DNeasy Blood and Tissue kit (Crawley, West Sussex, UK) 
Sample loading solution (SLS) (Beckman Coulter UK Ltd., Buckinghamshire, UK) 
Sodium chloride (VWR International Ltd., Lutterworth, UK) 
Sodium dodecyl sulphate (SDS) (VWR International Ltd., Lutterworth, UK) 
Tris base (VWR International Ltd., Lutterworth, UK) 
Tris chloride (VWR International Ltd., Lutterworth, UK) 
TRIzol® reagent (Invitrogen, Paisley, UK) 
 
 
2.2.2 Buffers 
 
DNA lysis buffer: 20g DTAB (final concentration 8%), 22g NaCl (1.5M), 25mls of 1M 
Tris Cl pH 7.8 (100mM). Made up to 250mls with DDW.  
 
Gel loading buffer: 3.9mls glycerol, 500µl 10% SDS, 25mg bromophenol blue, made 
up to 10mls with DDW.  
 
TBE (10x): 108.9g Tris base, 55.7g Boric acid, 7.4g EDTA, made up to 1 litre with 
DDW.  
 
 
2.2.3 DNA extraction 
 
For some patients diagnosed prior to the start of the work in this thesis (August 2011), 
DNA was available in the UCLH DNA bank held within the Department of 
Haematology. These were predominantly patients that had consented to participate in 
one of the MRC/NCRI trials. Wherever possible for patients diagnosed prior to August 
2011 and without stored DNA, archived bone marrow aspirate smears were obtained. 
DNA was extracted from material on these slides using the DNeasy Blood and Tissue 
kit (QIAGEN). Slides with coverslips were immersed in xylene for 24 hours to enable 
easier removal of the coverslip. For each patient sample, a total of 200µl PBS and 20µl 
proteinase K was placed on the slides (divided between slides if >1 slide used per 
patient) and a scalpel blade used to scrape the material into a 1.5ml Eppendorf tube. 
Samples were then processed according to manufacturer’s instructions.  
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For patients diagnosed after August 2011, bone marrow aspirates that were surplus to 
diagnostic requirements were used to extract DNA.  Samples were processed as 
described in section 2.1.4 but the extracted buffy coats were resuspended at a 
concentration of 1x106 cells per 100µl 1x PBS.  Two volumes of DNA lysis buffer were 
then added, mixed well and incubated at 68°C for 5 minutes. After cooling, the 
suspension was mixed well with an equal volume of chloroform before being 
centrifuged at 2000g for 20 minutes. Following this, the upper layer (containing the 
DNA) was added to an equal volume of 100% ethanol to precipitate the DNA. The 
DNA samples were then centrifuged at >8000g, washed twice with 70% ethanol, and 
then dissolved in DDW by end-over-end rotation overnight at 4°C.  
 
 
2.2.4 Polymerase Chain Reaction (PCR) 
 
The non-proof reading enzyme BIOTAQTM DNA polymerase was used in combination 
with Bioline buffer and magnesium chloride according to manufacturer’s 
recommendations. Forward and reverse primers were used at 0.5µM each, dNTPs at 
200µM each, and approximately 50ng of genomic DNA template in a 20µl PCR 
reaction. PCR conditions included an initial denaturation step at 95°C for 1 minute, 
followed by successive cycles of denaturation (95°C for 30 seconds), annealing (30 
seconds), and extension (72°C for 30 seconds), followed by a final extension of 72°C 
for 5 minutes. The annealing temperatures for the specific primer pairs are stated in the 
appropriate methods section of chapter 4. 
 
 
2.2.5 Agarose gel electrophoresis 
 
PCR products were run and visualised on 2% agarose gel. Gels were made by adding 
2% weight/volume to 1x TBE.  The agarose was melted by heating in a microwave 
oven. After cooling, ethidium bromide to a final concentration of 100ng/ml was added 
to the gel mixture that was then poured into a mould and allowed to set. To run samples, 
the gels were submerged in 1x TBE containing ethidium bromide to a final 
concentration of 100ng/ml. PCR product (4µl) was then added to 1µl loading dye and 
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loaded into a well within the gel. To confirm the size of the PCR products, for each gel, 
one well was loaded with 4µl of Hyperladder IV. The samples were electrophoresed at 
a constant current of 70mA for 30 minutes, the products were then visualised under a 
UV transilluminator and an image taken. The gels were then electrophoresed for a 
further 30 minutes before repeating the visualisation and imaging.  
 
 
2.2.6 Fragment size separation using the Capillary Electrophoretic Genetic Analysis 
System (CEQTM) 8000 
 
The CEQTM 8000 system was used to identify and quantify size differences between 
PCR products where the mutation resulted in the insertion of base pairs.  Approximately 
50ng of genomic DNA was amplified using the BIOTAQTM DNA polymerase 
conditions as described in section 2.2.4 but using 0.25µM of forward primer, 0.25µM 
of a fluorescently labeled reverse primer, and 25-30 PCR cycles.  
 
CEQTM DNA Size Standard Kit 400 or 600 (3.5µl) was added to 1ml of SLS. Each PCR 
product (2µl) was added to 38µl SLS + CEQTM DNA size standard mix (or 36µl if 2 
different PCR products were being assessed at the same time). The total 40µl was 
loaded onto the sample plate and one drop of mineral oil layered on top. The samples 
were then analysed by fragment separation on the CEQTM 8000 Genetic analysis system. 
Following separation of the PCR products according to size, the area under each peak 
was determined by the instruments’ software algorithm, and the relative proportion of 
each peak determined by calculating the area under each peak as a percentage of total 
alleles. PCR products that had amplified sufficiently to saturate the fluorescent signal 
were rerun at a 1:10 dilution in PCR master mix. For PCR products with poor 
amplification, the PCR was repeated with an increased number of cycles up to a 
maximum of 30 cycles. 
 
 
 
2.3 Flow cytometry 
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2.3.1. Reagents  
 
Bovine Serum Albumin (Sigma Aldrich, Poole, UK) 
Calcium chloride (VWR International Ltd., Lutterworth, UK) 
Dulbecco’s Phosphate Buffered Solution (PBS) without calcium/magnesium (PAA 
Laboratories Ltd, Somerset, UK) 
Hydrochloric acid (1M) (Sigma Aldrich, Poole, UK) 
Propidium iodide (Invitrogen, Paisley, UK) 
Ribonuclease A (Sigma Aldrich, Poole, UK) 
Tri-sodium citrate (dihydrate) (Sigma Aldrich, Poole, UK) 
Triton X-100 (Sigma Aldrich, Poole, UK) 
Tris base (VWR International Ltd., Lutterworth, UK) 
Tris hydrochloride (Sigma Aldrich, Poole, UK) 
Trypsin solution (2.5%) (Sigma Aldrich, Poole, UK) 
Tween 20 (Sigma Aldrich, Poole, UK) 
 
 
2.3.2 Buffers/Solutions 
 
Sodium Citrate Buffer (10mM Sodium Citrate, 0.05% Tween 20, pH 6.0): Tri-sodium 
citrate (dihydrate) 2.94g in 1 litre of DDW. Adjusted to pH 6.0 with 1M hydrochloric 
acid before adding 500µl Tween 20. Stored at 4°C. 
 
Tris-HCl buffer (0.05M) containing calcium chloride (10mM ): 6.06g Tris-HCl, 1.39g 
Tris base, 1.11g calcium chloride in 1 litre DDW. 
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CHAPTER 3. DEFINING THE CELL CYCLE IN AML BLASTS 
FROM BIOPSIES, ASPIRATES, AND PERIPHERAL BLOOD 
3.1 Introduction 
3.1.1 Relationship between cell cycle state and outcome in patients with AML 
Numerous studies have sought to define the cell cycle status of leukaemic cells from 
patients with AML and relate this to clinical outcome (Table 3.1). The larger studies, 
those involving more than 100 patients, are discussed in greater detail. 
 
Preisler and colleagues treated mononuclear cells harvested from patient BMAs with 
tritiated thymidine (3HTdR) to label actively proliferating cells and expressed this as a 
relative proportion of total cells, i.e. the labelling index (LI) (Preisler et al, 1984). They 
found a significantly higher median LI for patients achieving CR compared to those 
with resistant disease for 39 patients that were treated with Ara-C alone (10.8% vs 6.8%, 
P=0.02), but not for 84 patients treated with Ara-C plus an anthracycline (9.6% vs 9%), 
nor for 26 patients treated with salvage regimens for relapsed disease (7.8% vs 6%). 
They concluded that the proportion of cells synthesising DNA at the time that treatment 
was initiated determined response to treatment, at least in part, only in those patients 
treated with Ara-C as a single agent. Of note, however, a high proportion of cycling 
cells did not guarantee sensitivity to Ara-C. 
 
In a series of studies, Raza and colleagues investigated cell kinetics in more than 120 
patients with “standard risk” AML, defined on the basis of age, comorbidities, and 
AML that was de novo (i.e. not related to treatment or a prior haematological disorder) 
(Raza et al, 1987; Raza et al, 1990; Raza et al, 1991). Using a double labelling 
technique, they sought to determine the length of S phase (Ts) and total duration of cell 
cycle time (Tc). Bromodeoxyuridine (BrdU), which is incorporated into newly 
synthesised DNA in place of thymidine, was infused into patients over one hour. BMAs 
(5ml) and bone marrow trephine biopsies (BMT) were then obtained. The LI of 
proliferating cells in the BMT was determined by staining with
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Table 3.1 Summary of studies relating cell cycle status/kinetics to clinical outcome in patients with AML. 
No. of 
patients  
Patient characteristics Source 
of cells 
Technique to assess cell cycle Main Findings Reference 
25  BMA Pulsed cytophotometry Lower % S/G2/M cells in AML than normal BM 
Patients with lowest S/G2/M did not respond to 
treatment 
(Hillen et al, 1975) 
51 Median age, 50 yrs BMA 3HTdR labelling ex vivo Higher LIs associated with increased remission rates. 
Effect more pronounced in patients aged >40 yrs, no 
impact of LI in those ≤40 yrs. 
For patients <60 yrs, increased LI associated with 
shorter remission and decreased survival 
(Hart et al, 1977) 
41  BMA 3HTdR labelling ex vivo Higher LI in those responsive to treatment (Zittoun et al, 1975) 
23 Childhood AML, median 
8 yrs (range, 0.1-16.4) 
BMA 3HTdR labelling ex vivo No correlation between LI and achievement or duration 
of remission 
(Murphy et al, 
1977) 
67 Previously untreated BMA 3HTdR labelling ex vivo No correlation between LI and achievement or duration 
of remission 
(Amadori et al, 
1980) 
78 56 previously untreated, 
22 relapsed 
BMA Flow cytometry Lower median % S phase cells in AML (8%) than ALL 
(10%), and normal BM (16%) 
Higher mean % S phase cells associated with lower 
circulating absolute blast counts 
%S phase cells did not predict for CR, length of 
remission, or OS 
(Dosik et al, 1980) 
61 38 previously untreated, 
23 relapsed 
BMT and 
BMA 
Flow cytometry to define G0/G1, S, 
and G2/M cells  
3HTdR labelling ex vivo 
BMAs unreliable for determining cell cycle kinetics 
S-phase LI from biopsies not predictive of response to 
therapy  
(Hiddemann et al, 
1982a) 
149 123 at presentation, 
26 relapsed 
BMA 3HTdR labelling ex vivo In newly diagnosed AML treated with Ara-C, higher LI 
associated with achieving remission  
No relationship between LI and remission in newly 
diagnosed or relapsed AML treated with anthracycline 
and Ara-C 
(Preisler et al, 1984) 
50 De novo 
Age range, 18-75 yrs 
BMA Flow cytometry 
 
No difference in % S phase cells in those achieving CR 
versus not. Increased G0/Early G1 cells associated with 
increased rates of CR 
(Ffrench et al, 1985) 
47 Median 44 yrs (range, 18-
78) 
6 APL 
BMA Flow cytometry 
3HTdR labelling ex vivo 
Higher number S/G2/M cells associated with increased 
rates of CR but shorter duration of longer-term 
responses 
(Riccardi et al, 
1986) 
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Table 3.1 (continued) 
73 Median 56 yrs (range, 22-
81) 
PB and 
BMA 
Flow cytometry Lower % S/G2/M cells in PB associated with higher 
rates of CR and longer responses 
(Guerci et al, 1989) 
54 Standard risk AML BMT and 
BMA 
BrdU infused in vivo. BMT LI 
determined. BMA double labelled 
ex vivo with 3HTdR. Length of S 
phase and total cell cycle time 
extrapolated from these  
Increasing age associated with shorter S phase and total 
cell cycle time. 
No relationship between cell cycle parameters and 
response to induction 
Patients with slower cycling cells had longer remission 
(Raza et al, 1990) 
128 (54 
from 
1990 
study) 
Standard risk AML (≤70 
yrs, no significant 
comorbidity, not sAML 
or tAML) 
BMT and 
BMA 
As for 1990 study  LI of BMT ≈3x higher than BMA with a positive but 
weak relationship. 
Total cell cycle time inversely related to BMT LI  
Remission longer for patients with higher BMA LI, 
longer length of S phase and higher total cell cycle time. 
No relationship between BMT LI and outcome  
(Raza et al, 1991) 
114 Median 54 yrs (range, 16-
82) 
38% Normal CGN 
59% Abnormal CGN 
3% Unknown  
BMA Cells cultured in serum- and 
cytokine-free media to assess 
autonomous proliferation. DNA 
synthesis assessed by 
incorporation of 3HTdR 
Higher rates of autonomous proliferation associated 
with inferior OS. 
(Lowenberg et al, 
1993)  
204 de novo AML 
 
126 PB,  
78 BMA 
Flow cytometry to define G0/G1, S, 
and G2/M phases of cycle 
No relationship between % S phase cells and response 
to induction therapy 
Increased % S phase cells associated with shorter 
survival 
(Vidriales et al, 
1995) 
66 de novo AML 
 
BMA Ex vivo 3HTdR incorporation 
following culture in GM-CSF 
High LI associated with early response to treatment on 
day 10-16 BM 
(Jahns-Streubel et 
al, 1995) 
36 de novo AML 
 
BMA As for 1995 study %S phase cells not associated with early clearance on 
day 5-7 marrow 
(Jahns-Streubel et 
al, 1997) 
226 181 de novo AML (27 = 
APL) 
45 sAML 
 
PB 
 
 
Mononuclear cells plated on 
methylcellulose +/- supporting 
factors; autonomous growth and 
plating efficiency assessed 
Highest autonomous growth in sAML post-MPN, 
lowest in APL  
CR not related to autonomous growth 
Higher proliferation associated with shorter survival 
(del Canizo et al, 
1998) 
187 de novo AML: 
25 favourable CGN 
99 normal CGN 
29 adverse CGN 
34 other 
BMA Ex vivo 3HTdR incorporation Highest rates of proliferation in favourable CGN, lowest 
rates in adverse CGN 
Lower proliferation in APL than other favourable risk 
CGN but still higher than normal CGN 
 
 
(Braess et al, 2001) 
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Table 3.1 (continued) 
91  BMA Ex vivo 3HTdR incorporation 
following culture in GM-CSF 
Higher proliferation in favourable risk CGN compared 
to adverse risk CGN 
(Jahns-Streubel et 
al, 2001) 
 
Abbreviations: 3HTdR, 3H-thymidine; Abn, abnormality; AML, acute myeloid leukaemia; ALL, acute lymphoblastic leukaemia; APL, 
acute promyelocytic leukaemia; Ara-C, cytarabine arabinoside; BM, bone marrow; BMA, bone marrow aspirate; BMT, bone marrow 
biopsy; BrdU, Bromodeoxyuridine; CGN, cytogenetics; CR, complete remission; GM-CSF, granulocyte-macrophage colony stimulating 
factor; LI, labelling index; MPN, myeloproliferative neoplasm; OS, overall survival; PB, peripheral blood; sAML, secondary AML; tAML, 
treatment related AML. 
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 anti-BrdU antibodies. The BMAs were processed using Ficoll Hypaque centrifugation 
and low density cells (mononuclear cells) were collected. The cells were processed on 
ice and centrifuged at 4oC “so that all metabolic activity in the cells was arrested prior 
to incubation in the second label”. The harvested mononuclear cells were then cultured 
for one hour at a density of 5-10 million cells per ml in RPMI with 10% FCS in the 
presence of 3HTdR, which was used as a second label of DNA synthesis. Ts was 
calculated using the formula Ts = (DL + 3HTdR) x t/BrdU, where DL was the number 
of double-labelled cells, 3HTdR and BrdU the percentage of positive cells for these 
labels, and t the time between the labels, which in this study was one hour. Tc was 
calculated using the formula Tc= Ts x GF/LI, where GF was the growth fraction and 
assumed to be 100%, and LI was the labelling index for BrdU of the trephine.  
 
The authors found that there was a large variation between patients in values for Ts 
(range, 4-49 hours) and Tc (16-292 hours). The relationship between the LI of the BMT 
and the derived cell cycle parameters was inconsistent between studies, however in the 
report with the largest number of patients (n = 128), the LI of the BMTs was negatively 
correlated with Tc and there was a positive correlation between Tc and Ts (Raza et al, 
1991). None of the cell cycle variables studied showed a statistically significant 
correlation with the attainment of CR following induction chemotherapy. The Tc was 
related to duration of remission, with patients with shorter Tc relapsing earlier, but there 
was no statistically significant correlation between remission duration and Ts. 
Furthermore, although patients with above median BrdU LI of BMAs had longer 
remission durations, this was not the case for the BrdU LI of the BMTs. The authors 
concluded that the most likely explanation for the observed relationship between 
remission duration of patients and some of the derived cell cycling kinetics of their 
leukaemic cells was that the cell cycle time played a role in determining the rate of 
leukaemic cell regrowth between courses of consolidation therapy and following the 
cessation of all therapy.  
 
In these investigations by Raza and colleagues, the LI of BMTs was significantly higher 
than that of BMAs. In the first study, the mean was 23% vs 9% respectively, P=0.0003 
(Raza et al, 1987). In a subsequent study (Raza et al, 1991), the mean and median LI 
(uptake of 3HTdR) in BMTs from 122 patients were 25.1% and 25.0% respectively, 
whereas in BMAs from 114 patients the complementary results were only 8.8% and 
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8.0%. In the 111 patients in whom results from both BMT and BMA were available, 
the correlation was 0.379. Although statistically significant (P= 0.0001), this 
correlation is generally weak given that, in theory, these results were supposed to 
represent the same cells, taken at the same time, from the same patients and providing 
accurate information on cell cycle kinetics. 
 
The study by Hiddemann(Hiddemann et al, 1982b) was a more thorough assessment of 
the discrepancy between values obtained from BMT and BMA samples. In a series of 
patients with either AML (n= 48) or other “non-leukaemic” disorders (n= 67), paired 
BMA and BMT samples were taken and assessed by flow cytometry for DNA (n=133). 
In over 70% of cases the results obtained from the biopsy were higher, with up to a 9.2-
fold difference. In 48 patients where RNA content was assessed, similar results were 
obtained with up to an 8.1-fold change. When samples were assessed by 
autoradiography for the 3HTdR LI (n=16), in all but one case results from the biopsy 
were higher, with a mean 1.82-fold difference and range up to 11.4 times higher. 
Results obtained from this technique and from flow cytometry were highly concordant 
(r=0.94, P<0.001).  Very similar results were also obtained in a further 56 samples 
assessed by liquid scintillation counting using 3HTdR uptake (counts per minute). In 
summary, results between the techniques used were highly concordant whereas results 
according to the source of blast cells showed significant differences.  
 
The authors offered two potential explanations for these results: either a selective 
enrichment of proliferating cells during the biopsy preparation process, or a relative 
decrease in the proportion of proliferating cells in the BMA samples due to the 
admixture of non-proliferating blood cells. The former possibility was excluded given 
the high concordance between three different biopsy preparation techniques. To 
investigate the latter possibility, the authors mixed material from biopsies and blood 
and found that they gave similar results to the corresponding aspirates. This suggested 
that the higher proportion of cells in G0/G1 in the BMA samples was due to 
contamination with non-proliferating peripheral cells. Crucially, this happens even 
when small volumes of aspirate are taken as the aspirate volumes in this study were 
reported to be between 0.5 and 1ml.  However, there was no conclusion as to the nature 
of the contaminating cells other than that they were “non-proliferating nucleated 
peripheral blood cells”, although quantitative and functional differences in committed 
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granulocytic progenitors (CFU-C) and lymphocytes that have been reported with blood 
contamination were discussed.  
 
Vidriales and colleagues assessed the prognostic value of the percentage of S phase 
cells, as assessed by flow cytometry of peripheral blood (PB) (n=126) or BMA samples 
(n=78) from 204 patients with de novo AML (Vidriales et al, 1995). The proportion of 
cells in S phase was only 2.3% in PB and 7.3% in the BMAs. The percentage of cells 
in S phase did not predict for response to intensive induction therapy, but increased 
numbers of cells in S phase were associated with shorter survival.  
 
More recently, Braess and colleagues examined the proliferation of mononuclear cells 
from BMAs, as assessed by the incorporation of 3HTdR into DNA in an ex vivo culture 
system (Braess et al, 2001). The highest and lowest proliferation rates were seen in the 
cells obtained from patients with favourable and adverse karyotypes respectively. 
Higher rates of proliferation correlated with improved outcome within the intermediate 
and adverse risk groups but not the favourable risk group. Variations in proliferation 
between patients within the favourable group did not affect outcome. APL patients had 
the lowest proliferation rates of the favourable groups, however this was still higher 
than the intermediate or adverse risk groups. The authors proposed that differences in 
proliferative activity are a characteristic of cytogenetically defined subgroups and that 
this may be related to the relative cytoreductive effects of Ara-C based induction on 
cells with different karyotypes. 
 
Other studies have assessed autonomous growth, i.e. cells growing in serum or 
cytokine-free media, as a means to try and infer cell cycle kinetics. Lowenberg and 
colleagues assessed autonomous growth in the cells taken from BMAs of 114 patients 
(Lowenberg et al, 1993). The rate of DNA synthesis was assessed by the incorporation 
of 3HTdR and three proliferative groups (high, intermediate, and low) were defined. 
There were no statistically significant correlations between the rate of autonomous 
proliferation and age, sex, WCC, percentage of leukaemic blasts in the marrow, or the 
number of cytogenetic abnormalities, although it was noted that all patients with t(8;21) 
had low levels of autonomous proliferation. Patients with M4 or M5 disease had higher 
rates of autonomous proliferation. All patients were included in a survival analysis; 91 
received anthracycline + Ara-C induction therapy. In multivariate analysis, autonomous 
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proliferation was an independent prognostic factor for OS at 3 years (low growth 36% 
vs high growth 3%, P<0.0001), and rates of CR also varied with proliferation group 
(low 68%, intermediate 62%, high 39%, P=0.04).  
 
A later study of 226 patients (del Canizo et al, 1998) examined PB-derived 
mononuclear cells plated in methylcellulose with and without stimulating factors to 
determine autonomous growth and plating efficiency. These were then used to derive 
an “autonomous proliferation index”. AML secondary to a myeloproliferative 
neoplasm had the highest rates of autonomous growth and proliferation index, whereas 
patients with M3/APL had the lowest autonomous growth but the highest plating 
efficiency. There was no correlation between autonomous growth or the derived index 
and rates of CR, but a higher proliferation index correlated with shorter survival. 
 
In summary, the results of previous investigations relating some of the cell cycle 
dynamics to clinical outcome in patients with AML are inconsistent, and in some cases 
the conclusions are diametrically opposed. Increased proliferation, or increased 
numbers of S-phase cells as a surrogate for this, has been found to be favourable, 
adverse, or of no prognostic value in predicting response to treatment, time to relapse, 
or overall outcome.  
 
 
3.1.2 Limitations of previous studies 
 
The conflicting results seen in these studies of cell cycle parameters in patients with 
AML are likely to reflect a number of established or potential differences between the 
studies. 
 
3.1.2.1 Differences in source of leukaemic cells 
 
The above studies show clear discrepancies in the average number of cells in S phase 
between BMTs, BMAs, and PB, with the highest values seen in BMTs and the lowest 
in PB. Using paired samples, Hiddemann and colleagues demonstrated a lower number 
of S phase cells in BMAs than BMTs (Hiddemann et al, 1982a). The subsequent studies 
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by Raza and colleagues corroborated the higher LI seen in BMTs than BMAs (Raza et 
al, 1990). The flow cytometric studies by Vidriales (Vidriales et al, 1995) showed 
higher average results for BMAs than PB, although the samples were not paired. Other 
studies using PB have shown a consistently lower proportion of S phase cells or LI by 
3H-thymidine incorporation than comparable studies using BMA samples. These lower 
values for BMAs and PB as compared to BMT samples have been ascribed to 
‘contamination’ by non-proliferating nucleated peripheral cells (Hiddemann et al, 
1982b), although without firm conclusions as to whether these are leukaemic blasts or 
other mononuclear cell types. 
 
3.1.2.2 Difference in techniques used to assess the cell cycle 
 
There are a number of differences between the studies in the techniques used to process, 
measure, and analyse the cell cycle profile or kinetics.  
 
i. Measurement of S phase cells by incorporation of 3HTdR or BrdU as compared to 
measurement of S/G2/M cells by flow cytometry.  
ii. In vivo labelling as compared to ex vivo labelling following various lengths and types 
of processing or culture. Such ex vivo growth during processing and/or subsequent 
culture is unlikely to represent the true nature of cell kinetics within the bone marrow 
microenvironment and under physiological cytokine stimuli. 
iii. Use of autonomous growth as opposed to measuring in vivo kinetics or kinetics with 
serum or cytokine support. This is more a measure of cell survival and resistance to 
apoptosis than of proliferation and, again, is unlikely to be representative of the cells 
within the bone marrow niche. 
iv. Exclusion of cases with lower levels of viable cells following processing. For example, 
Braess et al (2001) only included samples with >95% viability following processing. 
v. Assumptions used to derive formulae for inferring cell cycle kinetics. For example, the 
studies by Raza and colleagues assumed that the rate of cell export from the bone 
marrow equals that of cell production, and that cells are exported exclusively in G1. 
Furthermore, they assumed that there is a “steady state” rather than exponential growth 
in the ex vivo culture and a 100% proliferation fraction in BMTs. 
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3.1.2.3 Patient-, disease-, and treatment-related factors 
 
The patient-, disease-, and treatment-related factors vary between studies. 
 
i. In some studies there is limited information on patient age. This may be of importance 
given the difference in disease biology with age. The increased expression of, for 
example, drug efflux pumps with age may render cells resistant to cell cycle targeting 
agents regardless of cell cycle status. One study has suggested a difference in the impact 
of cell cycle status depending on the age group examined (Hart et al, 1977). 
ii. Earlier studies simply refer to acute non-lymphocytic leukaemia. There is limited 
information in some studies as to whether the AML was primary or secondary, initial 
presentation or relapse. 
iii. There is limited information on FAB types such that there is likely to be differences 
between studies in, for example, the number of patients included with M3/APL. This 
could have a large impact, particularly if patient numbers are small. Nevertheless, there 
is controversy even for cell cycle status of M3/APL. Raza (Raza et al, 1991) found that 
M3/APL subtypes were associated with slower cycling rates. In contrast, (Braess et al, 
2001) found that the APL subtype was cycling faster than all other leukaemia subtypes 
bar the core-binding factor leukaemias. 
iv. Treatments in some of the earlier studies pre-date the use of the standard remission 
induction of anthracycline + Ara-C “3+7”. Furthermore, not all studies contained 
consolidation treatment for patients achieving remission. Nevertheless, conflicting 
results have also been reported between studies in which patients received what is now 
accepted to be standard induction therapy followed by remission consolidation. 
v. There is limited information on patient’s cytogenetics or risk-group.  This may be 
important in view of the findings by (Braess et al, 2001) and (Jahns-Streubel et al, 2001) 
that different cytogenetic risk groups appear to have different measured cell-cycle 
parameters. 
vi. Some studies excluded patients with a marrow blast count below a certain threshold. 
(Braess et al, 2001) excluded cases with ≤70% bone marrow infiltration, and the studies 
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by (Dosik et al, 1980) and (Ffrench et al, 1985) required ≥70% and >80% marrow 
involvement respectively for a patient to be included in the cohort. This may select for 
de novo AML over secondary AML, which is likely to impact on cell cycle status, 
particularly in view of the different spectra of mutations associated with these entities 
(Lindsley et al, 2015). 
vii. All but three of the studies predate the discovery of FLT3-ITDs in AML, and all of the 
studies predate the identification of mutations in the NPM1 gene, disease-related 
molecular mutations now known to have a significant biological and prognostic impact.  
 
In summary, the discrepancies reported in the prognostic impact of cell cycle analysis 
are likely to reflect a combination of the above features. Perhaps one of the most 
fundamental features here is the potential difference introduced by the source of the 
blast cells. Despite the concerns raised by (Hiddemann et al, 1982b) about the variable 
impact of contamination of non-cycling cells in BMA samples, few studies have looked 
at outcome data where only BMT results have been considered, and such studies that 
do exist have only looked at LI as defined by the percentage of cells incorporating 3H-
thymidine. There is a need therefore to assess cycle status in the in vivo state, without 
blood cell contamination. 
 
A robust method for identifying cells in different stages of the cell cycle using IHC was 
described in Chapter 1, where expression of MCM2 can identify cells in cycle (not G0), 
MIB-1 (detecting MKI67) identifies actively proliferating cells, and geminin identifies 
cell that have progressed through the G1/S phase checkpoint (i.e. cells in S/G2/M 
phases). These cell cycle markers have not been used in aggregate to define the cell 
cycle status in patients with AML. 
 
 
3.1.3 Aims of this chapter 
Using these established cell cycle markers, the aims of the studies presented in this 
chapter were: 
 
1. To define the cell cycle state in PB, BMA, and BMT samples from patients with AML. 
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2. To assess potential differences in measured cell cycle states from the different sources 
of sample. 
3. To assess the potential impact of PB contamination on the results of cell cycle analysis. 
4. To assess the potential impact of these differences on biological studies.  
 
 
 
3.2 Materials and methods 
 
3.2.1 Patient samples 
Pre-treatment BMT and BMA samples, taken from the posterior superior iliac crest, 
and PB samples were collected from 8 patients with a diagnosis of AML. In 7 patients 
this was at initial presentation and in one patient (patient 5, Table 3.2) samples were 
taken at relapse prior to salvage therapy. The UCL/UCLH Research Ethics Committee 
approved the studies. Informed consent was obtained according to the Declaration of 
Helsinki. 
 
 
3.2.2 Processing of Patient Samples 
The BMTs were decalcified, formalin-fixed and paraffin-embedded in the UCLH core 
pathology facility using standard methods. For BMA samples, the first 2.5ml was used 
for diagnostic morphology, immunophenotyping, and cytogenetics. A further 5mls was 
processed for flow cytometry and cell cycle analysis. At the same time, 5mls of paired 
PB was processed. Samples were centrifuged at 600g for 5 minutes and buffy coats 
were collected. Samples were then resuspended, centrifuged for a further 5 minutes at 
600g before plasma was removed and discarded, and the residual buffy coat collected 
and pooled with the first buffy coat collection. 
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Cells were resuspended in 1x PBS up to a total volume of 2ml. A 1x ammonium 
chloride red cell lysis buffer (final concentration 0.8%) was prepared by making a 1 in 
10 dilution of 10x stock solution in DDW. Four volumes of this red cell lysis buffer 
(8mls) were added to the cell suspension, mixed well and incubated on ice for 10 
minutes. The cells were then pelleted at 400g and resuspended in 1x phosphate-buffered 
saline (PBS).  
 
Trypan blue exclusion was used to determine the number of viable cells in a suspension. 
In contrast to non-viable cells, viable cells with an intact cell membrane are able to 
exclude trypan blue. Thus, when visualised using light microscopy, viable cells (clear 
cytoplasm) can be readily distinguished from non-viable cells (blue cytoplasm). An 
aliquot of the cell suspension (10µl) was mixed with an equal volume of 0.4% trypan 
blue and transferred to a haemocytometer where the number of viable and non-viable 
cells were counted under a light microscope. 
 
Cells were washed in 1x PBS and pelleted by centrifugation at 400g before being re-
suspended and fixed in 10% neutral-buffered formalin (1x106 viable cells/ml). An 
aliquot was stored at -20°C until required for the flow cytometry experiments; in 
addition 1x106 cells were pelleted at 400g, re-suspended in 1ml 2% agarose 
(weight/volume in 1x PBS) pre-warmed to 60°C, centrifuged at 1500g for 20 seconds 
and then the agarose allowed to set. The agarose plugs were subsequently formalin-
fixed and paraffin-embedded in the UCLH core pathology facility using standard 
methods. 
 
 
3.2.3 Immunohistochemistry (IHC) and immunocytochemistry (ICC) 
Sections of 3µm thickness were cut from each formalin-fixed paraffin-embedded 
biopsy (by the UCLH pathology core) and pellet (by Miss Ayse Akarca, Research 
Department of Haematology, UCL) and transferred to glass microscopy slides. Tonsil 
tissue containing both glandular and epithelial components was processed at the same 
time and used as a positive control. Sections were immuno-stained using Leica Bond 
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Polymer Refine Detection and the Bond–MaxTM automated system (Leica Biosystems, 
Newcastle, UK).  
 
Sections were immunostained using the BondTM Polymer Refine Detection kit and 
BondTM–Max automated system (Leica Biosytems, Newcastle, UK). Within the 
automated system, the tissues sections were dewaxed and then heated to 100°C for the 
purposes of antigen retrieval. They were incubated with peroxide block for 5 minutes, 
washed 3 times and then incubated for 40 minutes with the respective primary antibody. 
Primary antibodies were used at the following concentrations: MCM2 (1:3000), 
Geminin (1:200), MIB-1 (1:90), and Cleaved Caspase 3 (1:300). They were then 
washed 3 times before incubation with rabbit anti-mouse antibody linked to horseradish 
peroxidase. Following a further wash step, the sections were incubated with goat anti-
rabbit antibody linked to horseradish peroxidase. Following further washes, the 
sections were incubated for 5 minutes with 3-3’-diaminobenzidine (DAB) enhancer 
before a 2-minute incubation with haematoxylin counterstain and a final wash step. Cut 
section of paraffin-embedded tonsil tissue containing both glandular and epithelial 
components was processed at the same time and used as a positive control.  
 
The stained sections were washed for 15 minutes in DDW and then dehydrated in 
ethanol. The ethanol was then removed in a series of xylene baths before applying 
coverslips. Following IHC/ICC staining, the sections were examined microscopically 
to check for efficient staining.  
 
The sections were examined at 40X magnification. For each section a minimum of 200 
blasts were assessed and LIs determined based on the presence of nuclear staining 
(number of positive cells as a percentage of the total number of positive and negative 
cells).  
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3.2.4 Flow cytometry 
3.2.4.1 Preparation of cell suspension from BMTs 
Cells from paraffin-embedded BMTs were prepared for flow cytometric analysis from 
50µm sections (cut by Miss Ayse Akarca, Research Department of Haematology, UCL) 
using a protocol adapted from previously published methods (Jordanova et al, 2003). 
Sections were dewaxed 3 times for 5 minutes in 2mls xylene and rehydrated in ethanol 
baths of descending concentration. After washing twice in 2mls 1X PBS, the sections 
were immersed in 2mls cold citrate solution (10mM, pH 6.0) and incubated for 60 
minutes at 80°C. Sections were then cooled to room temperature and pelleted by 
centrifugation at 400g. Pellets were digested for 10 minutes at 37°C in 2mls 0.1% 
trypsin solution in 0.05M Tris-HCl buffer containing 10mM calcium chloride. 
Digestion was then blocked with 1X PBS containing 1% bovine serum albumin. 
Following mechanical mincing by drawing the suspension through needles of 
decreasing gauge down to 27G, samples were filtered through 70µm then 40µm mesh 
nylon cell filters.  Samples were then washed in 1X PBS and processed for cell cycle 
analysis by flow cytometry in parallel with BMA and PB samples. 
 
3.2.4.2 Cell cycle analysis by flow cytometry 
For BMT samples, all harvested cells were pelleted, and for BMA and PB samples, 
5x105 formalin-fixed cells were pelleted at 400g. Cells were re-suspended in 1ml of a 
1:1 mix of cold PBS and 0.1% Triton X-100 in PBS for 3 minutes at room temperature, 
washed in PBS containing 0.1% bovine serum albumin and re-suspended in 500µl PBS 
containing 0.1% ribonuclease A and 5µL 2.5mg/µl propidium iodide. Cells were 
analysed on a BD AccuriTM C6 cytometer (BD Biosciences, New Jersey, USA). Blast 
cells were gated on the basis of forward and side scatter (FSC) and doublets excluded 
following plotting of FSC-A (area) against FSC-H (height). Cells were acquired 
through the flow cytometer at a rate of between 10 and 20 cell events per second. At 
least 500 events per sample were collected. DNA content was assessed on all gated 
cells in the FL2 channel (488nm laser, filter 585/40) to determine the percentage of 
blast cells in the S/G2/M phases of the cell cycle (≥2n).  
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3.2.5 RNA expression profiling of BMT, BMA and PB cells  
RNA was extracted from BMT, BMA, and PB samples collected from a single patient 
and processed within 30 minutes of collection. The biopsies were teased apart using a 
27G needle, suspended in RPMI containing 10% fetal calf serum and filtered through 
a 40µm cell strainer. The cells were pelleted at 400g, washed in cold 1X PBS, then 
suspended in 100µl TRIzol® (Life Technologies Ltd, Paisley, UK) and stored at -80oC 
until required. Buffy coats were harvested from the BMA and PB samples and the red 
cells lysed using 0.8% ammonium chloride. The remaining cells were washed, counted, 
pelleted, then suspended in 100µl Trizol per 1x106 cells and stored at -80oC. Samples 
were thawed on ice and processed using the PurelinkTM RNA Micro Kit with the 
addition of PurelinkTM DNase/Carrier RNA (Life Technologies) according to 
manufacturer’s instructions. RNA quality was checked using a micro capillary chip 
(RNA 6000 Nano) for the Agilent Bioanalyser 2100 (Agilent, Santa Clara, California, 
United States) according to manufacturer’s instructions. 
 
The RNA-seq analysis was performed with help and guidance from Dr Tony Brooks 
and Dr Mike Hubank, UCL Genomics, UCL Institute of Child Health. RNA was 
prepared for sequencing following the Illumina Truseq protocol, multiplexed, and 
sequenced (43bp paired-end) on an Illumina NextSeq 500 sequencer (Illumina, San 
Diego, California, United States) to yield approximately 15 million reads per sample. 
De-multiplexed FastQ data were analysed at UCL Genomics. Sequencing reads were 
aligned to reference genome GRCh38 using tophat v2.0.13. When using paired end data, 
PCR duplicates were removed using Picard tools (v1.100). GTF (Gene transfer format) 
files describing gene features were obtained from the Ensembl website 
(http://www.ensembl.org/info/data/ftp/index.html) and read count data for each 
genomic feature were obtained using the python scripts provided as part of the Deseq2 
package. Read count data were subsequently normalised and differential expression 
was computed using the Deseq2 procedure. Normalised read counts (normalised using 
the Deseq2 library size procedure) were generated for visualisation in GeneSpring 13.0 
(Agilent Technologies).  The set of scripts used are freely available at 
https://github.com/plagnollab/RNASeq_pipeline. 
 90 
 
Analysis was performed using GeneSpring wih training and guidance in use of the 
program provided by Dr Mike Hubank. For the purposes of analysis, and to try and 
minimise the impact of stromal contamination, only genes with Fragments Per Kilobase 
of transcript per Million mapped reads (FPKM) values ≥20 in both the BMT and PB 
samples were included. The proposed gene functions were assessed using data available 
from the National Center for Biotechnology Information 
(https://www.ncbi.nlm.nih.gov/gene), and genes coding for proteins with 
predominantly stromal roles were also excluded from the analysis. 
 
3.2.6 Statistical analysis 
Statistical analysis was performed using Graphpad Prism software version 6 (GraphPad 
Software Inc., California, USA). LIs and derived ratios for BMT, BMA, and PB 
samples were compared using the 2-tailed Wilcoxon matched-pairs signed rank test. 
Comparisons across all three tissue compartments simultaneously was performed using 
the Friedman test. Correlations between results for BMT, BMA, and PB samples were 
assessed using Spearman’s rank correlation.  Correlations between % S/G2/M results 
obtained by IHC for geminin and flow cytometry using propidium iodide were 
performed using Spearman’s rank correlation. Agreement between the two techniques 
for measurement was assessed by Bland-Altman plot. A P value <0.05 was considered 
significant.  
 
 
3.3 Results 
3.3.1 Cell cycle analysis in matched BMT, BMA and PB samples 
3.3.1.1 Patient characteristics  
The demographics of the eight patients whose cells were used for cell cycle analysis is 
shown in Table 3.2. The median age was 64 years (range, 34-74) and median peripheral 
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WCC at presentation was 27.5x109/l (range, 2-365). Four patients had a normal 
karyotype, two had a monosomal karyotype, one a complex karyotype, and no 
cytogenetic data was available for the patient that was assessed at relapse. 
 
Table 3.2 Demographics and presenting features of the 8 AML patients used in 
the matched sample analysis 
Case Age, yrs Sex WCC (x109/l) Cytogenetics 
1 62 M 141 Normal 
2 72 F 13 Normal 
3 60 F 131 Monosomal 
4 74 M 2 Complex 
5 70 M 4 Not available 
6 34 F 7 Normal 
7 65 F 42 Monosomal 
8 63 M 365 Normal 
 
 
3.3.1.2 Immunohistochemistry (IHC) and Immunocytochemistry (ICC) 
PB, BMA, and BMT samples from each patient were stained with antibodies against 
MCM2, MIB-1, and geminin, and LIs were determined for the percentage of positive 
blast cells as a proportion of total blast cells. Clear positive and negative cells were 
evident and representative images are shown in Figure 3.1. 
 
There was no significant difference between BMT, BMA, and PB samples in the 
proportion of blasts expressing MCM2 (medians 95.5%, 93.5%, and 94% respectively, 
P=0.21 for Friedman test of data to determine differences across all tissue types) (Figure 
3.2A). For paired comparisons of BMT vs BMA, BMT vs PB, and BMA vs PB, the 
values using a Wilcoxon matched-pairs signed rank test were P=0.28, P=0.17, and 
P=0.99 respectively, indicating that nearly all the blast cells were non-quiescent and in-
cycle, irrespective of location. The percentage of blasts in-cycle was also highly 
correlated between BMT and BMA samples (r=0.97, P=0.0006) (Figure 3.2B), BMT 
and PB samples (r=0.98, P=0.0004) (Figure 3.2C), and BMA and PB samples (r=0.95, 
P=0.001) (Figure 3.2D). There was, however, a significant difference in the proportion 
of blasts expressing MIB-1, median LI 63% for BMT versus 4% for PB samples 
 92 
(P=0.008) (Figure 3.3A), indicating that the BMT blasts had a very high proliferative 
fraction whereas, in general, PB blasts were not actively proliferating. There was a non-
significant correlation between the MIB-1 LI found in BMT as compared to BMA 
samples (r=0.6, P=0.1) (Figure 3.3B), and no correlation between the MIB-1 LI in PB 
and either BMT samples (r=-0.07, P=0.9) (Figure 3.3C), or BMA samples (r=-0.11, 
P=0.8) (Figure 3.3D).  
 
In accord with this, the median geminin LI indicating progression beyond G1 was 21% 
for BMT versus 1% for PB samples (P=0.008) (Figure 3.4A). The median for BMA 
samples was 6%, and was significantly different from both BMT samples (P=0.008) 
and PB samples (P=0.008). The correlation between geminin LI in BMT and BMA 
samples was weak and non-significant (r=0.42, P=0.3) (Figure 3.4B). There was no 
significant correlation in the geminin LI between PB samples and either BMT samples 
(r=0.19, P=0.7) (Figure 3.4C) or BMA samples (r=-0.27, P=0.3) (Figure 3.4D).  
 
For the derived MIB-1/MCM2 ratio, there were significant differences between blast 
cells obtained from BMT, BMA, and PB samples (medians 0.65, 0.24, and 0.035 
respectively, Friedman test for differences across the sample types P<0.0001, 
individual comparisons BMT vs BMA, BMT vs PB, and BMA vs PB, all P=0.008) 
(Figure 3.5A). There was a trend for a correlation between values obtained from BMT 
and BMA samples (r=0.7, P=0.06) (Figure 3.5B). There was no significant correlation 
between values obtained from PB and either BMT samples (r=-0.19, P=0.6) (Figure 
3.5C), or BMA samples (r=-0.25, P=0.5) (Figure 3.5D). 
 
The derived geminin/MIB-1 ratio did not significantly differ between the groups, 
although for some patients there were clearly large differences between the tissue 
compartments (Figure 3.6A). For example, for one patient (patient 4, Table 3.2), the 
geminin/MIB-1 ratios obtained for the BMT, BMA, and PB samples were 0.09, 0.07, 
and 0.5 respectively, and for another patient (patient 8, Table 3.2) they were 0.59, 0.23, 
and 0.13 respectively. None of the correlations for this ratio between the different 
sources of blast cells reached statistical significance (Figures 3.6B-D). 
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Figure 3.1 Detection of cell cycle proteins using immunohistochemistry.  Representative images of immunohistochemical and 
immumocytochemical staining for (A) MCM2, (B) MIB-1, and (C) geminin in control tonsil tissue and bone marrow biopsy (BMT), bone 
marrow aspirate (BMA), and peripheral blood (PB) samples from an AML patient. Images are shown at x20 magnification. 
Removed	for	Copyright 
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                             Figure 3.2 Comparison of MCM2 LIs in BMT, BMA, and PB samples taken from the 8 patients. 
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                                    Figure 3.3 Comparison of MIB-1 LIs in BMT, BMA, and PB samples taken from the 8 patients 
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                                Figure 3.4 Comparison of geminin LIs in BMT, BMA, and PB samples taken from the 8 patients. 
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                  Figure 3.5 Comparison of the MIB-1/MCM2 ratios in BMT, BMA, and PB samples taken from the 8 patients. 
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                     Figure 3.6 Comparison of the Geminin/MIB-1 ratios in BMT, BMA, and PB samples taken from the 8 patients. 
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3.3.1.3 Flow cytometry 
Samples from each source were also assessed using flow cytometry with propidium 
iodide and the percentage of blast cells in S/G2/M determined. Representative plots 
from one patient (patient 8, Table 3.2) are shown in Figure 3.7A. There was a good 
correlation between the proportion of propidium iodide-stained cells in S/G2/M and the 
geminin LI obtained from IHC/ICC, irrespective of sample source (r=.986, P<0.0001) 
(Figure 3.7B). Bland-Altman plots showing the difference between the two results for 
all samples and for the 3 tissue compartments assessed separately further indicate that 
there was minimal difference between the results (Figure 3.8.A-D, Table 3.3), and 
indicate that there was no apparent bias for either method. 
 
 
Table 3.3 Results of the Bland Altman analysis for agreement between % S/G2/M 
cells determined by immunohistochemistry/immunocytochemistry (geminin-
positive) and by flow cytometry using propidium iodide. 
 
 All tissue 
compartments 
BMT BMA PB 
Bias 
 
0.25 -0.625 0.75 0.625 
Standard 
deviation of 
bias 
1.82 2.72 1.382 0.744 
95% limits of 
agreement 
-3.325 - 3.825 -5.961 - 4.711 -1.762 - 3.262 -0.833 - 3.083 
 100 
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Figure 3.7 Cell cycle analysis using flow cytometry and correlation with 
IHC/ICC results. (A) Representative examples of propidium iodide staining to 
assess cell-cycle status in blast cells from BMT, BMA, and PB samples from one 
patient (patient 8). (B) Correlation between cell-cycle analysis results obtained 
using flow cytometry and IHC/ICC. 
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Figure 3.8 Bland-Altman plots comparing the proportion of geminin-positive by IHC/ICC and in S/G2/M phase by flow cytometry. 
Difference refers to the difference between the results of the same sample using the two methods (flow cytometry – IHC/ICC) and average 
to the mean of the results for the two methods. The large filled circle in figure D denotes 4 samples, all of which have the same position in 
this Bland-Altman plot. 
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3.3.2 Comparison of PB, BMA, and BMT samples using gene expression profiling 
RNA was prepared from BMT, BMA, and PB samples from one patient for gene 
expression profiling. The patient had a presenting WCC of 98x109/l and >90% blasts 
in all three samples, precluding any need for blast cell purification. This was important 
as seven previous attempts to do RNA comparisons between BMT, BMA, and PB 
samples from patients where blast numbers were low in the PB had resulted in the RNA 
signature being heavily influenced by the differences in tissues in terms of cell type 
composition. For example, larger numbers of lymphocytes in PB made true differences 
in the RNA signature from blasts difficult to assess as it was essentially a comparison 
of a blast/lymphocyte mixture versus purer blast population. Samples were processed 
within 30 minutes of collection. Good quality RNA was obtained from all samples, as 
assessed by analysis on an Agilent Bioanalyser 2100 (Figure 3.9). cDNA libraries were 
prepared and sequenced as described above, and the data was analysed using 
GeneSpring 13.0. 
 
A concern for analysis of the data was the likely impact of contaminating stromal tissue 
in the BMT sample that would influence the results. In an attempt to minimise this 
impact, two further approaches were taken. Firstly, genes with FPKM values <20 in the 
PB sample were excluded. This was partly to focus on more highly expressed genes but 
also an attempt to exclude major stromal genes that would be unlikely to be expressed 
at high levels in the peripheral blood. The value of 20 was chosen as an approximation 
of the median FPKM value as the median FPKM values in the BMT, BMA, and PB 
samples were 24.5, 19.9, and 22.7 respectively. As an illustration of this approach, 
COL1A1, which codes for the alpha chain of type 1collagen and is highly expressed in 
connective tissue, was excluded as it had FPKM values of 4.7 and 4.0 in the PB and 
BMA samples respectively, but the value in the BMT sample was 623.7, i.e. >130 fold 
higher. Following these exclusions, evaluable data was obtained from 10,363 genes, 
representing 51.6% of genes covered by the RNA-seq system employed. Next, in an 
attempt to further reduce the potential for influence of stromal tissue, the proposed gene 
function and expression profiles were examined using the National Center for 
Biotechnology Information database (https://www.ncbi.nlm.nih.gov/gene), and genes 
with a predominantly stromal expression profile or function were excluded.  
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Figure 3.9 Assessment of RNA quality by Agilent Bioanalyser 2100. Bands 
corresponding to 28S and 18S ribosomal RNA running at 5kb and 1.9 kb respectively 
are clearly visible in all samples. kb = kilobases. 
 
 
28S	 
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BMT	 BMA	 PB	 Size	in	kb	 
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There were 472 non-stromal genes expressed at ≥2-fold higher level in the BMT than 
the PB sample, of which 146 were related to the cell-cycle. These included members of 
the MCM family, e.g. MCM4, MCM6, MCM8, and MCM10, GMNN encoding 
geminin, and MKI67 encoding Ki-67, and targets of drug development such as CDC7 
and the polo-like kinases (Table 3.4). In contrast, a key regulator of the cell cycle, 
CDKN1C, was found to be expressed at >2-fold higher level in the PB than the BMT 
sample. When expression of these cell-cycle genes was viewed in aggregate, the profile 
of the BMA sample was clearly more akin to that of the PB than the BMT sample 
(Figure 3.10). Furthermore, differences in expression between the samples were not 
restricted to the cell cycle. For example, 14 different transcription factors apparently 
unrelated to the cell cycle were down-regulated in the BMA/PB samples as compared 
to the BMT sample (Table 3.5). These transcription factors have putative roles that 
include AP-1 signalling and the stress response. Interestingly, in a previous study that 
looked at differences between CD34+ myeloblasts derived from BMA or PB samples, 
FOSB and JUN were expressed at higher levels in marrow blasts compared to PB in all 
5 paired samples studied (Cheung et al, 2009) (Table 3.6) 
 
3.3.3 Impact of source of blasts for published gene expression studies 
In order to assess whether this haemodilution with PB-derived G1-arrested blasts may 
have an impact on other biological parameters, it was decided to see whether these 
changes would also been seen in studies of gene expression profiling. In 2004 Bullinger 
and colleagues published a study using cDNA microarrays to determine the levels of 
gene expression in peripheral blood or bone marrow aspirate samples from 116 adults 
with AML (Bullinger et al, 2004). Using unsupervised hierarchical clustering, they 
identified molecular subgroups with distinct gene expression profiles and identified a 
signature of 133 genes that were used to define prognostic subclasses and predict 
survival in an independent validation group. Follow-up studies verified the utility of 
this gene set, again using blood and aspirate samples (Radmacher et al, 2006). This 
signature was therefore assessed using the RNAseq data from the BMT, BMA, and PB 
samples. The resulting heatmap shows that, although there are clear similarities 
between the blast cells derived from the different sources, the BMA and
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Table 3.4 Cell cycle-related genes down-regulated in blast cells from the PB 
sample compared to the BMT sample. Genes mentioned in Chapter 1 in the context 
of the G1/S phase transition are in bold.  
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Figure 3.10 RNA expression of 146 cell cycle-related genes that had ≥2 fold difference in expression between the BMT and PB 
samples. The colour range refers to the median normalised loge2 values across samples.  
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Table 3.5 Fold differences in expression of transcription factors without a clear 
cell-cycle role that were down-regulated in the PB compared to the BMT sample. 
Functions were determined from the NCBI database. 
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Table 3.6 Fold difference in expression between paired samples from the patient 
studied of differentially expressed genes identified in the study by Cheung et al 
(2009). 
 
Gene Function BMT  
vs BMA  
BMT  
vs PB  
BMA  
vs PB  
RASGEF1B G-protein signalling 1.61 2.41 1.49 
MCL1 Enhances cell survival by inhibiting 
apoptosis, while an alternatively sliced 
isoform promotes cell death 
1.14 2.34 2.05 
DUSP1 MAP kinase phosphatase 1.65 5.63 3.42 
ATF3 Transcription factor involved in stress 
response 
2.25 30.38 13.49 
FOSB AP-1 transcription factors 6.35 14.22 2.24 
RGS1 G-protein signalling 12.69 33.17 2.61 
KLF6 Kruppel-like transcription factor 0.66 3.47 5.26 
KLF4 Kruppel-like transcription factor 2.81 6.45 2.29 
RGCC 
(C13orf15) 
Regulates cell cycle progression 1.51 2.58 1.71 
 
 
PB samples still clustered separately from the BMT sample (Figure 3.11). Indeed, there 
were a number of genes for which the expression profiles between the BMT and the 
BMA/PB samples were distinctly different. There were 45 genes with a significant 
discrepancy between the BMT and the BMA/PB samples (>2-fold difference or with 
FPKM >5 for one tissue but absent from the others) (Table 3.7). This represents 34% 
of all genes in the signature. Of note, there were multiple genes with an apparently 
“stromal” role that formed part of this signature, including the previously mentioned 
COL1A1, as well as PMP22, which is related to myelin, and FBLN2, which is related 
to the extracellular matrix.  
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Figure 3.11 Gene expression in the BMT, BMA, and PB samples of the 133 genes in the prognostic-predictor signature defined by 
Bullinger et al. (2004). The colour range refers to the median normalised loge2 values across samples.  
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3.4 Discussion 
 
There are several reasons why the investigation of the cell cycle status of leukaemia 
cells from patients with AML is potentially important. As discussed in chapter 1, excess 
proliferation is a common feature of AML and there are well-established routes to 
dysregulation. Studies of the cell cycle may therefore inform on fundamental biological 
aspects of the disease. Furthermore, the main treatment regimen used to treat patients 
with AML contains two agents (daunorubicin and Ara-C) that exert their effect, at least 
in part, in a cell cycle-dependent way. In addition, many of the newer agents in early 
phase trials target key cycle proteins. Defining the cell cycle characteristics of disease 
may therefore inform as to why patients respond differently to current and future 
therapies. However, despite the large number of studies trying to link the cell cycle 
status to clinical outcome, results have been inconsistent and even contradictory. A 
possibility is that these discrepancies relate to the different techniques used for analysis 
and, perhaps more fundamentally, to the source of blast cells. This chapter investigated 
differences in cell cycle parameters according to the source of blast cells and assessed 
how these differences might impact on the results of biological and clinical studies. 
 
Although previous studies examining the relationship between cell cycle status or 
kinetics of cells obtained from patients with AML have consistently shown lower 
values for the proportion of cells in S phase or S/G2/M phase in PB than BMA samples, 
and for BMA than BMT samples, few studies have taken paired samples to show that 
in an individual patient the results from cells obtained from BMAs and from BMTs are 
discordant, and none have also looked at PB samples as well such that cell cycle status 
in all three ‘compartments’ may be compared. This question is fundamental to 
measuring the cell cycle in AML as BMA samples are variably haemodilute. This may 
in theory introduce artifact and an inaccurate representation of the activity in the 
marrow. 
  
The studies presented here used immunohistochemistry and immunocytochemistry to 
compare expression of cell cycle-related proteins in BMT, BMA and PB samples from 
eight patients with AML. This allowed direct comparison of results obtained from 
blasts from the different tissue compartments and the degree of variability and artifact 
introduced depending on the source of cells. Although a similar number of blasts from 
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BMT and PB samples were in-cycle as defined by MCM2 expression, other parameters 
measured were significantly different between the two. A median of 63% of the blasts 
from BMT samples were actively proliferating as defined by expression of MIB-1, and 
24% had progressed beyond G1 into S/G2/M as defined by expression of geminin. The 
respective figures for MIB-1 and geminin from PB cells were 4% and 1%, indicating 
that the majority of blasts in PB exist in a G1 arrested state and are not actively 
proliferating.  
 
Haemodilution of BMAs with these out-of-cycle PB-derived blasts means that cell 
cycle analysis using BMA samples are not accurately representing the true in vivo cell 
cycle parameters and may give an artificially low result for the number of cells actively 
cycling, and the numbers of cells that have progressed beyond G1. A key point is that 
although the geminin/MIB-1 ratio in an individual patient can be similar in the BMT 
and BMA samples, in some patients the levels are markedly different. For example, 
patient 4 had a presenting WCC of 2 x109/l and geminin/MIB-1 ratios of 0.08 and 0.07 
in the BMT and BMA samples respectively, indicating that the speed of cycling 
measured from these compartments was essentially the same. In contrast, in patient 8, 
who had a presenting WCC of 365 x109/l, the geminin/MIB-1 ratios were 0.59 and 0.15 
respectively, indicating that the speed of cycling determined when using cells from the 
BMA sample was almost 4-fold lower than the true value as measured using the BMT 
sample. It is also noteworthy that the values for geminin/MIB-1 ratios in the PB blasts 
were not correlated with those in BMT samples, and in some patients were markedly 
higher in the PB. For example, for patient 4, the geminin/MIB-1 ratio in the PB sample 
was 0.5, far higher than the levels of 0.09 and 0.07 found in the BMT and BMA samples. 
It is likely that this reflects the fact that only 2% of blasts in the PB were MIB-1 positive, 
with evaluation of so few events leading to a wide margin of error for the geminin 
results and subsequently the geminin/MIB-1 ratio.  
 
In work performed in conjunction with these studies (Sellar et al, 2016) it was predicted 
that, because of the larger number of cells in a given volume of PB, the impact of 
haemodilution and artificially low measured geminin/MIB-1 ratios, would be greatest 
in those patients with a higher WCC. Therefore, if using BMA samples, the measured 
proliferative drive may be paradoxically lower in those patients with the highest 
proliferative drive. In the cohort of patients studied in this thesis, patient 8 had the 
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highest WCC and also the second highest geminin/MIB-1 ratio in their BMT sample. 
However, they had the second lowest geminin/MIB-1 ratio in their BMA sample. This 
further highlights the inaccurate and discrepant results obtained when using BMAs. 
 
Importantly, the results of the quantitative analysis of S/G2/M cells as determined by 
IHC/ICC for geminin were highly correlated with results obtained by flow cytometry 
following staining with propidium iodide. This demonstrates that the results obtained 
from the cell cycle analysis are reproducible when different techniques are used. This 
correlation was seen in cells obtained from BMTs and not just BMAs and PB. 
Furthermore, as correlation does not necessarily imply equivalence, it is noteworthy 
that the results were also shown to be essentially equivalent by Bland-Altman analysis, 
a statistical technique that better assesses whether different methods of measurement 
give the same result. The cell cycle flow cytometry assay was designed to assess the 
overall percentage of cells in S/G2/M. This is the same population of cells that should 
be positive for geminin. However, it would be of interest to perform a more extensive 
analysis by assessing S/G2/M after gating on MIB-1 positive cells. This would allow 
comparison of the two techniques not only for the assessment of actively cycling cells 
but also for the proportion of actively cycling cells that have progressed beyond G1 as 
a surrogate for the speed of cell cycling.  
 
In aggregate, these results show that using leukaemic cells from BMAs does not give 
an accurate reflection of the cell cycle status of cells in the bone marrow. Studies that 
use such results, either in whole or as part of an equation, to define cell cycle status are 
therefore likely to be inaccurate. As such, variations between patients will depend not 
just on true differences in cell cycle status, but also on the level of haemodilution as 
dictated by WCC, aspirate volume, and quality of the samples. These data thus 
demonstrate that for accurate cell cycle analysis of cells from patients with AML, 
biopsies must be used. The studies also demonstrate that IHC/ICC can give equivalent 
results to flow cytometry, with the added advantage that is more suited to the use of 
archived tissue. 
 
This haemodilution of BMA samples with PB-derived G1 arrested blasts is likely to 
have an impact on other biological parameters. For example, gene expression profiling 
has been extensively studied in AML (Shivarov & Bullinger, 2014), but such studies 
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use PB and BMA samples to derive the results. To examine whether sample source is 
important, and to enable comparative analysis of cells with equivalent blast populations 
without the need for processing that could potentially alter gene expression, samples 
were obtained from a patient who had >90% blasts in their BMT, BMA, and PB. For 
each source of cells, RNA expression profiles were obtained from RNAseq data. 
Analysis was focused on “non-stromal genes” with FPKM values ≥20 in the PB and 
BMT samples and ≥2-fold difference between the PB and BMT values. Despite being 
a near pure blast population from the same patient, there were significant differences in 
profiles between the BMT and PB samples in expression of key cell cycle genes, 
including in genes that had already been demonstrated to be differentially expressed at 
the protein level by IHC/ICC. Furthermore, cluster analysis showed that the expression 
profiles for cell cycle-related genes was most similar between the BMA and PB samples. 
In addition, there were a number of genes that are not normally regarded as “cell-cycle” 
genes that were also differentially expressed, including key transcription factors. Again, 
the BMA and PB samples were more similar to each other than to the BMT sample. 
Although it is not possible to say that the cell populations were identical, small 
differences in cellular composition are unlikely to swamp the cell cycle signal of the 
predominant blast populations and account for the large differences seen between the 
samples.  
 
Differences in the “non cell cycle” gene groups may reflect true differences in 
expression between the different blast populations or, potentially, differences in the 
relative abundance of other cell types. For example, some lymphocyte genes were 
expressed at higher levels in PB than in the BMA or BMT samples (e.g. for CD3D, 
which is in the signature gene list derived by Bullinger et al (2004), the FPKM values 
were respectively 5.5, 4.1, and 1.6). This was one of the reasons for restricting the main 
analysis to the more highly expressed genes (FPKM ≥20 in both BMT and PB) on the 
basis that this should limit the impact of low abundance cells that nonetheless may have 
potentially large fold changes in their frequency. Furthermore, there were multiple 
genes with crucial roles in myeloid cell biology that were differentially expressed 
between the compartments (Table 3.5) that have been implicated as having biological 
or prognostic importance in AML. These include FOSB and JUN, which supports the 
finding of a previous study showing that these transcription factors had a higher 
expression in cells from BMAs than PB. JUN has recently been shown to be a key 
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regulator of the unfolded protein response in AML (Zhou et al, 2016). 
 
To further explore the impact of these differences on gene expression profiling, the 
FPKM values for this same patient were examined in the context of the signature of 
133 genes found to be predictive for clinical outcome by Bullinger et al (2004). Once 
again, the results from cells obtained from the BMA and PB were more closely aligned 
than the results from the BMT cells. When the gene list was examined for those genes 
that were most differentially expressed (Table 3.7) many of the genes with the biggest 
demonstrable differences could be seen to be to of questionable direct relevance to 
myeloid cells. Indeed, many were more related to lymphocyte biology e.g. IL6ST and 
CD3D, or stroma, e.g.COL1A1. 
 
A concern, therefore, is whether the predictive effects of this gene set, or of studies of 
individual genes, predominantly reflects differences in the samples used and the level 
of marrow contamination with peripheral blood blasts or lymphocytes. For some 
studies, cells from BMAs and PB have been used in the same set and used 
interchangeably. In fact, studies showing equivalence may be correct, but simply 
because, once the diagnostic BMA sample has been used for morphology, flow 
cytometry, cytogenetic, molecular analysis, and clinical trials, the remaining sample 
that is available for biobanking and subsequent expression profiling is so haemodilute 
that it is essentially PB-derived cells.  
 
Although superior in accuracy for cell cycle analysis, and presumably for cell cycle 
profile by gene expression profiling, there are several caveats before unequivocal 
advocacy of BMT samples for the latter analysis can be made. Firstly, although the 
results were clearly different between the BMT and BMA/PB cells in the patient studied 
here, they do represent only one patient. Further patients would need to be assessed to 
see whether samples cluster by patient, by source of cells, or by a combination of both 
these factors. However, a potential problem in assessing further patients is the relative 
ease of obtaining cells from BMTs and in sufficient numbers for reliable analysis. 
Obtaining relatively pure populations of cells is possible but would limit the number of 
cells, and it is not clear how such processing would affect RNA stability prior to RNA 
extraction and analysis. Nevertheless, future comparisons of paired samples would 
require equivalent numbers of blast cells from the different tissue sources in order to 
 119 
minimise the impact of different proportions of myeloid cells on the analysis.  
 
A further consideration is the potential impact of these cell cycle analyses for clinical 
studies. As described in the introduction, there are a number of agents that target cell 
cycle proteins that are in advanced stages of clinical trials. It is notable that two of these 
targets, PLK1 and Aurora kinase B, were amongst the genes with the most discrepant 
RNA expression levels (Table 3.4). This could mean that attempts to correlate 
expression with clinical response would be compromised. The same caveat exists for 
PIM1 and the inhibitors of PI3K. Both of these genes were differentially expressed 
between BMT and PB blasts, and these are important pathways in the development of 
novel therapeutics to treat AML. 
 
Finally, these studies suggest that circulating blasts will be less susceptible to treatment 
with cell-cycle phase specific agents such as Ara-C, the mainstay of current AML 
therapy. Nevertheless, by virtue of not having entered quiescence, these cells may be 
capable of rapid proliferation if they recirculate back to the BM. This is particularly 
relevant to the potential use of CXCR4 inhibitors to mobilise blast cells into the 
circulation prior to the administration of chemotherapy (Nervi et al, 2009).  
 
In summary, the data from this chapter demonstrate that the blasts from PB of AML 
patients exist in a G1-arrested state and, as a result of haemodilution, this leads to 
inaccurate information of the cell cycle status of bone marrow blasts as assessed by 
experiments performed on BMA samples. For accurate assessment of cell cycle state 
cells from BMTs must be used. These data have potential implications for biological 
studies of gene expression profiling, the design and assessment of efficacy of drug trials, 
the design of new therapies, and clinical studies of prognosis and risk stratification. 
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CHAPTER 4. DEFINING A COHORT OF PATIENTS WITH AML 
 
4.1 Introduction 
 
In Chapter 1 the main diagnostic and prognostic criteria for patients with AML were 
discussed, and these have contributed to the establishment of well-defined patient 
cohorts. Such cohorts are crucial to allow accurate comparisons of treatment 
approaches and new prognostic variables within trials and between trials to aid 
clinicians and patients. In addition to establishing cohorts in the context of clinical trials, 
‘real-world’ patient cohorts may be established from population registries (Derolf et al, 
2009). Cohort comparisons have consistently shown that the outcomes of patients under 
60 years of age have improved over time, whilst patients over 60 have seen little benefit. 
Furthermore, with the exception of patients with APL in whom the treatment approach 
has changed considerably, improvements have been modest and are an “aggregation of 
marginal gains”, with the greatest impact potentially seen from improved supportive 
care and transplant outcomes rather than novel treatment agents. 
 
The corollary of such well-defined cohorts with robust outcome data is that any study 
that seeks to make accurate statements about new treatments or new prognostic markers 
must use or establish a cohort that demonstrates demographic and outcome equivalence 
to published cohorts. In Chapter 3 it was shown that for accurate cell cycle analysis in 
patients with AML, biopsy samples must be used. The focus of the work presented in 
this chapter was to establish a cohort of patients with AML who had biopsies available 
for IHC analysis of DNA replication licensing proteins and cell cycle status. In order 
to allow interpretation of cell cycle dynamics in a useful clinical and biological context, 
the analysis set out to examine general equivalence of this cohort with large published 
cohorts in terms of the presenting genetic features, the robustness of prognostic factors, 
the response of patients to treatment, and overall patient outcomes.  
 
 
4.1.1 Required features of the cohort 
 
In chapter 1 the enduring importance of clinical features such as age, presenting WCC, 
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and cytogenetics in relation to clinical outcome was emphasised. For patients within 
the intermediate cytogenetic risk group, the mutation status of FLT3 and NPM1 are also 
of prognostic significance and need to be defined. 
 
 
4.1.2 FLT3  
 
FLT3 (Fms-like tyrosine kinase 3), also known as foetal liver kinase-2 (FLK-2) or stem 
cell kinase-1, is a 993 amino acid class III membrane-bound receptor tyrosine kinase 
encoded by a 24 exon gene located on chromosome 13 (13q12). FLT3 is expressed on 
the surface of normal HPCs within the BM, thymus and liver, as well as on the surface 
of more mature blood cells including monocytes, and has a crucial role in normal 
haematopoiesis. It is also expressed on the leukaemic cells from the majority of patients 
with AML and acute lymphoblastic leukaemia (ALL), and the blast crisis phase of 
chronic myeloid leukaemia (CML) (Stirewalt & Radich, 2003).  
 
 
4.1.2.1 Mutations in the juxtamembrane domain of FLT3 
 
In 1996, using RT-PCR, Nakao and colleagues identified unexpectedly long FLT3 
transcripts that were shown to result from a region of duplicated genomic DNA within 
the juxtamembrane (JM) domain encoded by exons 14 and 15, and called them FLT3 
internal tandem duplications (FLT3ITD) (Nakao et al, 1996). Subsequently, these 
duplications have been shown to be somatic, to range from 3 up to approximately 400bp 
and, as they are always multiples of 3bp, to remain in-frame. They disrupt the negative 
regulatory activity of the JM domain resulting in constitutive activation of the receptor 
and enhanced RAS, MAPK, and STAT5 signaling (Stirewalt & Radich, 2003). This 
alters the normal physiological role of FLT3 in cell proliferation, differentiation and 
survival.  
 
Screening of large cohorts of patients has demonstrated that FLT3ITD occur in 
approximately one quarter of cases of AML in young adults and up to a third of patients 
with cytogenetically normal AML (Table 4.1). However, the reported incidence varies 
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considerably, partly relating to heterogeneity in the age and cytogenetic status of the 
patients studied. In up to 23% of FLT3ITD patients more than one FLT3ITD may be 
present, and in some patients up to 5 have been reported (Kottaridis et al, 2003).  
 
 
4.1.2.2 Mutations in the tyrosine kinase domain of FLT3 
 
In up to 7% of de novo AML, missense point mutations have been detected leading to 
activating mutations affecting codons D835 and I836 in the second tyrosine kinase 
domain (TKD) (Abu-Duhier et al, 2001; Yamamoto et al, 2001). These mutations are 
thought to disrupt key amino acids that stabilise the activation loop in a closed 
configuration (Griffith et al, 2004). Although the exact significance of TKD point 
mutations has proved controversial, they appear to differ from FLT3ITD in that they are 
less potent in their transforming ability, less susceptible to tyrosine kinase inhibition 
with drugs, and have less clearly defined prognostic implications (Mead et al, 2008a; 
Mead et al, 2008b).  
 
 
4.1.2.3 Biological consequences of FLT3ITD 
 
FLT3ITD promotes ligand-independent dimerisation, auto-phosphorylation, and 
constitutive activation of the receptor, which promotes ligand-independent proliferation 
and, in model systems, a block of myeloid differentiation. In a mouse bone-marrow 
transplant model, the introduction of Flt3ITD induced a myeloproliferative phenotype 
without demonstrable leukaemia (Kelly et al, 2002). In a transgenic model, Flt3ITD 
under the control of a Vav promoter also resulted in a myeloproliferative disorder with 
long disease latency, but in some cases in B or T-lymphoid disease, again without a 
clear acute leukaemia phenotype (Lee et al, 2005). Nevertheless, the transforming 
potential of Flt3ITD is clear when combined with other genetic lesions. In mouse models, 
genetic lesions that result in 
 123 
 
 
Table 4.1 The major studies published on the impact of a FLT3ITD mutation on CR and OS rates for patients with AML. 
 
No. of 
patients 
Median Age, yrs 
(range) 
FLT3ITD 
(% of patients ) CR OS Reference 
201 49 (15-85) 23 NS Reduced (Kiyoi et al, 1999) 
106 Mean 41 (15-74) 13 NR Reduced (Abu-Duhier et al, 2000) 
854 41 (16-63) 27 NS Reduced (Kottaridis et al, 2001) 
140  67 (56-88) 29 NS NS (Stirewalt et al, 2001) 
224 41 (29)  30 NS Reduced (Frohling et al, 2002) 
979 NR 20 NS NS (Thiede et al, 2002) 
563 NR 22 NS NS (Schnittger et al, 2002) 
159 44 (15-65) 25 NS NS (Boissel et al, 2002) 
146 NR 19 NS Reduced (Moreno et al, 2003) 
234 NR (children) 12 Reduced Reduced (Zwaan et al, 2003) 
109 70 (60-90) 18 NS NS (Andersson et al, 2004) 
630 NR (0-21) 12 NS NS (Meshinchi et al, 2006) 
 
Abbreviations: CR, complete remission; NR, not reported; NS, not significant; OS, overall survival 
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more rapid transformation when combined with a Flt3ITD include PML-RARα (Sohal 
et al, 2003), NUP98-Hox (Palmqvist et al, 2006), AML1-ETO (Schessl et al, 2005), 
and MLL-ENL (Ono et al, 2005).  
 
Further evidence that FLT3ITD are often cooperating events in disease transformation 
or evolution rather than initiators of leukaemia comes from clinical studies. In many 
patients the mutant fraction is <25% at disease presentation. This suggests that fewer 
than half of the leukaemic cells in these patients are heterozygous for the mutation and, 
therefore, implies that the mutation is not present in the majority of the leukaemic cells, 
although an alternative explanation for lower mutant allele burden in some cases is the 
presence of contaminating non-leukaemic cells within the sample. Furthermore, 
FLT3ITD can be highly unstable and at relapse may be lost in up to 20% of patients, 
suggesting persistence of an earlier leukaemic clone lacking the FLTITD (Kottaridis et 
al, 2002). 
 
 
4.1.2.4 Detection of FLT3ITD 
 
Detection of FLT3ITD can be performed accurately, rapidly, and with minimal expense. 
PCR products can be generated using primers flanking exons 14 and 15 in which the 
majority of FLT3ITD occur, and the wild-type (FLT3WT) band and any larger band 
representing a mutant readily separated using agarose gel electrophoresis (Figure 4.1). 
However, as will be discussed in the later section on clinical outcome, the mutational 
burden (ratio of FLT3ITD to FLT3WT alleles or percentage of FLT3ITD) may be important 
to both clinical features and clinical outcome, and gel electrophoresis does not 
accurately provide this information. Instead, using a fluorescently-labelled primer, the 
labelled PCR products can be separated according to size using a capillary system 
fragment analyser and quantified, and hence the mutational burden relative to the 
smaller WT fragment can be established (Figure 4.2). 
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Figure 4.1 Analysis of FLT3 mutation status by PCR and agarose gel electrophoresis.  
Mutations (ITD) are seen as larger slower moving bands relative to the wild type (WT).  
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Figure 4.2 Analysis of FLT3 and NPM1 mutation status and mutation burden using fragment analysis.  
The larger fragments for the respective genes representing the mutant allele are indicated by an arrow. 
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4.1.2.5 Clinical characteristics of AML patients who have FLT3ITD 
 
Studies of the clinical features of patients with FLT3ITD have been generally consistent 
in showing an association with a high presenting WCC and higher percentage of blasts 
in marrow samples (Kottaridis et al, 2001). Studies of paediatric cohorts have generally 
shown a lower incidence of FLT3ITD than those seen in adult patients (Meshinchi et al, 
2006) (Table 4.1). 
 
Correlation with FAB subtypes has demonstrated that FLT3ITD are particularly common 
in patients with M3 (APL), more specifically the microgranular variant (M3v), as well 
as AMLs with a monocytic/monoblastic component (M4 and M5a). Some, but not all 
studies, have observed an increased frequency in patients with de novo AML compared 
to those with secondary AML arising as a transformation from myelodysplasia. In a 
recent study using strictly defined disease ontogeny, there was a trend towards an 
increased presence of FLT3ITD in de novo AML over secondary AML, although this 
was not statistically significant (Lindsley et al, 2015). In terms of cytogenetic risk 
groups, in addition to being found more commonly in patients with t(15;17), FLT3ITD 
are also more common in patients with t(6;9). With these notable exceptions, they are 
otherwise found at reduced frequency in patients with favourable and adverse 
cytogenetics, being significantly enriched in the intermediate risk cytogenetic risk 
group. 
 
 
4.1.2.6 Clinical outcome of patients with FLT3ITDAML 
 
Details of the major studies investigating the prognostic importance of FLT3ITD 
mutations in >100 non-APL AML patients are summarised in Table 4.1. Except in 
patients with APL, FLT3ITD are generally associated with poor prognosis and decreased 
OS (Kiyoi et al, 1999; Kottaridis et al, 2001; Frohling et al, 2002; Small, 2006), 
although not all studies have shown this (Stirewalt et al, 2001; Boissel et al, 2002; 
Schnittger et al, 2002; Thiede et al, 2002). Such discrepancies may relate to differences 
in ages between cohorts, treatment approach including rates of allogeneic transplant, 
mutation frequency and the relative mutant burden. Most studies have not shown 
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decreased CR rates but rather that inferior survival comes from the significantly 
increased CIR.  
 
In one study size (length) of FLT3ITD influenced survival, with longer FLT3ITD 
conferring a worse prognosis, although this has not been found in subsequent studies 
(Ponziani et al, 2006; Stirewalt et al, 2006; Gale et al, 2008). In addition to the low 
mutant levels (<25% of total FLT3 alleles) mentioned earlier, some patients have a 
mutant level greater than 50%, suggesting loss of the WT FLT3 allele. This occurs by 
uniparental disomy and is associated with a particularly poor outcome (Gale et al, 2008). 
In the study by Thiede and colleagues, although the OS was non-significant for FLT3ITD 
overall, for patients with higher mutant burden (greater than the median mutant:WT 
ratio of 0.78), there was a demonstrably inferior OS (Thiede et al, 2002). 
 
However, a potentially key confounding factor is that many of the earlier studies pre-
dated the discovery of mutations in the NPM1 gene (NPM1MUT), a mutation that is both 
positively correlated with FLT3ITD and has significant prognostic implications. 
 
 
4.1.3 Nucleophosmin 
 
Nucleophosmin (NPM1), encoded by the NPM1 gene localised at chromosome 5q35, 
is a nucleocytoplasmic shuttling protein that is normally most prominent in nucleoli. It 
has diverse proposed functions including acting as a molecular chaperone, a target of 
CDK2-cyclin E complexes in centrosome duplication, and involvement in the 
regulation of the p14ARF–p53 tumour suppressor pathway crucial to DNA repair and 
genomic stability (Grisendi et al, 2006). Overexpression of NPM1 has been found in 
several types of solid tumours, and the level of overexpression has been linked to stage, 
disease recurrence and progression (Grisendi et al, 2006). 
 
 
4.1.3.1 Mutations in NPM1 
 
In 2005, Falini and colleagues described abnormal cytoplasmic location of NPM1 in 
approximately a third of a cohort of patients with AML, with an even higher incidence 
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in patients with cytogentically normal AML (CN-AML) (Falini et al, 2005). In these 
patients they identified a number of mutations within exon 12 of the NPM1 gene, most 
commonly 4 bp insertions, with the most frequent of these (type A mutations) a 
duplication of the TCTG tetranucleotide at positions 956 through to 959. Other 
mutations (B-D) were also 4 bp insertions but of different nucleotide sequence. A 
further 2 mutations with a larger 9bp insertion (E and F) were also described. 
Regardless of the exact nature of the mutation, the consequence was to cause a 
frameshift in the C-terminal region of the protein. All six mutant proteins had alteration 
in at least one of the tryptophan residues at positions 288 and 290 and shared the same 
terminal amino acid sequence (VSLRK). Transfection experiments showed that the 
presence of this abnormal sequence correlated with abnormal protein localisation. In 
addition to leading to the loss of a nuclear localisation signal, Mariano and colleagues 
have subsequently shown that the new sequence of amino acids is a functional nuclear 
export signal (Mariano et al, 2006). 
 
Since this original description, almost 50 NPM1 mutation variants have been described, 
which are almost exclusively within exon 12. Further studies on larger cohorts of 
patients have consistently shown NPM1 mutations in approximately one third of 
patients, with rates of over 50% in NK AML, and with the overwhelming majority of 
mutations being of Type A. Intriguingly, mutation rates in childhood cohorts are 
consistently <10% and predominantly non-type A mutations (Cazzaniga et al, 2005; 
Brown et al, 2007; Hollink et al, 2009).  
 
 
4.1.3.2 Biological consequences of NPM1 mutations 
 
There are a number of proposed mechanisms by which the abnormal localisation of the 
mutated NPM1 protein may contribute to leukaemogenesis. These include a gain of 
function, with the relocated mutant NPM1 protein having increased interactions with 
cytoplasmic proteins and potential new interaction partners, or a loss of function as the 
result of absence from or decreased abundance in the nucleolus. WT NPM1 is also 
affected through the formation of heterodimers, with loss of WT protein to the 
cytoplasm. Experimental evidence of specific effects includes loss of activity of ARF 
and activation of c-MYC (den Besten et al, 2005; Colombo et al, 2006; Bonetti et al, 
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2008). Further in vitro studies have shown that mutant NPM1 can promote oncogenic 
transformation of primary cells in cooperation with E1A (Cheng et al, 2007).  
 
However, many of the insights into pathogenesis have come from animal models, and 
these support the suggestions that the disease-causing potential of these mutations 
results from both haploinsufficiency as well as a specific role for the mutated 
cytoplasmic form of NPM1. Npm1 knockout mice show increased levels of genomic 
instability and susceptibility to cancer, and haploinsufficient (Npm1 mutant/null) mice 
develop spontaneous tumours with a preponderance of myeloid malignancies 
(Sportoletti et al, 2008). Introduction of the mutation results in excess proliferation of 
myeloid cells in both murine and zebrafish models (Bolli et al, 2010; Cheng et al, 2010). 
In the mouse this was a myeloproliferative disorder, in contrast to the zebrafish where 
expansion of more primitive cells and progenitor cells was seen. Crucially, the 
introduction of mutant protein was insufficient to induce frank AML. There are 
numerous explanations for this including inability of sufficient follow–up, non-
pathophysiological levels of mutant to wild-type protein, protein expression in a 
myeloid precursor without the potential for transformation, or simply lack of requisite 
cooperating events. 
 
 
4.1.3.3 Detection of NPM1 mutations 
 
In the original report by Falini et al (2005), the presence of mutations was detected by 
immunohistochemistry (IHC), and confirmed by Sanger sequencing in a subset of 
patients. Whilst IHC remains a reliable way of detecting mutant NPM1 protein, it has 
largely been superseded by molecular analysis. For initial screening, fragment analysis 
can rapidly and reliably detect insertions causing size change in the PCR product 
(Thiede et al, 2006). Such a method does not discriminate type A mutations from rare 
variants, although there is no clear published evidence that such variants are clinically 
distinct in terms of prognosis. Other groups have used mutation-specific probes and 
melting curve analysis for screening, and these analyses are able to discriminate 
between type A, B, and D mutations (Schnittger et al, 2005). Such techniques have 
proved useful for screening large number of patients, with the potential for multiplexing 
in order to simultaneously screen for other genetic mutations such as FLT3ITD. These 
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techniques are also relatively sensitive in being able to reliably detect mutations down 
to mutant levels of approximately 5%. In practice, these levels of sensitivity are not 
required at diagnosis as NPM1MUT are usually heterozygous and found in all leukaemic 
cells of NPM1MUT AML, implying that they are early events in leukaemogenesis. 
 
In addition, NPM1MUT are one of the most stable mutations, being rarely lost at relapse, 
and only very occasionally found in remission. As such, NPM1 has been pursued as a 
potentially useful marker for minimal residual disease monitoring. In this scenario, 
techniques with a sensitivity of 5% are inadequate. Quantitative real time PCR 
techniques have been developed that may detect one abnormal cell in 100 000. The 
clinical feasibility and utility of such an approach has recently been demonstrated (Ivey 
et al, 2016). 
 
 
4.1.3.4 Presenting clinical features of NPM1MUT patients  
 
Falini et al (2005) described several clinical features of patients with AML containing 
the newly discovered NPM1 mutations, including an association with CN-AML, a high 
frequency of FLT3ITD, and the absence of CD34 and CD133 on blasts. Subsequent 
studies on large numbers of patients have broadly confirmed these findings and made 
additional observations, as summarised in Table 4.2. These features are deemed to be 
sufficiently distinct that AML with mutated NPM1 is a separate entity in the 2016 
revision of the WHO classification (Arber et al, 2016). 
 
 
4.1.3.5 Clinical outcome for patients with NPM1MUT 
 
A number of studies have investigated the role of NPM1MUT in the outcome of patients 
with AML (Table 4.3). The majority of these studies also take into consideration the 
impact of FLT3ITD. The studies are in general agreement that in younger adult patients, 
in contrast to FLT3ITD, NPM1MUT predict for 
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Table 4.2 Clinical and genetic features of patients with NPM1MUT AML. 
 
Presenting Clinical Features Higher incidence in females (in most but not all studies) 
 
High presenting WCC (independent of FLT3ITD) 
 
Associated with de novo AML, rare in sAML 
 
Close association with IR and especially CN-AML 
 
More often monocytic component (FAB type M4 or M5) 
 
Negative for CD34 in >90% of cases  
Genetic Features Mutually exclusive with t(8;21), t(16;16)/inv(16), and t(15;17) 
Generally mutually exclusive with CEBPA double mutants 
 
Heterozygous; early event in leukaemogenesis 
 
Stable at relapse 
 
Unique gene expression profile including increase in HOX genes 
 
Distinct microRNA profile (e.g. upregulation of miR-10a and miR-10b) 
Table adapted from (Falini et al, 2005) 
Abbreviations: IR, intermediate risk cytogenetics; CN, cytogenetically normal; sAML, secondary AML; WCC, presenting white cell count.  
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Table 4.3 Major studies published exploring the impact of NPM1 mutations on the outcome of patients with AML. 
No. of 
patients 
Disease type/ 
Treatment 
Median 
Age, yrs 
(range) 
NPM1MUT NPM1/FLT3 genotype      Main outcome findings Reference 
591 
 
De novo  
 
Not given 
(15-60) 
35% Not reported NPM1MUT an independent prognostic factor for better 
CR 
(Falini et al, 2005) 
300 NK  
Intensive 
 
Not given 
(16-60) 
48% 20% NPM1MUTFLT3ITD 
29% NPM1MUTFLT3WT 
13% NPM1WTFLT3ITD 
39% NPM1WTFLT3WT 
NPM1MUTFLT3WT genotype prognostic for improved 
CR, RFS, OS 
No difference between other genotypes 
No benefit for HSCT in NPM1MUTFLT3WT 
(Dohner et al, 2005) 
275 De novo 
Intensive 
44 (15-78) 35% 17% NPM1MUTFLT3ITD  NPM1MUT improved OS, EFS, and DFS independent of 
CGN, age and FLT3ITD 
(Verhaak et al, 2005) 
401 NK 
Intensive 
60 (17-82) 53% 21% NPM1MUTFLT3ITD  
31% NPM1MUTFLT3WT 
11% NPM1WTFLT3ITD 
34% NPM1WTFLT3WT 
 
NPM1MUT improved CR and EFS; trend for improved 
OS. Favourable impact lost with FLT3ITD 
Better EFS, RFS and OS in NPM1MUTFLT3WT 
No difference in outcome between NPM1WTFLT3ITD 
and NPM1MUTFLT3ITD 
(Schnittger et al, 2005) 
107 Intensive 
 
0-18 
(35% <5 
years) 
7% 
(27% of 
NK) 
1% NPM1MUTFLT3ITD  
6% NPM1MUTFLT3WT  
9% NPM1WTFLT3ITD  
84% NPM1WTFLT3WT  
All NPM1MUT patients achieved CR 
No deaths from disease at last follow-up, but short 
follow-up 
(Cazzaniga et al, 2005) 
257 All subtypes 
Intensive 
 (15-85) 25% 14% NPM1MUTFLT3ITD  
11% NPM1MUTFLT3WT 
9% NPM1WTFLT3ITD  
66% NPM1WTFLT3WT  
Impaired CR in NPM1MUT; no impact of FLT3ITD 
NPM1MUT associated with increased RR, no impact on 
OS 
Favourable impact of NPM1MUT in FLT3ITD 
(Suzuki et al, 2005)  
106 NK 
Intensive 
44 (15-65) 47% 18% NPM1MUTFLT3ITD  
29% NPM1MUTFLT3WT  
13% NPM1WTFLT3ITD  
40% NPM1WTFLT3WT  
CR not improved in NPM1MUT  
No difference in outcome for NPM1MUT vs NPM1WT 
FLT3ITD not prognostic for OS 
(Boissel et al, 2005) 
1485 De novo (82%) 
Intensive 
15-87 27% 
(46% of 
NK) 
11% NPM1MUTFLT3ITD  
16% NPM1MUTFLT3WT  
10% NPM1WTFLT3ITD  
63% NPM1WTFLT3WT  
 
Improved CR in NPM1MUT  
In multivariate analysis, NPM1MUT improved OS 
(Thiede et al, 2006) 
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Table 4.3 (continued) 
295 Intensive 
 
9.5 (0-
19.5) 
8% 
(20% of 
NK) 
3% NPM1MUTFLT3ITD  
5% NPM1MUTFLT3WT  
16% NPM1WTFLT3ITD  
76% NPM1WTFLT3WT  
No difference in EFS, or OS for NPM1MUT vs NPM1WT  
FLT3ITD had greater impact on outcome than 
NPM1MUT, predicting for inferior EFS, and OS. 
FLT3WT patients trend towards improved EFS in 
NPM1MUT, but no difference in OS. 
(Brown et al, 2007) 
1425 De novo  
Non-APL 
(92%) 
Intensive 
43 41% 
(62% of 
NK) 
17% NPM1MUTFLT3ITD  
24% NPM1MUTFLT3WT  
11% NPM1WTFLT3ITD  
47% NPM1WTFLT3WT  
 
Improved CR, RR, OS, with NPM1MUT 
NPM1WTFLT3WT and NPM1MUTFLT3ITD had 
intermediate prognosis 
No difference in CR but worse RR, DFS, OS with 
increasing FLT3ITD mutant levelFLT3ITD mutant level 
was the most significant factor for RR but increased 
RR even when low level 
(Gale et al, 2008) 
872* NK 
Intensive 
48 (16-60) 53% Not reported separately *not all patients had molecular analysis – n=570 for 
NPM1, n=531 for FLT3  
NPM1MUTFLT3WT associated with increased CR 
No benefit of HSCT in NPM1MUTFLT3WT 
(Schlenk et al, 2008) 
297 De novo 
(96%) 
Intensive 
10 8% 
(22% of 
NK) 
3% NPM1MUTFLT3ITD  
5% NPM1MUTFLT3WT  
14% NPM1WTFLT3ITD  
78% NPM1WTFLT3WT 
  
NPM1MUT improved EFS, not OS 
NPM1WTFLT3ITD inferior OS  
NPM1MUT borderline improved EFS and OS in NK 
 
(Hollink et al, 2009) 
1284 De novo  
Non-APL 
Intensive 
45 (16-59, 
n=520) 
 
 
 
66 (60-85, 
n=764) 
 
   
66% 
 
 
 
 
52% 
30% NPM1MUTFLT3ITD  
37% NPM1MUTFLT3WT  
7% NPM1WTFLT3ITD  
26% NPM1WTFLT3WT  
 
33% NPM1MUTFLT3ITD  
19% NPM1MUTFLT3WT  
8% NPM1WTFLT3ITD 
40% NPM1WTFLT3WT 
 
NPM1MUTFLT3WT increased CR, remission duration, 
RFS, and OS 
(Buchner et al, 2009) 
148 De novo 
NK 
Intensive 
≥ 60 56% 22% NPM1MUTFLT3ITD  
34% NPM1MUTFLT3WT  
9% NPM1WTFLT3ITD  
35% NPM1WTFLT3WT  
Overall and for patients ≥70 years, NPM1MUT predicted 
for increased CR, DFS, and OS. 
For patients 60-69 years, NPM1MUT had higher CR but 
not DFS or OS 
 
(Becker et al, 2010) 
Table 4.3 (continued) 
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219 NK 60-83 55% 24% NPM1MUTFLT3ITD  
31% NPM1MUTFLT3WT  
9% NPM1WTFLT3ITD  
36% NPM1WTFLT3WT 
FLT3ITD similar CR FLT3WT 
FLT3ITD shorter DFS/OS when adjusted for NPM1 
Impact of FLT3ITD seen for patients 60-69 but not ≥70 
yrs 
(Whitman et al, 2010) 
303 De Novo 
IR  
≤60 years 
 
53% 21% NPM1MUTFLT3ITD  
32% NPM1MUTFLT3WT  
10% NPM1WTFLT3ITD  
37% NPM1WTFLT3WT  
In NPM1MUT, low FLT3ITD burden (ratio <0.5) had 
similar RR, OS, and DFS to FLT3WT 
FLT3ITD ratios ≥0.5 had inferior RR, OS, and DFS 
(Pratcorona et al, 2013) 
1609 Intensive 46 45% Not reported separately NPM1MUT improved CR and OS; decreased CIR 
FLT3ITD (including low level) increased CIR 
(Linch et al, 2014) 
1312 Intensive 
 
 
 
 
Non-intensive 
 
68  
 
 
 
 
75  
21% 9% NPM1MUTFLT3ITD  
8% NPM1MUTFLT3WT  
13% NPM1WTFLT3ITD  
70% NPM1WTFLT3WT  
 
8% NPM1MUTFLT3ITD  
6% NPM1MUTFLT3WT  
11% NPM1WTFLT3ITD  
75% NPM1WTFLT3WT 
NPM1MUT but not ITDMUT predicted CR (intensive 
treated) 
NPM1 no effect on OS (intensive and non-intensive)  
NPM1MUTFLT3WT relapsed more slowly, improved OS  
 
(Lazenby et al, 2014) 
156 
(+1258)  
Intensive 60 (55-83) 33% 17% NPM1MUTFLT3WT 
(55-65) 
26% NPM1MUTFLT3WT 
(>65 years) 
NPM1MUTFLT3WT improved OS in patients 55-65 but 
not >65 yrs  
Results confirmed in large validation cohort (1258 
patients) 
(Ostronoff et al, 2015) 
301 Intensive 67 (60-85) 43% 28% NPM1MUTFLT3WT  NPM1MUTFLT3WT improved OS  (Dickson et al, 2016) 
 
Abbreviations: CIR, cumulative incidence relapse; CGN, cytogenetics; CR, complete remission; DFS, disease-free survival; EFS, event-free survival; 
FLT3ITD, FLT3 with internal tandem duplication; FLT3WT, FLT3 without internal tandem duplication; HSCT, haematopoietic stem cell transplant; IR, 
intermediate risk cytogenetics; NK, normal karyotype; NPM1MUT, NPM1 mutated; NPM1WT, NPM1 wild-type; OS, overall survival; RFS, relapse-free 
survival; RR, relapse risk. 
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chemosensitivity. Some studies have demonstrated a favourable impact of NPM1MUT 
on OS independent of FLT3ITD status, whereas others show favourable impact only in 
the absence of FLT3ITD. Studies showing no impact, limited impact, or even a negative 
impact of NPM1MUT contain far fewer patients. In the largest study of intensively 
treated younger adults, those with NPM1MUT in the absence of FLT3ITD had the best 
outcome, those with NPM1WTFLT3ITD the worst outcome, and patients who were 
NPM1MUTFLT3ITD or NPM1WTFLT3WT had an intermediate prognosis (Gale et al, 
2008).  
 
The impact of an NPM1MUT in children and teenage and young adult patients appears 
less marked. In older patients, there are conflicting results as to which subpopulations 
of the elderly derive particular benefit, with one study suggesting no benefit for 
those >65 years (Ostronoff et al, 2015) and another only benefit for those >70 years 
(Becker et al, 2010). 
 
 
4.1.3.6 Impact of additional cytogenetic lesions in NPM1MUTAML 
 
In a study of 631 patients with NPM1MUT, cytogenetic lesions were found in almost 
15%, with the most frequent chromosomal abnormalities including gain of 
chromosomes 4, 8, or 21 and loss of chromosome Y or the long arm of chromosome 9 
(Haferlach et al, 2009).  The presence of such chromosomal abnormalities did not 
appear to alter immunophenotype, gene expression profile, or clinical outcome. 
 
 
4.1.4 Aims of chapter 
 
The aims of this chapter were: 
1. To identify a cohort of patients with AML with pre-treatment biopsy samples available 
for subsequent IHC analysis of DNA replication licensing proteins and cell cycle status. 
2. To define the major prognostic demographic features of this patient cohort, including 
the cytogenetic, FLT3ITD, and NPM1MUT status. 
3. To define the response to treatment of this cohort. 
4. To compare the demographic and outcome data with previously established published 
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cohorts, with a focus on the UK MRC trials. 
 
 
4.2 Patients and methods 
 
4.2.1 Identification of patients 
 
Local research ethics approval for the study was obtained from the Joint UCL/UCLH 
Committees on the Ethics of Human Research. Hospital records were reviewed to 
identify all new cases of AML who presented to UCLH between 1st January 2003 and 
December 31st 2011. Sources of information included histopathology departmental 
coding, haematology bone marrow aspirate report logs, pharmacy records, clinic lists, 
death and discharge summaries, and referrals for allogeneic transplant (HSCT). 
Pathology records were reviewed to determine patients that had had a diagnostic BMT 
prior to induction therapy. Patient electronic and paper records were reviewed to define 
patient demographics including age, sex, presenting WCC, cytogenetics, FAB type, and 
whether the AML was de novo, secondary to a previous haematological disorder 
(sAML), or therapy-related (tAML).   
 
Details of treatment and outcome were collected. This included information on 
induction therapy received, induction death, achievement of CR, consolidation or 
salvage treatment, treatment with HSCT, time to relapse, DFS, and OS. CR was defined 
as a normocellular BM containing <5% blasts and showing evidence of normal 
maturation of other BM elements and with a PB neutrophil count of ≥1 x 109/l and a 
platelet count of ≥100 x 109/l. One patient achieved BM remission with incomplete 
count recovery but was counted as achieving CR for the purposes of analysis. 
Remission failures were classified as partial remission (PR, defined as 5%-15% blasts 
or <5% blasts but with a hypocellular BM), resistant disease (RD, >15% blasts in the 
BM) or induction death (ID, i.e., related to treatment or hypoplasia). Where evaluation 
was not possible, deaths within 30 days of entry were classified as ID and deaths later 
than 30 days after entry as RD. OS was defined as the time from diagnosis to death. For 
patients achieving CR, DFS was the time from the date of first CR to an event (death 
in first CR or relapse). Patients who died in remission, for example following HSCT, 
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were classified as having non-relapse mortality (NRM).  Data was censored at death or 
last follow-up prior to 1st August 2014. 
 
 
4.2.2. Treatment received 
 
Some patients received treatment as part of one of four national clinical trials that were 
recruiting during the period of study, AML15 and AML17 for younger adults, and 
AML14 and AML16 for older adults. The main treatment regimens used in the trials 
are described in supplementary tables 1 and 2, and examples of clinical trial protocols 
in supplementary figures 1, 2, and 3. 
 
The AML15 trial recruited 3484 patients, predominantly <60 years of age, between 
May 2002 and January 2009. The trial was subdivided into the non-APL arm (n=3106) 
and the APL arm (n=378). In the non-APL arm, a main focus was to compare the 
induction regimens ADE (Ara-C, daunorubin, etoposide), DA (daunorubicin, Ara-C) 
and FLAG-Ida (fludarabine, Ara-C, G-CSF, and idarubicin). In addition, patients who 
had FLT3ITD at diagnosis were randomised to recieve, or not, a FLT3 inhibitor 
(lestaurtinib) after each course of the allocated induction and consolidation 
chemotherapy. Patients could also be randomised to receive Gemtuzumab ozogamicin 
(GO). Another key question was the role of HSCT in intermediate-risk patients. For 
patients with APL, the trial assessed the ‘MRC approach’ of anthracycline plus Ara-C 
in combination with ATRA (All-trans-retinoic acid) with the ‘Spanish approach’ that 
omits Ara-C but has 24 months of ATRA maintenance. 
 
The AML17 trial initially randomised between DA and ADE and between 2 different 
doses of GO (3mg/m2 vs 6mg/m2). However, following the demonstration of superiority 
of 90mg/m2 of daunorubicin over lower doses (45mg/m2) (Fernandez et al, 2009), a 
new randomisation for induction was adopted. This was between DA90 (90mg/m2 
daunorubicin) and DA60 (60mg/m2 daunorubicin). After course 1, patients were 
defined by risk of relapse using a validated score (see Table 1.7) based on age, 
presenting WCC and presence of secondary disease in order to guide whether treatment 
should be escalated to FLAG-Ida or DClo (daunorubicin and clofarabine), followed by 
HSCT. In addition, patients with CBF-AML received GO, patients with a FLT3 
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mutation were eligible for lestaurtinib versus placebo randomisation, and non-poor risk 
patients without CBF-AML or on the lestaurtinib randomisation were eligible for an 
everolimus versus placebo randomisation. For patients with APL, one of the main 
focuses of the trial was a randomisation between idarubicin + ATRA versus ATRA + 
ATO (arsenic trioxide). 
 
The AML14 trial recruited 1593 older patients with AML or high-risk myelodysplasia 
(MDS) between December 1998 and March 2006 and had both intensive and non-
intensive treatment approaches. In the intensive arm, there were two main 
randomisation questions in the context of induction treatment with DAT chemotherapy 
(daunorubicin, Ara-C, thioguanine): firstly, to compare a daunorubicin dose of 
35mg/m2 (DAT35) with 50mg/m2 (DAT50), and secondly to evaluate an increased daily 
dose of Ara-C (200mg/m2 compared to 400mg/m2). In addition, patients receiving the 
DAT35 option could be randomised to receive the cyclosporin analogue and p-
glycoprotein inhibitor PSC-833, a drug that delays the excretion of daunorubicin. The 
non-intensive arm of the trial initially compared LDAC (low dose Ara-C) with or 
without ATRA with best supportive therapy. This approach ended prematurely as 
survival was significantly better in the LDAC-treated cohort. Between June 2004 and 
March 2006, 108 patients were recruited to the non-intensive arm and randomised 
between LDAC and LDAC, with the addition of 5mg of GO on day one of each course.  
 
The AML16 trial also had both intensive and non-intensive arms. In the intensive part 
of the study, patients were randomised between induction with DA50 or DClo, with a 
further GO randomisation available in both arms. For patients who were in remission 
after 2 cycles of induction treatment, there was an option for randomisation between no 
treatment or a further cycle of DA. Following this, patients could undergo a reduced-
intensity HSCT or could be further randomised between no further therapy or 
demethylation treatment with azacytidine. The non-intensive arm of the trial followed 
a ‘pick-a-winner’ format (Hills & Burnett, 2011) where LDAC treatment had a GO 
randomisation but also a number of other agents including ATO, clofarabine, and the 
farnesyltransferase inhibitor tipifarnib. 
 
For patients who were not enrolled onto one of the national clinical trials, the general 
intensive approach was remission induction using DA50 followed by a further cycle of 
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DA50 for patients achieving response, and for patients not proceeding to allogeneic 
transplant, consolidation cycles of MACE (amsacrine, Ara-C, etoposide) and MidAC 
(mitoxantrone, Ara-C), or high dose Ara-C (1.5g/m2). For patients receiving non-
intensive treatment, the general approach was LDAC with GO where supply of the drug 
permitted. 
 
Where donor availability permitted, patients with relapsed disease, high-risk disease 
according to AML17 score, high risk-cytogenetics, or intermediate-risk cytogenetics in 
the absence of an isolated NPM1 mutation proceeded to HSCT. In general, patients 
aged ≤40 years received myeloablative conditioning with cyclophosphamide and total 
body irradiation (Cy/TBI) for sibling donors, and with the addition of fludarabine 
(Flu/Cy/TBI) where the donor was matched-unrelated (MUD) or mismatched-unrelated 
(MMUD). A T-deplete strategy was used with alemtuzumab in the stem cell product 
prior to infusion. For most patients >40 years or with comorbidity, a reduced-intensity 
approach using fludarabine, melphalan and in vivo alemtuzumab was used.  
 
 
4.2.3 Molecular analysis 
 
Molecular analysis was performed on DNA extracted from diagnostic samples 
extracted as described in chapter 2. 
 
 
4.2.3.1 Screening and quantification of FLT3ITD 
 
Patient mutational status for FLT3 (FLT3ITD vs FLT3WT) was determined by PCR 
amplification of the juxtamembrane domain of FLT3 using sequence-specific forward 
and reverse primers as described in chapter 2. The primer sequences and annealing 
temperature are shown in Table 4.4. The larger PCR product of a FLT3ITD was seen as 
a slower moving band (Figure 4.1), and all patient samples with such a band or bands 
were scored as FLT3ITD positive. 
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Table 4.4 Primers and annealing temperatures used to assess NPM1MUT and FLT3ITD status and percentage mutant alleles. 
 
Exon/Domain Primer Sequence Annealing 
temperature (oC) 
FLT3 exons 14 and 15 
(including intervening 
intron) 
FLT3ex11/F 
 
FLT3ex12/R 
5’-GCAATTTAGGTATGAAAGCCAGC-3’ 
5’-CTTTCAGCATTTTGACGGCAACC- 3’ 
 
62 
FLT3 exons 14 and 15 
(including intervening 
intron) 
FLT3ex11/F 
 
FLT3ex12/R* 
5’-GCAATTTAGGTATGAAAGCCAGC-3’ 
5’-CTTTCAGCATTTTGACGGCAACC- 3’ 
 
62 
NPM1 exon 12 NPMex12/F 
 
NPMex12/R* 
5’ -CTTAACCACATTTCTTTTTTTTTTTTTCCAG- 3’ 
 
5’ -GGACAACATTTATCAAACACGGTAG- 3’ 
62 
* indicates fluorescently-labelled primer 
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For quantification of FLT3ITD mutant level or where DNA sample quality was poor, 
PCR amplification was carried out as before except using a fluorescently-labelled 
forward primer, 25 cycles of PCR, and analysed using the CEQTM 8000 Genetic 
Analysis System as described in chapter 2. The primer sequences and annealing 
temperature are shown in Table 4.4. A representative analysis is shown in Figure 4.2. 
 
 
4.2.3.2 Screening and quantification of NPM1 mutations 
 
The presence of an NPM1 mutation was determined by amplification of NPM1 exon 12 
using sequence-specific primers with a fluorescently-labelled reverse primer (Table 
4.4), and 28 cycles of PCR, and analysed using the CEQTM 8000 Genetic Analysis 
System as described in chapter 2. A representative analysis is shown in Figure 4.2. 
 
 
4.2.4 Statistical analysis 
 
The comparison of continuous variables between 2 groups was performed using the 
Mann-Whitney U test. The comparison of continuous variables across multiple groups 
was performed using the Kruskal-Wallis test. Contingency data between 2 groups was 
assessed using either the Chi-square or Fisher’s exact test as appropriate. Where a trend 
was being assessed over multiple groups, the Chi-square test for trend was employed. 
Correlation was assessed using Spearman’s rank correlation coefficient. OS and DFS 
were assessed using the method of Kaplan-Meier, and the difference between groups 
by the log-rank (Mantel-Cox) test. All tests were two-tailed. All the above statistics 
were performed using Graphpad Prism version 6 (GraphPad Software, Inc., California, 
USA). Multivariate analysis was performed using multinomial logistic regression and 
SPSS version 22 (IBM, New York, USA). The values for CIR and NRM were 
calculated using the competing risks method (Scrucca et al, 2007) using ‘R’ version 
3.2.1 (www.r-project.org/). A P value <0.5 was considered statistically significant. 
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4.3 Results  
 
4.3.1 Characteristics of patient cohort 
 
In total, 202 patients with a new diagnosis of AML made between January 2003 and 
December 2011, and in whom trephine biopsies were taken prior to treatment, were 
identified. In 15 cases the sample block could not be located in the tissue archive.  A 
further six patients were subsequently excluded either because there was inadequate 
material for further IHC (n=5), or because of a coincident infiltration with a B-cell 
malignancy, leaving a total cohort of 181 patients. The number of patients accrued per 
year of the study is shown in Figure 4.3. Fifteen patients (8%) had APL and 166 had 
other forms of AML. There was a trend towards patients with APL being younger; 
median age 44 years vs 56 years in the non-APL patients (P=0.07). The frequency of 
APL and other cytogenetic subtypes in the 94 patients aged <60 years with available 
cytogenetic data was broadly similar to the frequencies seen in the large MRC data set 
of younger adults (Table 4.5), the main difference being an increase in patients with 
adverse cytogenetics (20% vs 10%) and a decrease in those with an intermediate-risk 
abnormal karyotype (7% vs 25%). 
 
The main demographic features for the non-APL patients are shown in Table 4.6. Just 
over half of the patients (57%) were aged <60 years. There was no difference in sex 
distribution between the older (≥60 years) and younger cohorts. Patients in the younger 
cohort were more likely to have de novo disease and a significantly higher presenting 
WCC (median 22.5 vs 9 x 109/l respectively, P=0.04). Even excluding the APL patients, 
there were fewer patients with favourable-risk cytogenetics in the older cohort (4% vs 
16%, P=0.03), and a trend towards a greater number of patients with failed cytogenetics 
(22% vs 11%, P=0.05). 
 
The main demographic features for the APL patients are shown in Table 4.7. As 
indicated above, there was a trend towards younger patients in the APL cohort, with 12 
(80%) aged <60 years at diagnosis. One patient had secondary disease following 
chemotherapy for a prior malignancy.  
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Figure 4.3 The number of patients identified with suitable bone marrow biopsy samples available for further analysis, grouped by 
year of diagnosis.  
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Table 4.5 Comparison between frequency of cytogenetic lesions in the MRC cohort and the UCLH cohort with available cytogenetic 
data.  
 
Risk group  
 
Refined MRC 
classification* 
 
Proportion of 
patients in MRC 
cohort 
(n=5876) 
Proportion of all 
patients in UCLH 
cohort 
(n=151) 
Proportion of 
patients <60 years 
in UCLH cohort 
(n=94) 
Proportion of 
patients ≥60 years 
in UCLH cohort 
(n=57) 
Favourable 	 t(15;17) 
 
t(8;21) 
 
inv(16) or t(16;16) 
12% 
 
8% 
 
3% 
10% 
 
5% 
 
5% 
13% 
 
7% 
 
6% 
5% 
 
2% 
 
2% 
Intermediate Normal Karyotype 
 
Other non-complex 
42% 
 
25% 
48% 
 
13% 
45% 
 
7% 
51% 
 
23% 
Adverse  10% 19% 20% 18% 
*Classified according to (Grimwade et al, 2010) 
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Table 4.6 Presenting features of patients with non-APL AML 
 All patients <60 years ≥60 years P 
No. patients (%) 166 (100) 94 (57) 72 (43)  
Median age, years (range) 56 (13-86) 41.5 (13-59) 69 (60-86)  
Sex, (%) 
Male 
Female 
 
90 (54) 
76 (46) 
 
47 (50) 
47 (50) 
 
43 (60) 
29 (40) 
0.27 
Type of AML (%) 
De Novo 
Secondary 
Therapy-related 
 
136 (82) 
19 (11) 
11 (7) 
 
83 (88) 
4 (4) 
7 (7) 
 
53 (74) 
15 (21) 
4 (6) 
0.02 (de novo vs sAML/tAML) 
 
Median WCC x 109/l (range) 17 (0-385) 22.5 (0-385) 9 (1-301) 0.04 
FAB type, no. (%) 
     M0 
     M1 
     M2 
     M4 
     M5 
     M6 
     M7 
     Unknown 
 
12 (7) 
39 (23) 
65 (39) 
17 (10) 
25 (15) 
2 (1) 
1 (<1) 
5 (3) 
 
6 (6) 
26 (28) 
35 (37) 
11 (14) 
12 (13) 
1 (1) 
1 (1) 
2 (2) 
 
6 (8) 
13 (18) 
30 (42) 
6 (8) 
13 (18) 
1 (1) 
0 (0) 
3 (4) 
 
 
 
 
 
 
 
 
NS for all 
Cytogenetics (% all/known) 
     Favourable 
     Intermediate 
         NK 
     Adverse 
     Failed 
     Unknown 
 
15      (9 /11) 
92      (55/68) 
76      (46/56) 
29      (17/21) 
30         (16/-) 
4          (2/-) 
 
13       (14/16) 
50       (53/61) 
43       (46/52) 
19       (20/23) 
10          (11/-) 
2          (2/-) 
 
2          (3 /4) 
42      (58/78) 
29      (39/54) 
10      (14/19) 
16        (22/-) 
2        (3/-) 
 
0.03 
0.06 
0.99 
0.67 
0.05 
0.99 
Abbreviations: NK, normal karyotype; sAML, secondary AML; tAML; treatment-related AML 
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Table 4.7 Presenting features of patients with APL 
 
 All patients Patients <60 
years 
Patients ≥60 
years 
Number (%) 15 (100) 12 (80) 3 (20) 
Median age, years 
(range) 
44 (16-70) 42 (15-66) 64 (64-70) 
Median WCC x 109/l 
(range) 
3 (0-99) 4.5 (0-99) 2 (1-4) 
Sex (%) 
Male 
Female 
 
8 (53) 
7 (47) 
 
6 (50) 
6 (50) 
 
2 (67) 
1 (33) 
Type of AML (%) 
De Novo 
Secondary/Treatment 
 
14 (93) 
1 (7) 
 
11 (92) 
1 (8) 
 
3 (100) 
0 (3) 
 
 148 
4.3.2 Presenting features according to cytogenetic risk group in non-APL patients 
 
The presenting clinical features according to cytogenetic risk group are shown in Table 
4.8. Patients with favourable-risk cytogenetics had the youngest median age (44 years), 
followed by patients in the adverse, intermediate, and failed/unknown cytogenetic 
groups (52, 57, and 62.5 years respectively, P=0.03, Kruskal-Wallis test across all 
groups). This remained significant when patients with failed/unknown cytogenetics 
were excluded (P=0.03). The intermediate-risk group had the highest presenting WCC 
(median 28 x 109/l), followed by the favourable, adverse, and failed/unknown groups 
(medians 21, 11, and 2.5 x 109/l respectively, P=0.008). However, when the 
failed/unknown group was excluded there was no significant difference across the 
favourable, intermediate, and adverse groups (P=0.13). The adverse-risk group had a 
greater proportion of male patients (72%), but this did not reach statistical significance 
when compared to the proportions seen in the other cytogenetic risk groups (P=0.06). 
There were no patients with secondary AML in the favourable group compared with 
10%, 14%, and 20% in the intermediate, adverse, and failed/unknown groups 
respectively, but this did not reach statistical significance. 
 
4.3.3 Presenting features according to molecular risk group in the non-APL cohort 
 
FLT3ITD status was available in 151 non-APL patients. Thirty-one (21%) had a FLT3ITD, 
with the majority of these (n=18, 58%) having a intermediate mutant level (25-50%) 
(Table 4.9). However, there was a broad range of mutant levels suggesting that there 
were patients with minor clones with heterozygous mutations (i.e. <25% mutant) 
(although sample impurity cannot be excluded), as well as patients with >50% 
mutational burden indicative of homozygous mutations in at least some of the cells 
(Figure 4.4). The median FLT3ITD burden was 37% (range 5-93%). The frequency of 
FLT3ITD patients in the FLT3ITD-LOW, FLT3ITD-INT, and FLT3ITD-HIGH groups were 23%, 
58%, and 19% respectively (Table 4.9). The equivalent figures for an, albeit younger, 
population of patients from the MRC trials were 29%, 56% and 15% (Gale et al, 2008). 
Thus, the general distribution of FLT3ITD burden seen in the UCLH cohort, with the 
greatest number of patients having a mutant burden of 25-50%, was consistent with 
other studies. 
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Figure 4.4 The total FLT3ITD mutant allele level in 31 FLT3ITD patients. 
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Table 4.8 Presenting clinical features according to cytogenetic risk group in non-APL patients 
 
 Favourable 
(non-APL) 
Intermediate Adverse Failed/unknown P 
Number 
(% total/known) 
15 (9/11) 92 (55/68) 29 (17/21) 30 (18)  
Median age, years 
(range) 
44 (16-64) 57 (13-86) 52 (13-81) 62.5 (18-83) 0.03 
(0.03 excluding 
failed/unknown cases) 
Sex (%) 
   Female 
   Male 
 
6 (40) 
9 (60) 
 
44 (48) 
48 (52) 
 
8 (28) 
21 (72) 
 
15 (50) 
15 (50) 
 
 
NS for all 
Median WCC x 109/l 
(range) 
21 (3-47) 28 (1-385) 11 (0-346) 2.5 (1-205) 0.008 
(0.13 excluding failed 
/unknown cases) 
AML type (%) 
   De novo 
   Secondary 
   Treatment 
 
13 (87) 
0   (0) 
2   (13) 
 
80   (87) 
9     (10) 
3      (3) 
 
21  (72) 
4     (14) 
4     (14) 
 
22   (73) 
6     (20) 
2      (7) 
 
 
 
NS for all 
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Table 4.9 Presenting features in the patients with non-APL disease and known FLT3ITD status 
 Total (%) FLT3WT (%) FLT3ITD (%) P 
 
FLT3ITD-LOW 
(%) 
 
FLT3ITD-INT 
(%) 
FLT3ITD-HIGH (%) P 
Total (%) 151 (100) 120 (79) 31 (21)  7 (5) 18 (12) 6 (4)  
Type of AML (%)  
De Novo 
Secondary 
Treatment 
 
125 (83) 
17 (11) 
9 (6) 
 
96 (80) 
15 (13) 
9 (8) 
 
29 (94) 
2 (6) 
0 (0) 
 
 
 
0.11 
 
6 (86) 
1 (14) 
0 (0) 
 
17 (94) 
1 (6) 
0 (0) 
 
6 (100) 
0 (0) 
0 (0) 
0.29 
FAB type (%) 
M0 
M1 
M2 
M4 
M5 
M6 
M7 
Unknown 
 
11 (7) 
38 (25) 
62 (41) 
15 (10) 
20 (13) 
2 (1) 
0 (0) 
2 (1) 
 
10 (8) 
22 (18) 
56 (47) 
10 (8) 
17 (14) 
2 (2) 
1 (1) 
2 (2) 
 
1 (3) 
16 (52) 
6 (19) 
5 (16) 
4 (13) 
0 (0) 
0 (0) 
0 (0) 
 
0.46 
0.0005 
0.007 
0.31 
0.99 
0.99 
0.99 
0.99 
 
0 (0) 
2 (29) 
3 (43) 
2 (29) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
 
1 (6) 
11 (61) 
3 (17) 
1 (6) 
2 (11) 
0 (0) 
0 (0) 
0 (0) 
 
0 (0) 
3 (50) 
0 (0) 
2 (33) 
1 (17) 
0 (0) 
0 (0) 
0 (0) 
 
0.96 
0.4 
0.05 
0.9 
0.3 
0.99 
0.99 
0.99 
Sex (%) 
Female 
Male 
 
70 (46) 
81 (54) 
 
54 (45) 
66 (55) 
 
16 (52) 
15 (48) 
 
 
0.55 
 
5 (71) 
2 (29) 
 
9 (50) 
9 (50) 
 
2 (33) 
4 (67) 
 
0.17 
Median age, years (range) 56 
(13-86) 
57 
(13-86) 
54 
(13-81) 
0.46 58 
(20-81) 
54 
(13-73) 
53 
(14-61) 
0.6 
Median WCCx109/l (range) 17 (0-385) 12 (0-346) 58 (2-385) <0.0001 23 (2-180) 62.5 (8-231) 103.5 (35-385) 0.12 
Cytogenetics 
(% all/known) 
Favourable 
Intermediate 
     Normal 
Adverse 
Failed 
Unknown 
 
 
14 (9/11) 
85 (56/66) 
69 (46/54) 
25 (17/20) 
24 (16/-) 
3 (2/-) 
 
 
12 (10/12) 
60 (50/61) 
46 (38/46) 
23 (19/23) 
22 (18/-) 
3 (3/-) 
 
 
2 (6/7) 
25 (81/86) 
23 (74/79) 
2 (6/7) 
2 (6/-) 
0 (0/-) 
 
 
0.74 
0.01 
0.003 
0.06 
0.17 
0.99 
 
 
1 (14/17) 
5 (71/83) 
3 (43/50) 
0 (0/0) 
1 (14/-) 
0 (0/-) 
 
 
1 (6/6) 
15 (83/83) 
15 (83/83) 
1 (6/6) 
1 (6/-) 
0 (0/-) 
 
 
0 (0/0) 
5 (83/83) 
5 (83/83) 
1 (17/17) 
0 (0/-) 
0 (0/-) 
 
 
 
 
 
 
NS 
for all 
Abbreviations: FLT3ITD-LOW, <25% mutant alleles; FLT3ITD-INT, 25-50% mutant alleles; FLT3ITD-HIGH, >50% mutant alleles; NS, non-
significant.
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The frequency of FLT3ITD in the intermediate karyotype group was 30%. A higher 
percentage of FLT3ITD compared to FLT3WT patients had an intermediate karyotype (86% 
vs 61%, P=0.01) and normal karytoype (NK) (79% vs 46%, P=0.003), and a non-
statistically significant decrease in sAML/tAML. They also had a higher presenting 
WCC, with a relative increase in WCC with mutational burden (r=0.4, 95% CI 0.05-
0.67, P=0.025) (Figure 4.5). FLT3ITD patients were also more likely than FLT3WT 
patients to be FAB type M1 (52% vs 18%, P=0.0005) and less likely to be M2 subtype 
(19% vs 47%, P=0.007). There was no difference in age or sex distribution. Many of 
these presenting features have been demonstrated in large published cohorts. These 
include the negative association with M2 FAB type (Thiede et al, 2002) and the positive 
association with intermediate-risk and NK cytogenetics, and increased WCC 
(Kottaridis et al, 2001; Gale et al, 2008).   
 
A total of 49 of the 150 patients non-APL patients in whom NPM1 status was available 
(33%) had NPM1MUT, and this proportion rose to 49% and 58% respectively when only 
the intermediate karyotype or NK patients were considered (Table 4.10). In fact, only 
2 patients with known karyotype and NPM1MUT were not in the intermediate risk group. 
The percentage of patients with NPM1MUT in the cohort overall, and in the intermediate 
and NK cytogenetic groups, were broadly in keeping with the large published cohorts. 
For example, in the MRC cohort (Gale et al, 2008) the proportion of patients with 
NPM1MUT overall, in the intermediate and NK groups was 41%, 51%, and 62% 
respectively.  
 
Patients with NPM1MUT were less likely to have M2 FAB type compared to NPM1WT 
(29% vs 48%, P=0.02), with a non-significant increase in M1 (33% vs 21%, P=0.16) 
and M4 (14% vs 8%, P=0.26), and a significant increase in M5 (22% vs 9%, P=0.04). 
NPM1MUT patients were more likely to have de novo than secondary or treatment-
related AML than NPM1WT patients (P=0.04). Although there were more females than 
males with an NPM1 mutation, overall (55% vs 45%), this did not reach statistical 
significance. There was no difference in age between NPM1WT and NPM1MUT patients, 
but the latter had a significantly higher presenting WCC, median 54 vs 8 x 109/l 
(P<0.0001). In contrast to FLT3ITD, the mutant burden was far less variable (Figure 
4.6A), with a median of 46% (range, 19-54%), in keeping with the majority of cells 
being heterozygous for the mutation. In fact, only 4% of patients
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Figure 4.5 Correlation between FLT3ITD burden and presenting WCC in 31 FLT3ITD patients. 
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Table 4.10 Presenting features in the patients with non-APL disease and known 
NPM1 status 
 Total (%) NPM1WT (%) NPM1MUT 
(%) 
P 
Total (%) 150 (100) 101 (67) 49 (33)  
Type of AML (%) 
   De Novo 
   Secondary 
   Treatment 
 
124 (83) 
17 (11) 
9 (6) 
 
79 (78) 
15 (15) 
7 (7) 
 
45 (92) 
2 (4) 
2 (4) 
0.04 
FAB type (%) 
   M0 
   M1 
   M2 
   M4 
   M5 
   M6 
   M7 
   Unknown 
 
11 (7) 
37 (25) 
62 (41) 
15 (10) 
20 (13) 
2 (1) 
1 (1) 
2 (1) 
 
10 (10) 
21 (21) 
48 (48) 
8 (8) 
9 (9) 
2 
1 
2 
 
1 (2) 
16 (33) 
14 (29) 
7 (14) 
11 (22) 
0 
0 
0 
 
0.1 
0.16 
0.02 
0.26 
0.04 
0.99 
0.99 
0.99 
Sex (%) 
   Female 
   Male 
 
70 (47) 
80 (53) 
 
43 (43) 
58 (57) 
 
27 (55) 
22 (45) 
0.17 
Median age, years 
(range) 
56 (13-86) 59 (13-86) 54 (13-77) 0.76 
Median WCC x 109/l 
(range) 
18 (0-385) 8 (0-346) 54 (2-385) <0.0001 
Cytogenetics 
(% all/known) 
   Favourable 
   Intermediate 
        Normal 
   Adverse 
   Failed 
   Unknown 
 
 
14 (9/11) 
85 (57/69) 
69 (46/56) 
25 (17/20) 
23 (15/-) 
3 (2/-) 
 
 
14 (14/18) 
43 (43/54) 
29 (29/36) 
23 (23/29) 
18 (18/-) 
3 (3/-) 
 
 
0 (0/0) 
42 (86/95) 
40 (82/91) 
2 (4/5) 
5 (10/-) 
0 (0/-) 
 
 
0.002 
<0.0001 
<0.0001 
0.0009 
0.24 
0.55 
FLT3 status (%) 
   FLT3WT 
   FLT3ITD 
 
119 (79) 
31 (21) 
 
91 (90) 
10 (10) 
 
28 (57) 
21 (43) 
 
 
<0.0001 
FLT3ITD level 
(% of FLT3ITD) 
   ITD-LOW 
   ITD-INT 
   ITD-HIGH 
 
 
7 (23) 
18 (58) 
6 (19) 
 
 
5 (50) 
4 (40) 
1 (10) 
 
 
2 (10) 
14 (67) 
5 (24) 
 
 
 
 
0.03 
Abbreviations: ITD-LOW, <25% mutant alleles; ITD-INT, 25-50% mutant alleles; 
ITD-HIGH, >50% mutant alleles. 
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Figure 4.6 The mutant level and relationship to FLT3ITD in NPM1MUT patients. (A) The distribution of NPM1 mutant burden in 49 
NPM1MUT patients. (B) The relative mutant burden of FLT3ITD and NPM1MUT in the 21 patients with both mutations. 
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had NPM1 mutant level <25% and 4% >50%. This lack of variability was particularly 
striking when relative mutant burden was compared for the 21 patients harbouring both 
an NPM1MUT and a FLT3ITD (Figure 4.6B). This decreased variability mirrors that seen 
in the MRC data for NPM1MUT with a median of 43% (range 6-78%), where only 8% 
of NPM1MUT had levels <25%, and 3% >50% (Gale et al, 2008).  
 
The frequency of the combined NPM1/FLT3 genotypes for the non-APL cohort for 
NPM1MUTFLT3ITD, NPM1MUTFLT3WT, NPM1WTFLT3ITD, and NPM1WTFLT3WT 
genotypes was 14%, 19%, 7%, and 61% respectively. The equivalent figures for the 
MRC cohort were 17%, 24%, 11%, and 47%. This higher frequency of 
NPM1WTFLT3WT genotype may reflect the larger number of patients with adverse 
cytogenetics in the UCLH cohort, as when only the intermediate-risk patients were 
considered the frequency of the respective genotypes was 16%, 21%, 7%, and 29%. 
 
Of interest is the increasing likelihood of having an NPM1 mutation where there is a 
higher FLT3ITD allele burden (Table 4.10). This was previously recognised in the MRC 
studies (Gale et al, 2008) where the frequency of patients with NPM1MUT in the FLT3WT, 
FLT3ITD-LOW, FLT3ITD-INT, and FLT3ITD-HIGH groups was 34%, 51%, 59%, and 81% 
respectively (P<0.0001). The equivalent figures in the UCLH cohort were 24%, 29%, 
78%, and 83%, with an association between NPM1MUT and FLT3ITD (P<0.001), and a 
trend for increased percentage of patients with NPM1MUT with increasing FLT3ITD level 
(P=0.03).  
 
 
4.3.4 Treatment 
 
Overall, 140 non-APL patients (84%) were known to have received intensive treatment, 
with higher rates in patients aged <60 years (96%) than in those ≥60 years (69%) 
(P<0.0001). Patients aged <60 years were also more likely to have received their 
induction treatment in the context of a national clinical trial (P=0.015) (Table 4.11). An 
overview of the frequencies of the different regimens used is shown in Table 4.12, with 
the majority of patients receiving DA50. A further three patients had intensive-style 
treatment with high-dose or intermediate dose Ara-C but 
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Table 4.11 Overall treatment approach in the patients with non-APL disease  
 
 All patients Patients <60 years Patients ≥60 years 
Number of patients (%) 166 (100) 94 (57) 72 (43) 
Clinical Trial, no. (%) 
      
      14 
      15 
      16 
      17 
 
Treated Off trial 
94 (57) 
 
8 (5) 
47(28) 
18 (11) 
21 (13) 
 
72 (43) 
62 (66) 
 
0 (0) 
42 (45) 
0 (0) 
20 (21) 
 
32 (34) 
32 (44) 
 
8 (11) 
5 (7) 
18 (25) 
1 (1) 
 
40 (56) 
Treatment (%) 
     Int 
     Int (no anthracycline) 
     Non-Int 
     No treatment/UK 
 
140 (84) 
3 (2) 
17 (10) 
6 (4) 
 
90 
2 
1 
1 
 
50 
1 
16 
    5 
 
Abbreviations: Int, intensive treatment; Non-Int, non-intensive treatment; UK, unknown  
 
Table 4.12 Initial induction regimens used in the 140 intensively treated non-APL 
patients  
 
Intensive 
Regimen 
Number of patients 
(%) 
Also received ATRA 
(%) 
Also received GO 
(%) 
DA 
     DA50 
     DA60 
     DA90 
99 (71) 
97 (69) 
1 (<1) 
1 (<1) 
2 (1) 12 (9) 
ADE 31 (22) 1 (<1) 4 (3) 
FLAG-Ida 7 (5) 0 (0) 3 (2) 
DClo 3 (2) 0 (0) 1 (<1) 
 
Abbreviations: DA, cytarabine and 50, 60, or 90 mg/m2 daurobicin; ADE, cytarabine, 
duanorubicin, etopsoide; FLAG-Ida, fludarabine, cytarabine, idarubicin, G-CSF; DClo, 
daunorubicin, clofrabine; GO, gemtuzumab ozogamicin. Details of regimens are given in 
supplementary table 1. 
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without an anthracycline as part of their initial induction treatment because of cardiac 
concerns in the acute setting. These patients were not included in the analysis of the 
intensively treated patients. Seventeen patients received non-intensive therapy. A 
further five patients elected to receive supportive care, with one patient electing to 
return to their native country prior to commencing therapy (treatment unknown) and 
being lost to follow-up. Thus, in keeping with the MRC trials as a whole, the majority 
of patients (91%) were treated with either DA50 or ADE, indicating that the treatment 
regimens used in the UCLH cohort effectively matched the predominant regimens used 
in the AML15 trial and the initial version of the AML17 trial. There is little evidence 
of a clinical outcome difference for using ADE over DA50. 
 
The majority of APL patients, overall and in both age cohorts, had their initial treatment 
in the context of a national clinical trial (overall, 9 out of 15 patients, 60%). All patients 
received ATRA in combination with an anthracycline with or without Ara-C apart from 
one patient who received ATRA-ATO as part of the AML17 trial. 
 
 
4.3.5 Response to intensive induction treatment 
 
Of the 140 intensively treated non-APL patients, 17 (12%) died in the first 30 days and 
were labelled as ID. Compared to those who survived beyond 30 days (regardless of 
remission status), they had a higher median presenting WCC (median 62 vs 16 x 109/l, 
P=0.02) and were significantly older (median 64 vs 52 years, P=0.002) (Table 4.13). 
There were no demonstrable differences with respect to sex, de novo disease or 
cytogenetic risk group. These results were in keeping with a multicentre study showing 
that the most important predictors for early death (first four weeks in this study) are age 
and performance status, but that a high presenting WCC (>100 x 109/l) is also 
associated with ID (Walter et al, 2011). 
 
For patients who survived beyond 30 days, the features of those achieving CR following 
one cycle of intensive induction therapy and at any time are presented in 
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Table 4.13 Features of intensively treated non-APL patients who did or did not die 
in the first 30 days 
 
 ID 
(death in first 30 
days) 
Not ID 
(survived beyond 30 
days) 
P 
Patient no. (%) 17 (12) 123 (88)  
Median age, years (range) 64 (18-81) 52 (13-76) 0.002 
Sex (%) 
Male (%) 
Female (%) 
 
10 (59) 
7 (41) 
 
64 (52) 
59 (48) 
0.8 
Type of AML (%) 
De Novo (%) 
Secondary/Treatment (%) 
 
12 (71) 
5 (29) 
 
107 (87) 
16 ( 
0.14 
Median WCC x 109/l (range) 62 (2-376) 16 (0-385) 0.02 
Cytogenetics  
 (% all/known) 
     Favourable 
     Intermediate 
           NK 
    Adverse 
    Failed/Unknown 
 
 
1 (6) 
10 (74) 
6 (35) 
1 (6) 
5 (29) 
 
 
12 (10) 
70 (57) 
58 (47) 
22 (18) 
19 (15) 
 
 
0.99 
0.34 
0.77 
0.46 
0.17 
Abbreviation: ID, induction death 
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Table 4.14 Response to first induction treatment for intensively treated patients 
surviving beyond 30 days 
 
 RD post cycle 1 CR post cycle 1 P 
Patient no. (%) 31(22) 92 (66)  
Median age, years (range) 57 (14-74) 50.5 (13-76) 0.16 
Sex (%) 
Male  
Female 
 
12 (39) 
19 (61) 
 
46 (50) 
46 (50) 
 
0.3 
Type of AML (%) 
De Novo 
Secondary/Treatment  
 
28 (90) 
3 (10) 
 
79 (86) 
13 (14) 
 
0.76 
Median WCC x 109/l (range) 8 (1-385) 21.5 (0-231) 0.23 
Cytogenetics  
No. (% all/% known) 
     Favourable 
     Intermediate 
           NK 
    Adverse 
    Failed/Unknown 
 
 
0 (0/0) 
12 (39/48) 
12 (39/48) 
13 (42/52) 
6 (19/-) 
 
 
12 (13/15) 
58 (63/80) 
46 (50/63) 
9 (7/9) 
13 (11/-) 
 
 
0.07 
0.01 
0.49 
<0.0001 
0.6 
Abbreviation: RD, resistant disease 
 
Table 4.15 Presenting features of intensively treated patients who did or did not 
attain remission at any time 
 
 CR never achieved CR achieved P 
Patient no. (%) 22 (16) 101 (72)  
Median age, years (range) 59 (14-73) 50 (13-76) 0.06 
Sex (%) 
Male  
Female  
 
8 (36) 
14 (64) 
 
51 (50) 
50 (50) 
0.25 
Type of AML (%) 
De Novo  
Secondary/Treatment  
 
19 (86) 
3 (14) 
 
88 (87) 
13 (13) 
0.99 
Median WCC x 109/l (range) 7.5 (1-385) 21 (0-346) 0.22 
Cytogenetics  
 (% all/known) 
     Favourable 
     Intermediate 
           NK 
    Adverse 
    Failed/Unknown 
 
 
0 (0/0) 
7 (32/41) 
7(32/41) 
10 (45/59) 
5 (23/-) 
 
 
12 (12/14) 
63 (62/72) 
51 (50/59) 
12 (12/14) 
14 (14/-) 
 
 
0.36 
0.02 
0.29 
0.0002 
0.33 
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Tables 4.14 and 4.15 respectively. Patients with PR and refractory disease were 
grouped within remission failures. There were no significant differences between the 
groups with respect to sex, presenting WCC, or de novo disease. Patients failing CR 
following one cycle were non-significantly older (Table 4.14) and this age difference 
approached significance when patients achieving CR at any time were considered 
(Table 4.15). The group that never attained remission had a significantly greater 
proportion of patients with adverse-risk cytogenetics (59% vs 14%, P=0.0002) (Table 
4.15). 
 
Response to induction therapy was assessed according to NPM1 (n=128) and FLT3 
(n=129) mutational status (Table 4.16). Compared to NPM1WT, NPM1MUT patients 
were significantly associated with achievement of CR after course 1 (84% vs 61%, 
P=0.009), although this significance was lost for those achieving CR at any point 
because of the increased proportion of NPM1WT patients that went into CR after further 
courses (89% v 71%, P=0.08). For those patients with intermediate karyotype and 
known molecular status (n= 73 for both NPM1 and FLT3), NPM1MUT status was 
associated with a significantly greater chance of achieving remission, both after one 
cycle of treatment (86% vs 56%, P=0.005) and at any time (89% vs 67%, P=0.03) 
(Table 4.17). FLT3ITD did not influence the achievement of CR in either the whole 
intensively treated cohort or in patients with intermediate-risk cytogenetics. However, 
when the combined NPM1/FLT3 genotype was assessed, the lowest CR rate after one 
cycle of intensive treatment was seen in the NPM1WTFLT3ITD patients, both in the non-
APL cohort as a whole (50%, P=0.02), and the intermediate-risk cytogenetic group 
(29%, P=0.009). There were no significant differences seen in the numbers who 
eventually attained remission after subsequent rounds of treatment. This association 
between NPM1 status but not FLT3 status with the achievement of remission following 
intensive induction treatment mirrors that seen in the majority of the large published 
cohorts described in Tables 4.1 and 4.3, including the studies of patients treated on 
MRC trials (Kottaridis et al, 2001; Gale et al, 2008). 
 
To assess whether characteristics in the UCLH cohort found to be associated with 
failure to achieve CR, either because of ID or RD, were independent factors for 
predicting response to therapy, these factors were entered into a multivariate 
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Table 4.16 Response to intensive induction treatment in non-APL patients according to genotype.  
 NPM1WT 
(n=85) 
NPM1MUT 
(n=43) 
P* FLT3WT 
(n=100) 
FLT3ITD 
(n=29) 
P* NPM1WT 
FLT3WT 
(n=75) 
NPM1MUT 
FLT3WT 
(n=24) 
NPM1WT 
FLT3ITD 
(n=10) 
NPM1MUT 
FLT3ITD 
(n=19) 
P* 
Status after course 1 
 
CR (%) 
RD (%) 
ID (%) 
 
 
52 (61) 
24 (28) 
9 (11) 
 
 
36 (84) 
3 (7) 
4 (9) 
 
 
 
 
0.009 
 
 
64 (64) 
25 (25) 
11 (11) 
 
 
21 (72) 
6 (21) 
2 (7) 
 
 
 
 
0.5 
 
 
43 (57) 
22 (29) 
10 (13) 
 
 
20 (83) 
1 (4) 
3 (13) 
 
 
5 (50) 
4 (40) 
1 (10) 
 
 
16 (84) 
2 (11) 
1 (5) 
 
 
0.02 
CR ever 60 (71) 33(89) 0.08 70 (70) 24 (83) 0.2 48 (64) 21 (88) 8 (80) 16 (84) 0.07 
*P values refer to attaining CR vs not attaining CR. 
 
Table 4.17 Response to intensive induction treatment according to genotype in patients with intermediate-risk cytogenetics.  
 NPM1WT 
(n=36) 
NPM1MUT 
(n=37) 
P* FLT3WT 
(n=50) 
FLT3ITD 
(n=23) 
P* NPM1WT 
FLT3WT 
(n=29) 
NPM1MUT 
FLT3WT 
(n=21) 
NPM1WT 
FLT3ITD 
(n=7) 
NPM1MUT 
FLT3ITD 
(n=16) 
P* 
Status after course 1 
 
CR (%) 
RD (%) 
ID (%) 
 
 
20 (56) 
9 (25) 
7 (19) 
 
 
32 (86) 
2 (5) 
3 (8) 
 
 
 
 
0.005 
 
 
36 (72) 
6 (12) 
8 (16) 
 
 
16 (70) 
5 (22) 
2 (8) 
 
 
 
 
0.99 
 
 
18 (62) 
5 (17) 
6 (21) 
 
 
18 (86) 
1 (5) 
2 (10) 
 
 
2 (29) 
4 (57) 
1 (14) 
 
 
14 (88) 
1 (6) 
1 (6) 
 
 
0.009 
CR ever 24 (67) 33(89) 0.03 38 (76) 19 (83) 0.8 19 (66) 19 (90) 5 (71) 14 (88) 0.1 
*P values refer to attaining CR vs not attaining CR. 
 
Abbreviations: CR, complete remission; CR ever, reflects patients who attain CR at some point regardless of the number of treatment 
courses; ID, induction death; RD, resistant disease. 
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analysis. All four factors maintained their significant association with the achievement 
of CR (WCC, P=0.002; NPM1 status, P<0.0001; cytogenetic risk group, P=0.002; age 
P=0.008). FLT3ITD status remained non-significant for predicting response to induction 
treatment (P=0.3). 
 
 
4.3.6 Overall survival and disease-free survival 
 
The major outcomes of OS and DFS were then assessed for the intensively treated 
patient cohort (including APL) (n=155). The median OS for the whole cohort was 815 
days, with 3-year and 5-year actuarial OS of 47% and 39% respectively. For the 116 
patients achieving remission, the median DFS was 852 days, with 3-year and 5-year 
actuarial DFS of 47% and 43% respectively.  
 
 
4.3.6.1 Overall survival and disease free survival according to age and cytogenetics 
 
The outcomes of the intensively treated cohort for DFS and OS according to age are 
shown in Table 4.18 and Figure 4.7. Age ≥60 years was associated with a significantly 
decreased 5-year DFS and OS. There was also a significant difference in DFS and OS 
according to cytogenetic risk group. In keeping with the MRC risk groups, patients in 
the favourable cytogenetic group had the best DFS and OS, and patients with adverse 
cytogenetics the worst (Table 4.18, Figure 4.8). Similar results were seen when only 
patients aged <60 years (an age group that more closely resembles the MRC study) 
were assessed, with 5-year OS in the favourable, intermediate, and adverse cytogenetic 
groups of 86%, 52%, and 8% respectively (P<0.0001).  
 
Again, in keeping with the MRC data, within the favourable risk-risk group, patients 
with APL performed better than those with either t(8;21) or inv(16)/t(16;16), although 
the numbers in each subgroup were small and this did not reach statistical significance, 
with 5-year OS of 100%, 83%, and 50% respectively (P=0.16). Previous studies have 
shown an increased relapse risk in patients with inv(16)/t(16;16) compared to t(8;21), 
but because of their ability to be salvaged, they 
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Table. 4.18 Outcome in the 155 intensively treated patients according to age and cytogenetic risk group 
 
 No. pts 
(%) 
Median DFS  
(days) 
DFS@5 years 
(%) 
P 
HR (95% CI) 
Median OS  
(days) 
OS@5 years 
(%) 
P 
HR (95% CI) 
Age (%) 
 
<60 years 
≥60 years 
 
 
102 (66) 
53 (34) 
 
 
2238 
392 
 
 
52% 
19% 
0.02 
0.44 (0.24-0.81) 
 
 
2287 
282 
 
 
50% 
19% 
<0.0001, 
0.31 (0.19-0.51) 
 
 
Cytogenetics  
 (% all/known) 
 
Favourable 
 
Intermediate 
 
Adverse 
 
Failed/UK 
 
 
 
28 (18/21) 
 
80 (52/61) 
 
23 (15/18) 
 
24 (15/-) 
 
 
 
Undefined 
 
764 
 
392 
 
414.5 
 
 
 
76% 
 
40% 
 
27% 
 
14% 
0.0007 
 
 
 
 
 
 
 
 
 
 
 
Undefined 
 
559 
 
210 
 
335.5 
 
 
 
83% 
 
38% 
 
7% 
 
27% 
<0.0001 
 
Abbreviations: CI, confidence intervals; DFS, disease-free survival; HR, hazard ratio; OS, overall survival 
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Figure 4.7 Outcome according to age in the total group of 155 intensively treated patients. (A) Overall survival and (B) disease-free 
survival. 
0 1000 2000 3000 4000
0
50
100
Pe
rc
en
t s
ur
vi
va
l
Days
<60 years ≥60 years
n	=	102	 
P	<	0.0001 n	=	53	 
0 1000 2000 3000 4000
0
50
100
Pe
rc
en
t s
ur
vi
va
l
Days
<60 years ≥60 years
n	=	30	 P	=	0.02 
n	=	86	 
A B 
 166 
 
 
 
 
 
Figure 4.8 Outcome according to MRC cytogenetic risk group in the total group of 155 intensively treated patients. (A) Overall 
survival and (B) disease-free survival. 
0 1000 2000 3000 4000
0
50
100
Pe
rc
en
t s
ur
vi
va
l
Days
Favourable
Intermediate
Adverse
Failed/Unknown
n = 23 P < 0.0001 
n = 24 
n = 80 
n = 28 
0 1000 2000 3000 4000
0
50
100
Pe
rc
en
t s
ur
vi
va
l
Days
Favourable
Intermediate
Adverse
Failed/Unkown
n = 12 
n = 14 
n = 64 
P = 0.004 
n = 26 
B A 
 167 
have comparable OS (Allen et al, 2013). In keeping with this, there was a significant 
difference in DFS between the groups, with 5-year DFS for APL, t(8;21) and 
inv(16)/t(16;16) 100%, 67%, and 20% respectively (P=0.002).  
 
 
4.3.6.2 Survival analysis according to genotype 
 
The DFS and OS in 73 intensively treated patients with intermediate-risk cytogenetics 
according to the NPM1MUT and FLT3ITD status are shown in Table 4.19. Patients with 
NPMMUT had significantly improved DFS and OS compared to NPM1WT patients 
(Figure 4.9). There was no association between FLT3ITD status and either DFS or OS 
(Figure 4.10). There was a trend for inferior survival when patients <60 years were 
analysed separately for FLT3ITD and FLT3WT, with 5-year DFS 39% vs 58% (HR 1.94, 
95% CI 0.76 - 4.94, P=0.16) and 5-year OS 43% vs 56% (HR 1.47, 95% CI 0.62-3.52, 
P=0.76). 
 
 
4.3.6.2.1 Intermediate-risk patients according to combined NPM1/FLT3 genotype 
 
For the cohort of intensively treated intermediate-risk patients with known NPM1 and 
FLT3 status (n=73), DFS and OS were assessed according to the combined NPM1 and 
FLT3 status. The median OS for the 4 genotype groups, NPM1MUTFLT3ITD, 
NPM1MUTFLT3WT, NPM1WTFLT3ITD, and NPM1WTFLT3WT, was 815 days, undefined, 
309 days, and 366 days respectively (P=0.0004) and the 5-year OS was 49%, 73%, 0% 
and 16% respectively (Table 4.19, Figure 4.11A). The median DFS for the 4 genotypes 
was 777 days, undefined, 220 days, and 325 days respectively (P=0.0003, and the 5-
year DFS 49%, 70%, 0% and 19% respectively (Table 4.19, Figure 4.11B). When only 
those patients <60 years were considered, the 5-year DFS was 53%, 61%, 0%, and 30% 
respectively (P=0.01), and the 5-year OS was 53%, 87%, 0%, and 23% (P=0.008).  
 
Thus the NPM1MUT patients performed as expected, with improved DFS and OS when 
considered in isolation, and they performed particularly well in the absence of 
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Figure 4.9 Outcome according to NPM1 mutation status in the 73 intensively treated patients with intermediate-risk cytogenetics 
and known mutation status. (A) Overall survival and (B) disease free-survival. 
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Figure 4.10 Outcome according to FLT3 mutation status in the 73 intensively treated patients with intermediate-risk cytogenetics 
and known mutation status. (A) Overall survival and (B) disease-free survival.    
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Figure 4.11 Outcome according to the combined NPM1/FLT3 mutation status in the 73 intensively treated patients with 
intermediate-risk cytogenetics and known mutation status. (A) Overall survival and (B) disease-free survival. 
0 1000 2000 3000 4000
0
50
100
Pe
rc
en
t s
ur
vi
va
l
Days
NPM1WTFLT3WT
NPM1MUTFLT3WT
NPM1WTFLT3ITD
NPM1MUTFLT3ITD
n = 7 
n = 29 
n = 21 
P = 0.0004 
n = 16 
A 
0 1000 2000 3000 4000
0
50
100
Pe
rc
en
t s
ur
vi
va
l
Days
NPM1WTFLT3WT
NPM1MUTFLT3WT
NPM1WTFLT3ITD
NPM1MUTFLT3ITD
n = 5 
n = 20 n = 14 
P = 0.0003 
n = 19 
B 
 171 
 
 
 
Table 4.19 Outcome according NPM1 and FLT3 mutation status in 73 intensively treated patients with intermediate-risk 
cytogenetics 
 
 No. pts 
(%) 
 
Median DFS 
(days) 
DFS@5 
years (%) 
P 
HR (95% CI) 
Median OS 
(days) 
OS@5 
years (%) 
P 
HR (95% CI) 
CIR@5 years 
(%) 
P 
NPM1 status 
 
NPM1MUT 
NPM1WT 
 
 
37 (51) 
36 (49) 
 
 
2399 
283 
 
 
60% 
15% 
0.0009 
0.29 (0.14-0.60) 
 
 
 
 
2440 
311 
 
 
62% 
13% 
0.0001 
0.30 (0.16-0.55) 
 
 
 
 
30% 
73% 
0.001 
 
 
FLT3 status 
 
FLT3ITD 
FLT3WT 
 
 
23 (32) 
50 (68) 
 
 
336 
778 
 
 
36% 
41% 
0.29 
1.50 (0.71-3.17) 
 
 
 
 
478 
668 
 
 
34% 
38% 
0.9 
1.23 (0.65-2.32) 
 
 
 
 
47% 
50% 
0.87 
 
 
Combined 
 
NPM1MUTFLT3ITD  
NPM1MUTFLT3WT  
NPM1WTFLT3ITD  
NPM1WTFLT3WT 
 
 
16 (22) 
21 (29) 
7 (10) 
29 (40) 
 
 
777 
Undefined 
220 
325 
 
 
49% 
70% 
0% 
19% 
0.0003 
 
 
 
 
 
815 
Undefined 
309 
366 
 
 
49% 
73% 
0% 
16% 
0.0004 
 
 
 
 
 
35% 
24% 
80% 
71% 
0.002 
 
 
 
 
Abbreviations: CI, confidence intervals; CIR, cumulative incidence of relapse; DFS, disease-free survival; HR, hazard ratio; OS, overall survival 
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a FLT3ITD (Table 4.19). In contrast, FLT3ITD when considered in isolation was not 
associated with an inferior OS. Although some of the studies investigating FLT3ITD 
without incorporating NPM1 status have demonstrated an inferior survival (Kottaridis 
et al, 2001), some large studies, including the largest and third largest studies of adults 
(Schnittger et al, 2002; Thiede et al, 2002) also failed to see an impact prognostic 
impact of FLT3ITD. Furthermore, the finding of inferior survival for NPM1MUTFLT3ITD 
genotype patients was in keeping with the major studies considering the combination 
of mutations in both unselected cohorts and in intermediate karyotype/NK cohorts 
(Table 4.3). One anomaly of the UCLH cohort compared to published data was the 
apparent inferior outcome of NPM1WTFLT3WT compared to NPM1MUTFLT3ITD patients 
for both DFS and OS, although this did not reach statistical significance. When these 2 
groups were compared directly, the 5-year DFS was 49% vs 19% (HR 1.96, 95% CI 
0.94 - 3.79, P=0.08) and 5-year OS 49% vs 16% (HR 1.69, 95% CI 0.76 - 3.75, P=0.2).   
 
 
4.3.6.2.2 Outcome according to FLT3ITD burden 
 
The outcome was then assessed according to FLT3ITD burden to see if it worsens with 
increasing mutation level, as has been suggested (Gale et al, 2008; Pratcorona et al, 
2013), and whether those patients with the lowest mutant burden still have the inferior 
outcomes seen in the FLT3ITD group as a whole when compared to FLT3WT. This is a 
contentious issue as some studies have shown low-level FLT3ITD have the same 
outcome as FLT3WT, while other larger studies have shown that OS and CIR are similar 
for FLT3ITD levels of <25% and 25-50% (Linch et al, 2014). Although there was a shift 
in OS rates for FLT3ITD patients with <25% mutant if an attempt was made to adjust for 
sample purity, this did not affect the CIR (Linch et al, 2014). 
 
As before, three groups were defined: FLT3ITD-LOW (<25% mutant), FLT3ITD-INT (25-
50%), and FLT3ITD-HIGH (>50%). In the intermediate cytogenetic risk group, for 
intensively treated patients, the median OS for the 3 groups was 422, 2440, and 233 
days respectively (P=0.003). The 3-year OS was 20%, 53%, and 0% (Figure 4.12A). 
The median DFS for the 3 groups was 181, 2399, and 175 days (P=0.0002) and the
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Figure 4.12 Outcome according to FLT3ITD mutant level in 23 intensively treated patients with intermediate-risk cytogenetics. (A) 
Overall survival and (B) disease-free survival. FLT3ITD-LOW (<25% mutant), FLT3ITD-INT  (25-50% mutant), FLT3ITD-HIGH (>50% mutant). 
FLT3WT is included for comparison. P values refers to analysis with FLT3WT excluded. For (A) P = 0.009 and (B) P<0.0001 when FLT3WT 
is included. 
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Figure 4.13 Outcome following remission in intensively treated patients with intermediate-risk cytogenetics 
according to FLT3 mutation status. (A) Cumulative incidence of relapse (CIR) and (B) non-relapse mortality 
(NRM).   
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 3-year DFS 0%, 62%, and 0% respectively (Figure 4.12B). Thus, as with the FLT3ITD 
group as a whole, the largest group of patients with FLT3ITD-INT had a similar outcome 
to FLT3WT patients. In contrast, patients with either FLT3ITD-LOW or FLT3ITD-HIGH had a 
poorer outcome with actuarial survival of 0% at 3 years, albeit with small numbers in 
these groups. Previous reports from MRC studies have shown that, unless adjusting for 
sample impurity, FLT3ITD-LOW patients have poorer outcome than FLT3WT and a CIR 
comparable to higher FLT3ITD levels (Gale et al, 2008; Linch et al, 2014). 
 
 
4.3.7 Relapse-risk in the intermediate-risk cytogenetic group according to genotype  
 
The CIR was then assessed in the intermediate-risk cytogenetic group in order to assess 
whether these differences in OS and DFS according to genotype could be attributed to 
differences in the risk of relapse. As a large number of patients in the intermediate-risk 
group, particularly those with higher risk genotypes, undergo HSCT, a competing risk 
methods was employed to distinguish between those patients who relapsed as compared 
to those patients who died in remission, predominantly for treatment-related causes, e.g. 
infection, or graft-versus-host disease (GVHD), so called non-relapse mortality (NRM). 
 
A total of 57 patients with intermediate-risk cytogenetics and with NPM1 and FLT3 
status available attained remission and were eligible for the competing risks analysis. 
In the assessment according to FLT3, the 5-year CIR was 50% in the FLT3WT group 
versus 47% in the FLT3ITD group (P=0.87) (Table 4.19, Figure 4.13A). There was also 
no significant difference in the NRM at 5 years (9% vs 17%, P=0.34) (Figure 4.13B). 
In the same 57 patients, a competing risks analysis according to NPM1 mutation status 
showed that there was no difference in the NRM rate between patients who were 
NPM1WT and those who were NPM1MUT (14% vs 10%, P=0.97) (Figure 4.14B). 
However, the NPM1WT patients had a significantly increased CIR at 5 years compared 
to the NPM1MUT patients (73% vs 30%, P=0.001) (Table 4.19, Figure 4.14A). 
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Figure 4.14 Outcome following remission in intensively treated patients with intermediate-risk cytogenetics according to 
NPM1 mutation status. (A) Cumulative incidence of relapse (CIR) and (B) non-relapse mortality (NRM).   
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Figure 4.15 Outcome following remission in intensively 
treated patients with intermediate-risk cytogenetics 
according to the combined NPM1/FLT3 mutation status. (A) 
Cumulative incidence of relapse (CIR) and (B) non-relapse 
mortality. 
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The CIR and NRM were then assessed according to the combined NPM1/FLT3 
genotypes (Table 4.19, Figure 4.15). The 5-year CIR for the NPM1MUTFLT3ITD, 
NPM1MUTFLT3ITD, NPM1WTFLT3ITD, and NPM1WTFLT3WT groups were 35%, 24%, 
80%, and 71% respectively (P=0.002), and there was no difference in the NRM (15%, 
6%, 20%, 12%; P=0.62). When the NPM1MUTFLT3ITD and NPM1WTFLT3WT patients 
were compared directly, the difference in CIR was not statistically significant (P=0.08). 
The difference in relapse risk between the groups was not obviously due to a large 
difference in the rate of HSCT between the groups as the proportion of patients 
undergoing HSCT in the respective groups was 29%, 26%, 40%, and 32% respectively.  
 
Thus, the commonly reported decreased relapse risk associated with NPM1MUT was 
seen most prominently in the context of a FLT3WT genotype, however, in the context of 
a FLT3ITD it did appear to mitigate the possible inferior outcome. The inferior CIR 
reported as the reason for inferior OS in FLT3ITD patients was not seen in the group as 
a whole, but was seen in the context of NPM1WT. 
 
 
4.4 Discussion 
 
This chapter gives details of a cohort of 181 in-house patients with a new diagnosis of 
AML that were selected because they had diagnostic trephine biopsies available for the 
assessment of DNA replication licensing proteins and cell cycle status using IHC. It is 
noteworthy that the number of patients with available biopsies in the first 2 years of the 
study (2003 and 2004) is fewer than in later years (2005 to 2011). There are a number 
of possible reasons for this apparent increase with time. Firstly, it may represent a true 
increase in the number of patients either being diagnosed with AML or, more likely, 
being referred to UCLH for intensive treatment. Secondly, the ease of identifying 
appropriate cases from electronic and paper records diminished on searching further 
back into the archives, although the number of sources used to identify patients, 
including pathology and haematology laboratory records, should have lessened the 
likelihood of having missed cases. 
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Referral patterns for intensive treatment may also explain why this cohort is younger 
(median age 56 years) than cohorts based on trials or populations, where the median 
age of diagnosis is often ≥65 years. However, UCLH is a central referring hospital for 
intensive treatment, which may skew the AML population towards younger patients 
deemed fit for intensive induction therapy, with or without HSCT, and away from older 
patients receiving non-intensive treatment or supportive therapy. Furthermore, because 
older patients are more likely to have secondary disease, it may be that a biopsy sample 
is deemed unnecessary for a diagnosis of AML where either PB or BMA may be 
sufficient for diagnostic purposes.  
 
Despite these caveats on age, there were a number of features of the cohort that it made 
it potentially useful for a study. Firstly, the younger cohort could be readily compared 
with large clinical trials such as the MRC/NCRI AML trials, which have been 
extensively described in terms of cytogenetic and molecular features, particularly in the 
younger-aged patient cohorts. Two of the main studies describing MRC patient data 
that were used as comparators in this chapter focussed on younger adults. The median 
age of patients in the cytogenetic study (Grimwade et al, 2010) was 44 years and in the 
study of NPM1 and FLT3 it was 43 years (Gale et al, 2008). Despite this disparity in 
overall age, the UCLH cohort performed generally well in terms of relative frequency 
of cytogenetic groups and NPM1/FLT3 genotype. The only apparent discordance was 
the increased frequency of patients with adverse cytogenetics seen in the cohort 
compared to the MRC data, even when only patients <60 years were considered. The 
cohort as a whole had overall frequencies of NPM1MUT, FLT3ITD, and combined 
genotypes in keeping with larger cohorts including the MRC studies, particularly when 
the effect of the large numbers of patients with adverse cytogenetics was mitigated by 
only considering the relative frequencies in the intermediate-risk cytogenetics and NK 
groups. Furthermore, the expected association between NPM1MUT and FLT3ITD 
genotypes was observed, as well as the association for both mutations with 
intermediate-risk cytogenetics. The data on NPM1MUT and FLT3ITD mutant burden were 
also consistent with large trials, including MRC data (Gale et al, 2008). Whereas there 
was a large spread of FLT3ITD mutant levels between patients, with 58% of patients 
having levels of 25-50%, the NPM1MUT burden was tightly grouped with 92% in the 
25-50% mutant range, indicating heterozygous mutation in all or almost all leukaemic 
cells. Other features consistent with published cohorts were the association of both 
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NPM1MUT and FLT3ITD with increased WCC, and the further association between 
increasing WCC with increasing FLT3ITD burden.  
 
When considering FAB types, the negative association between FLT3ITD and M2 noted 
by others was seen, but not the association with M5. Furthermore, NPM1MUT was 
associated with M5 but not M4 subtypes. This may reflect the difficulty in trying to 
retrospectively infer FAB type from historic laboratory reports, or inaccuracy of 
reporting given the move away from using FAB type and the increasing reliance on 
cytogenetic and molecular data rather than morphologic and cytochemical data. In 
terms of assessing the UCLH patients however, these are relatively minor points in a 
cohort that performs very well in terms of demographic equivalence to larger cohorts, 
in particular those from the MRC UK trials. 
 
In terms of outcome, particularly response to induction therapy, it is noteworthy that 
the majority of patients in the cohort who were treated intensively received DA50 or 
ADE, two treatments with essentially similar outcomes that have formed the backbone 
of MRC induction therapy. This was important when comparing outcomes of treatment 
with other trials, including the UK-based studies. However, when considering IDs, the 
largest study reported is of over 3000 patients treated on unspecified protocols at 
institutions in the USA (Walter et al, 2011). The authors found that the two most 
important factors predicting for death in the first four weeks of treatment were 
performance status and age, with higher WCC at diagnosis also predicting for early 
NRM. In the UCLH cohort, increasing age was also associated with an increased risk 
of early death. The importance of WCC and age was also demonstrated in multivariate 
analysis for response to intensive induction therapy. However, the performance status, 
a key predictor of response to treatment and survival, was not reliably available for this 
UCLH cohort. Patients entering clinical trials routinely have an ECOG performance 
status recorded electronically at the point of trial entry or registration. However, this 
information is often not available in the hospital record, or patients are being treated 
off-trial (72 of 175, 41% in this study), and trying to retrospectively deduce the 
performance status from the patient’s notes was very difficult and felt to be too 
unreliable to be of value or to allow accurate analysis. 
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When considering DFS and OS, the importance of patient age for outcome was evident. 
For intensively treated patients, OS was markedly lower in the older patients (≥60 
years). Nonetheless, the median age for the whole cohort was 56 years, the majority of 
patients were aged <60 years, the majority of those ≥60 years were treated intensively, 
and the prognostic factors seen in the outcome data were essentially the same, whether 
the whole intensively treated cohort or only those patients <60 years were being 
considered. 
 
The outcome data for the cytogenetic risk groups that has been established using over 
five and a half thousand patients (Grimwade et al, 2010) also held true in this smaller 
UCLH cohort. Patients with APL had a superior outcome to all other forms of AML, 
and there were clear survival differences for patients within the favourable, 
intermediate, and adverse groups (Figure 4.8A). Interestingly, even within the 
favourable group, the greater propensity for patients with inv(16)/t(16;16) to relapse 
compared t(8;21) as evidenced by a markedly inferior DFS but similar OS was as 
previously noted in larger studies of the CBF-leukaemias treated on MRC trials (Allen 
et al, 2013). The patients with adverse-risk cytogenetics performed as poorly as in other 
studies.  
 
For outcome according to genotype, the impact of both mutations was generally as 
expected according to the larger published cohorts in that the presence of NPM1MUT 
predicted for achievement of CR in both univariate and multivariate analysis whereas 
the presence of FLT3ITD did not. Furthermore, patients with NPM1MUT had a clear 
survival advantage for both OS and DFS. Patients with FLT3ITD did not have clearly 
inferior OS and DFS when ITDs were considered in isolation. However, when the 
NPM1 status was also taken into consideration, patients who had a NPM1WTFLT3ITD 
genotype had a significantly inferior OS and DFS. A study of patients treated on MRC 
trials published prior to the discovery of NPM1MUT showed a clearly inferior OS for 
patients with FLT3ITD (Kottaridis et al, 2001). However, similarly to this UCLH cohort, 
this was not evident in some other large studies (Schnittger et al, 2002; Thiede et al, 
2002). Furthermore, when the combined NPM1/FLT3 genotype was taken into 
consideration, the UCLH cohort performed similarly to the large study of MRC trial 
patients (Gale et al, 2008) in that the best outcomes were seen in NPM1MUTFLT3WT 
patients and the worst outcomes in the group with NPM1WTFLT3ITD. 
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When outcome was assessed according to FLT3ITD burden, patients in the intermediate-
risk cytogenetic group and with the highest mutant burden (>50% mutant), representing 
patients with at least some leukaemic cells with homozygous mutations, had inferior 
outcome to those patients with intermediate mutant burden (25-50%). However, 
patients with the lowest mutant burden (<25%) had similar outcomes to those patients 
with the highest mutant burden. NPM1MUT were found at the expected frequency within 
the FLT3ITD-LOW group (40% in this study) compared with the large study of patients 
treated on MRC trials (Gale et al, 2008) (51% of the cohort). Importantly, this study 
reflected the findings of a recent report of MRC trial patients (Linch et al, 2014), in 
which, if no adjustment was made for sample purity, FLT3ITD-LOW patients had similar 
OS to FLT3WT, and even if adjustment was made for sample purity, they had similar 
CIR. This was independent of NPM1 mutation status. This is important as two prior 
smaller studies suggest that in NPM1MUT patients, only those with FLT3ITD mutant level 
≥33% (i.e. a WT:mutant allele ratio of >0.5) had a worse outcome (Schnittger et al, 
2011; Pratcorona et al, 2013). In any case, in this UCLH cohort, only 8 patients had a 
FLT3ITD mutant level <33%, of whom only 5 had NPM1MUT, and this is too small a 
number of patients from which to draw firm conclusions on subgroup analysis. 
 
As NPM1MUT had improved CR rates, it was next assessed whether the improved 
survival was also because of decreased relapse rates. In addition, many patients with 
FLT3ITD receive HSCT, and inferior survival may be due to either relapse or NRM. A 
competing risks analysis was therefore performed, with NRM and relapse as mutually 
exclusive events. This showed that patients with NPM1MUT have a significantly 
decreased CIR, and those with FLT3ITD mutations were only associated with an 
increased CIR in the absence of NPM1MUT. There were no differences in NRM between 
the groups. This lack of increased CIR with FLT3ITD was at odds with data from the 
MRC10, 12, and 15 trial patients (Kottaridis et al, 2001; Gale et al, 2008; Linch et al, 
2014), as was the trend towards an increased CIR in the NPM1WTFLT3WT cohort. 
However, the significant decrease in CIR in NPM1MUT patients, as well as the highest 
CIR in the NPM1WTFLT3ITD group, was in keeping with these studies. 
 
There are several limitations to the present cohort. Firstly, it is small with a wide age 
range. The project started in 2011, with all samples collected retrospectively. Although 
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taking more recent cases than 2011 would have been feasible, there would only have 
been limited follow-up time available. Such cases may have been useful for response 
to induction therapy, but the mean time to relapse for patients with NPM1MUT was 616 
days, which would suggest that a minimum follow-up time of 2 years would be 
necessary. An attempt to find cases earlier than 2003 was also problematic due to 
difficulties in getting accurate identification from records, lack of availability of 
electronic records, and challenges in locating archived tissue. The number of patients 
in these earlier years was also limited, potentially for the reasons outlined above. A 
further way of expanding numbers would have been to use patients from other large 
teaching hospitals. However, the practice of performing a biopsy in parallel with each 
diagnostic aspirate is not universal, and it is not a requirement in guidelines where 
adequate diagnostic material is available from aspirate and blood and the diagnosis is 
not in doubt (British Committee for Standards in et al, 2006). After contacting three 
large UK institutions failed to identify further cases, this approach was not pursued. 
 
A further potential limitation for evaluating outcomes of the cohort was the lack of 
uniformity of treatment, a result of the large numbers of patients recruited to national 
clinical trials that included several different randomisations. However, it should be 
noted that where variations in treatment in such trials have influenced outcome, the 
benefits of the different treatments have been modest and only seen using hundreds of 
patients. Indeed, the outcome data for large cohorts demonstrating the importance of 
cytogenetics, NPM1 and FLT3 status have usually merged the data of patients receiving 
different forms of intensive therapy, and many include patients from different trials. 
Furthermore, with the exception of some of the earlier studies reporting the impact of 
FLT3ITD on outcome, the prognostic impact of cytogenetics, NPM1MUT, and the 
NPM1/FLT3 genotype are broadly similar between reports from groups using different 
treatment regimens. 
 
Only limited genetic profiling of the cohort was performed, NPM1MUT and FLT3ITD 
being the most frequent and prognostically important mutations, albeit in 
cytogenetically intermediate-risk patients. However, as outlined in chapter 1, many 
other recurrent mutations with varying degrees of prognostic importance have recently 
been described. Some of these are hotspot mutations that can be rapidly identified (e.g. 
IDH1 and IDH2), others such as mutations in DNMT3A require analysis of a greater 
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number of exons, and for some patients there would have been insufficient amounts of 
DNA to allow for such analysis. As yet, they are not part of the ELN classification, and 
for some their impact remains controversial. 
 
In summary, this chapter has defined a medium-sized heterogeneous cohort of patients 
with AML with diagnostic biopsies available for IHC analysis of DNA replication 
licensing proteins and cell cycle analysis. Importantly, the main prognostic 
demographic features of AML were found to be present at equivalent rates and 
generally associated with the same clinical features and survival outcomes reported in 
the literature for studies of larger patient cohorts. 
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CHAPTER 5. ANALYSIS OF DNA REPLICATION LICENSING 
PROTEINS AND CELL CYCLE STATUS IN PATIENTS WITH 
AML 
 
5.1 Introduction 
 
In chapter 1, the biology of the normal G1-S phase transition was described. Using this 
knowledge of biology, it has been shown that stages of the cell cycle can be defined in 
fixed samples by the detection of DNA replication licensing proteins using IHC.  
Furthermore, it was shown in chapter 3, that in the case of patients with AML, IHC on 
fixed biopsies provides a more accurate assessment of the in vivo state than does 
assessment of aspirates that are variably contaminated by peripheral blood. How such 
defined cell cycle status correlates with outcome is controversial and, as previously 
discussed, some of this controversy may arise from that fact that cell cycle analysis has 
not been performed using biopsies where G0, in-cycle and S/G2/M populations could 
be defined. Furthermore, there is limited information on how cell cycle status in AML 
relates to well-defined biological, cytogenetic and molecular risk-factors. 
In chapter 4, a cohort of patients with a new diagnosis of AML and with available 
biopsies taken prior to treatment was therefore studied and the clinical outcome for this 
cohort defined according to some of the major known prognostic factors including age, 
presenting WCC, cytogenetics, and NPM1/FLT3 mutational status.  This chapter 
describes the results of studies using the biopsies from this patient cohort to investigate 
the potential heterogeneity in cell cycle status between  patients, and the correlation 
with clinical features and outcomes. 
The specific aims of the studies performed in this chapter were to: 
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1. Define the heterogeneity in expression of DNA replication licensing proteins 
and the cell cycle status in cells from bone marrow biopsies from the defined 
UCLH cohort.  
2. Assess how the expression of DNA replication licensing proteins and cell cycle 
status relates to well defined biological, molecular, and cytogenetic features. 
3. Assess how the expression of DNA replication licensing proteins and cell cycle 
status relates to response to treatment, relapse, and overall clinical outcome. 
 
 
5.2 Materials and methods 
 
5.2.1 Patient cohort 
 
All patients presenting with newly diagnosed AML to University College London 
Hospital between 1st January 2003 and December 31st 2011 and who had had a 
diagnostic bone marrow biopsy performed prior to treatment, as described in Chapter 
4, were included in this study. Patient demographic, clinical, molecular data, and 
outcome data were described in Chapter 4. 
 
5.2.2 Immunohistochemistry (IHC) 
 
Serial sections of formalin-fixed paraffin-embedded BMTs were processed and stained 
as described in chapters 2 and 3 using antibodies to MCM2 to assess non-quiescent 
cells, regardless of whether or not they were actively cycling (positive in G1, S, G2 and 
M but not G0), MIB-1 (equivalent to Ki-67) for actively proliferating cells (positive in 
a proportion of cells in G1, and cells in S, G2 and M but not G0) and geminin for cycling 
cells that have progressed beyond G1 (positive in S/G2/M but not G1 and G0), as well as 
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cleaved caspase 3 to assess the proportion of cells undergoing apoptosis. Primary 
antibodies were used at the following concentrations: MCM2 (1:3000), Geminin 
(1:200), MIB-1 (1:90), and Cleaved Caspase 3 (1:300). The MIB-1/MCM2 ratio was 
calculated as a measure of the number of cells arrested in G1 and the geminin/MIB-1 
ratio as a surrogate for the speed at which cells were cycling. Tonsil tissue containing 
both glandular and epithelial components was processed at the same time and used as 
a positive control.  
 
5.2.3 Validation of an automated counting system 
 
This was an iterative process and was performed with supervision and assistance from 
Dr Marco Loddo (Department of Pathology, UCL, London, UK and Oncologica®, 
Cambridge, UK). The proportion of positive blast cells (the labelling index, LI) for each 
of the primary antibodies was first determined manually on 30 patient biopsies. Digital 
files of all biopsy sections were created using a Leica SCN400 scanner (Leica, Wetzlar, 
Germany). At least three separate representative areas from different sections of the 
biopsy were selected and JPEG files created and printed. The LI was then determined 
after counting a minimum of 1000 cells, with stromal cells, megakaryocytes, 
lymphocytes and late erythroid cells excluded by morphological criteria. The digital 
images obtained for each primary antibody from these 30 biopsies were then evaluated 
using the Ariol® automated scanning microscope and image analysis system 
(Turashvili et al, 2009). The system was trained to differentiate and enumerate positive 
and negative cells and to exclude stromal cells, megakaryocytes, lymphocytes and late 
erythroid cells using criteria for colour, size and shape. The gates for positive and 
negative cells according to colour, size and shape were adjusted until digital analysis 
of images matched the results achieved by manual counting in areas of high and low 
staining intensity, including paratrabecular areas, and there were no obviously negative 
cells counted as positive and no obviously positive cells that were not detected as such. 
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Having trained the system, new areas of the same 30 biopsies were then assessed. These 
were assessed manually and using the automated system, counting at least 1000 cells 
per IHC marker per biopsy, and positive cells expressed as a proportion of total blast 
cells (the LI). These paired analyses were tested for agreement by correlation and by 
Bland-Altman analysis. In addition, for these same 30 biopsies, 5 different areas from 
different parts of the biopsy including paratrabecular areas were selected, assessed for 
LI, and the consistency between readings examined by standard error of the mean 
(SEM), standard deviation (SD), and the coefficient of variation (CV). The total LI 
calculated from all positive and negative cells across the five areas from these biopsies 
was taken forward for the final cohort analysis. Automated analysis was also performed 
on the biopsy samples from the remaining 151 patients. Again, where multiple areas 
were assessed for a biopsy, the LI reflects the total positive and negative cells from all 
areas examined. 
 
5.2.4 Haematopoietically normal bone marrow biopsies 
 
A series of 10 haematopoietically normal bone marrow biopsies was provided by Dr 
Teresa Marafioti (Consultant Haematopathologist, Department of Pathology, UCLH, 
London, UK). These had been assessed as histologically normal during the routine work 
up of patients with a new diagnosis of follicular NHL. They were stained and manually 
assessed for each of the specific markers as previously described. 
 
5.2.5 Statistical analysis 
 
Statistical analysis was performed using Graphpad Prism 6 software, ‘R’ version 3.1.1. 
and SPSS version 22 as before. Consistency within a biopsy sample was assessed using 
SD, SEM, and CV as above. Correlations were calculated using Spearman’s rank 
correlation coefficient. A Bland-Altman analysis was performed to assess agreement 
between the two methods. Differences between two cohorts were calculated using the 
Mann-Whitney-U test, and between more than two cohorts using the Kruskal-Wallis 
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test. Survival data was calculated using Kaplan-Meier estimates, with definitions of CR, 
OS, and DFS as previously described (see section 4.2.1), and differences were assessed 
using the log-rank (Mantel-Cox) test. All these survival tests were performed using 
Graphpad Prism 6 software. ‘R’ was used for calculating the CIR using a competing 
risks analysis, with relapse and non-relapse mortality as competing events from the time 
of first remission, using the cmprsk package as previously described (Scrucca et al, 
2007). Nominal and binary logistic regression multivariate analysis was performed 
using SPSS version 22. All tests were two-tailed and a P value of <0.05 was considered 
significant.  
 
5.3 Results  
 
5.3.1 Validation of the automated counting system 
 
Following completion of the programme training as outlined in section 5.2.3, new areas 
from the same 30 biopsies were selected.  On using the Ariol® automated system to 
analyse the newly selected areas, there was a good correlation with the LIs determined 
for these areas by the manual counting; r= 0.97 (P<0.0001) for MCM2, 0.98 (P<0.0001) 
for geminin, 0.99 (P <0.0001) for MIB-1, and 0.99 (P<0.0001) for cleaved caspase 3 
(Figure 5.1). As correlation measures the strength of the relationship between two 
variables, not the agreement between them, and two methods designed to measure the 
same variable should agree rather than simply correlate, a Bland-Altman analysis was 
performed. This showed that there were good agreements between the two methods and 
minimal apparent bias (Figure 5.2,
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Figure 5.1 Correlation between the manual and automated counts performed on 30 biopsies. (A) MCM2, (B) MIB-1, (C) geminin, 
and (D) cleaved caspase. Assessed using Spearman’s rank correlation co-efficient. 
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 Figure 5.2 Bland-Altmann analysis of the manual and automated LI performed on 30 biopsies. (A) MCM2, (B) MIB-1, (C) geminin, 
and (D) cleaved caspase. Difference = (Manual LI – Automated LI). Average = (Manual LI + Automated LI)/2. 
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Table 5.1 Overall results of the Bland-Altman analysis to assess agreement 
between the manual and automated counting systems.  
 
Protein Bias Standard Deviation 
of bias 
95% limits of agreement 
MCM2 -0.37 2.39 -5.05 – 4.30 
MIB-1 0.27 2.14 -3.92 – 4.46 
Geminin -0.13 1.80 -3.66 – 3.40 
Cleaved Caspase -0.09 0.45 -0.98 – 0.80 
A negative number shows bias towards a higher number in the automated LI, and a 
positive number shows bias towards a higher number in the manual LI. 
 
 
Table 5.1). For example, for MCM2, the bias towards a higher result from automated 
assessment was 0.17 and for geminin was 0.13, with SDs of bias of 2.39 and 1.8 
respectively. In contrast, for MIB-1 there was a bias towards a higher result by manual 
assessment of 0.27, with an SD of 2.17. It should be appreciated that these results do 
not suggest that either method gives a better or more accurate result, simply that they 
generally agree. It was therefore concluded that the automated counting method was 
able to provide LI results that were consistent with careful manual assessment and could 
therefore be used to assess the remainder of the cohort and allow rapid assessment of 
large numbers of cells.  
 
 
5.3.2 Consistency of LI within a biopsy sample 
 
Measurements from different areas of the same biopsy were consistent, with small 
values for SEM, SD, and CV (Figure 5.3, Tables 5.2-5). It can be seen that, even where 
the CV% was apparently high, e.g. biopsy 2 for cleaved caspase where the CV% was 
223% (Table 5.5), the actual difference between the LIs was small. In this 
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Figure 5.3 Repeated measures of LI taken from five different areas of 30 biopsies. (A) MCM2, (B) MIB-1, (C) geminin, (D) cleaved 
caspase.
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Table 5.2 Mean LI, SEM, SD, and CV% for repeated MCM2 measurements taken 
from different areas of 30 biopsies. 
Biopsy No. Mean LI SEM SD CV% 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
 
Median 
Range 
 
49.54 
59.14 
59.16 
63.14 
63.36 
69.16 
69.94 
71.68 
74.42 
77.54 
77.74 
79.26 
79.64 
79.66 
81 
83.04 
86.04 
86.4 
87.02 
90.24 
92.12 
92.12 
93.04 
93.34 
93.74 
93.98 
94.56 
95.54 
95.86 
97 
 
        84.54 
  (49.54 - 97) 
0.49 
0.81 
0.33 
0.41 
0.38 
0.38 
0.54 
0.61 
0.68 
0.26 
0.43 
0.8 
0.96 
0.95 
0.6 
0.61 
0.61 
0.65 
0.27 
0.3 
0.22 
0.22 
0.28 
0.25 
0.31 
0.35 
0.59 
0.61 
0.57 
0.71 
 
        0.55 
  (0.22 - 0.96) 
1.1 
1.81 
0.75 
0.92 
0.85 
0.86 
1.22 
1.37 
1.52 
0.59 
0.96 
1.78 
2.15 
2.13 
1.33 
1.36 
1.36 
1.45 
0.61 
0.66 
0.5 
0.5 
0.63 
0.57 
0.69 
0.78 
1.31 
1.36 
1.28 
1.58 
 
        1.16 
(0.5 - 2.15) 
2.22 
3.06 
1.26 
1.45 
1.35 
1.24 
1.74 
1.92 
2.05 
0.76 
1.24 
2.25 
2.7 
2.67 
1.64 
1.64 
1.58 
1.68 
0.7 
0.73 
0.54 
0.54 
0.68 
0.61 
0.73 
0.83 
1.38 
1.43 
1.34 
1.63 
 
1.44 
(0.54-3.06) 
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Table 5.3. Mean LI, SEM, SD, and CV% for repeated MIB-1 measurements taken 
from different areas of 30 biopsies. 
 
Biopsy No. Mean LI SEM SD CV% 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
 
Median 
Range 
 
4.72 
10.1 
16.84 
17.98 
19.96 
24.14 
24.84 
26.48 
32.76 
39.64 
41.66 
45.26 
46.18 
47.98 
49.06 
49.62 
50.02 
50.06 
53.58 
56.76 
62.14 
62.3 
63.76 
64.64 
65.94 
69.34 
75.18 
75.3 
76.94 
80.76 
 
       49.82 
 (4.72 - 80.76) 
0.09 
0.15 
0.14 
0.19 
0.16 
0.48 
0.09 
0.1 
0.16 
0.13 
0.3 
0.26 
0.15 
0.14 
0.24 
0.12 
0.27 
0.14 
0.24 
0.31 
0.18 
0.24 
0.2 
0.18 
0.13 
0.17 
0.12 
0.1 
0.11 
0.14 
 
        0.16 
(0.09 - 0.48) 
0.19 
0.34 
0.32 
0.42 
0.36 
1.07 
0.21 
0.23 
0.36 
0.3 
0.68 
0.59 
0.33 
0.31 
0.54 
0.28 
0.59 
0.32 
0.53 
0.7 
0.4 
0.54 
0.45 
0.4 
0.3 
0.39 
0.28 
0.22 
0.25 
0.32 
 
        0.36 
(0.19 - 1.07) 
4.08 
3.36 
1.91 
2.34 
1.83 
4.45 
0.83 
0.86 
1.09 
0.75 
1.63 
1.3 
0.72 
0.65 
1.1 
0.56 
1.19 
0.64 
0.99 
1.23 
0.65 
0.87 
0.71 
0.62 
0.45 
0.56 
0.37 
0.3 
0.33 
0.4 
 
         0.87 
(0.3 - 4.45) 
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Table 5.4. Mean LI, SEM, SD, and CV% for repeated geminin measurements 
taken from different areas of 30 biopsies. 
Biopsy No. Mean LI SEM SD CV% 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
 
Median 
Range 
 
1.96 
2.92 
6.12 
6.76 
7 
7.46 
8.56 
8.62 
9.36 
9.58 
11.86 
13.58 
16.32 
17.36 
17.66 
18.26 
20.8 
20.94 
22.44 
22.54 
24.94 
29.94 
30.86 
31.18 
34.12 
36.1 
39.36 
42.18 
45.44 
49.64 
 
       17.96 
(1.96 - 49.64) 
0.08 
0.06 
0.16 
0.08 
0.08 
0.09 
0.09 
0.11 
0.08 
0.14 
0.16 
0.17 
0.21 
0.22 
0.13 
0.26 
0.17 
0.16 
0.52 
0.5 
0.19 
0.13 
0.4 
0.45 
0.44 
0.42 
0.4 
0.46 
1.05 
0.22 
 
        0.18 
(0.06 - 1.05) 
0.18 
0.13 
0.35 
0.18 
0.17 
0.21 
0.21 
0.24 
0.18 
0.32 
0.35 
0.37 
0.47 
0.5 
0.29 
0.59 
0.38 
0.36 
1.17 
1.12 
0.42 
0.29 
0.89 
1.01 
0.97 
0.93 
0.9 
1.02 
2.34 
0.5 
 
         0.4 
(0.13 - 2.34) 
9.27 
4.47 
5.71 
2.69 
2.47 
2.78 
2.42 
2.77 
1.94 
3.33 
2.96 
2.73 
2.85 
2.87 
1.63 
3.21 
1.83 
1.71 
5.2 
4.97 
1.67 
0.96 
2.88 
3.24 
2.85 
2.58 
2.3 
2.43 
5.15 
1.01 
 
        2.82 
(0.96 - 9.27) 
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Table 5.5 Mean LI, SEM, SD, and CV% for repeated cleaved caspase 
measurements taken from different areas of 30 biopsies. 
Biopsy No. Mean LI SEM SD CV% 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
 
Median 
Range 
 
0.04 
0.02 
0.06 
0.4 
0.48 
0.62 
0.7 
0.66 
0.96 
1.02 
1.16 
1.48 
1.68 
1.94 
2.26 
2.66 
2.66 
3.06 
3.18 
3.26 
3.28 
3.96 
4.36 
6.46 
6.58 
6.86 
8.16 
8.56 
9.52 
13.16 
 
        2.46 
    (0.04-13.16) 
0.02 
0.02 
0.02 
0.03 
0.04 
0.04 
0.03 
0.04 
0.05 
0.04 
0.05 
0.06 
0.04 
0.05 
0.08 
0.07 
0.06 
0.08 
0.06 
0.07 
0.07 
0.07 
0.06 
0.28 
0.15 
0.1 
0.12 
0.12 
0.18 
0.09 
 
0.06 
(0.02- 0.28) 
 
0.05 
0.04 
0.05 
0.07 
0.08 
0.08 
0.07 
0.09 
0.11 
0.08 
0.11 
0.13 
0.08 
0.11 
0.18 
0.15 
0.13 
0.18 
0.13 
0.17 
0.15 
0.15 
0.13 
0.62 
0.33 
0.23 
0.27 
0.27 
0.4 
0.21 
 
0.13 
(0.04 - 0.62) 
136.93 
223.61 
91.29 
17.68 
17.43 
13.49 
10.1 
13.55 
11.88 
8.2 
9.83 
8.81 
4.98 
5.88 
8.04 
5.7 
5.04 
5.94 
4.1 
5.13 
4.52 
3.83 
3.08 
9.58 
5.09 
3.36 
3.31 
3.16 
4.23 
1.58 
 
        6.99 
(1.58 - 223.61) 
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case, the repeated LI results of cleaved caspase performed on different areas were 0, 0, 
0.1, 0, and 0. These results suggest that the LI was consistent and representative of the 
rest of the biopsy, regardless of which area was assessed.  
 
5.3.3 Cell cycle analysis and cleaved caspase staining 
  
Analysis of DNA replication licensing proteins in all 181 patients indicated that the 
majority of leukaemic blasts in the BMTs were not quiescent (median LI for MCM2, 
81%), and approximately one-third of the non-quiescent cells were MIB-1 positive 
(median LI, 32%) and therefore actively cycling (Table 5.6). The median LI for geminin 
was 17%, and approximately half of the actively cycling cells had progressed beyond 
G1 (median geminin/MIB-1 ratio, 0.51). There was, however, considerable 
heterogeneity within the cell cycle profile, with wide interquartile and overall ranges. 
Morphological examples of cases with high and low LI for MCM2 and for geminin are 
shown in Figures 5.4 and 5.5 respectively. Very few blasts were undergoing apoptosis 
(median LI for cleaved caspase, 3%). To explore these results further, they were 
correlated with well-defined AML risk factors and subgroups. 
 
Table 5.6 The median and interquartile ranges for the cell cycle markers  
and derived ratios for all 181 AML patients  
 
Antigen 
 
Median LI Interquartile range Overall range 
MCM2 81% 69-92% 40.5 - 100% 
MIB-1 32% 23-49% 0.1 - 81.7% 
Geminin 17% 10-24% 0 -66.1% 
Geminin/MIB-1 ratio 0.51 0.35-0.79 0 - 0.97 
MIB1/MCM2 ratio 0.42 0.29 – 0.60 0 - 0.99 
Cleaved caspase 2.7% 1.1-5.2% 0 - 17.2% 
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Figure 5.4 Morphological examples of cases with (A) low and (B) high LI for 
MCM2 (x40 magnification). 
A 
B 
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Figure 5.5 Morphological examples of cases with (A) low and (B) high LI for 
geminin (x 40 magnification). 
																		 
A 
B 
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5.3.4. Relationship of cell cycle profiles to biological risk factors  
5.3.4.1 Relationship to age 
There was no correlation between any of the cell cycle parameters and patient age at 
presentation (Figure 5.6A-C). In contrast, there was some evidence that the LI for 
cleaved caspase was positively correlated with increasing age (r=0.28, P=0.0001) 
(Figure 5.6D). This relationship was maintained when the results for patients with APL 
or sAML/tAML were excluded (r=0.3, P=0.0003 for both analyses).  
 
5.3.4.2 Relationship to presenting white cell count 
Figure 5.7 shows the relationship between the presenting WCC and the LIs for the cell 
cycle markers, the derived ratios MIB-1/MCM2 and geminin/MIB-1, and cleaved 
caspase. The presenting WCC was significantly correlated with the proportion of non-
quiescent cells as defined by MCM2 positivity (r=0.4, P<0.0001) (Figure 5.7A), but 
there was no statistical relationship to the proportion of actively cycling cells (for MIB-
1 LI, r=0.1, P=0.06) (Figure 5.7B). In contrast, it was positively correlated with the 
proportion of cycling cells beyond G1 and the speed of cell cycle in cycling cells (for 
geminin LI, r=0.4, P<0.0001; geminin/MIB-1 ratio, r=0.3, P<0.0001) (Figure 5.7C,E). 
It was also inversely correlated with the proportion of apoptotic cells (for cleaved 
caspase LI, total cohort, r=-0.2, P=0.002; excluding APL patients, r=0.3, P<0.0001) 
(Figure 5.7F). These results suggest that a higher WCC may occur in the context of 
faster cell cycle progression rates or lower levels of apoptosis. No significant 
differences in cell cycle parameters or the proportion of apoptotic cells were observed 
between the de novo and secondary AML patients (Table 5.7). 
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Figure 5.6 Correlation between age and the LI for the 181 patients with AML. (A) MCM2, (B) MIB-1, (C) geminin, and (D) cleaved 
caspase.
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Figure 5.7 Correlation between presenting white cell count and the LI or derived ratios in the 181 patients with AML. (A) MCM2, 
(B) MIB-1 and (C) geminin, or the derived ratios (D) MIB-1/MCM2 and (E) geminin/MIB-1,or (F) cleaved caspase. 
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5.3.4.3 Relationship to FAB type 
 
The LIs for all markers and the derived ratios were significantly different for patients 
with APL (FAB type M3) when compared to non-APL patients (Figure 5.8). Patients 
with APL had significantly fewer non-quiescent cells (median MCM2 LI, 68% vs 82%; 
P=0.03) (Figure 5.8A), actively cycling cells (median MIB-1 LI, 16% vs 34%; 
P=0.0005) (Figure 5.8B) and cells in S/G2/M (median geminin LI, 6% vs 18%, 
P<0.0001) (Figure 5.8C), and a greater proportion of cells in a G1-arrested state (MIB-
1/MCM2 ratio, 0.27 vs 0.45; P=0.002) (Figure 5.8D). In addition, they had a 
significantly lower median geminin/MIB-1 ratio (0.33 vs 0.52, P=0.005) (Figure 5.8E), 
a result that implies a longer average duration of G1 in actively cycling cells. The APL 
patients also had a significantly lower proportion of cleaved caspase-labelled cells 
(median, 0.9 vs 2.9, P=0.003) (Figure 5.8F). 
With M3 excluded, when other FAB types were assessed for differences between the 
groups with a sufficient number of patients (M0, M1, M2, M4, and M5), there were no 
statistically significant differences between the FAB types for any of the cell cycle 
markers, derived ratios, or cleaved caspase (Table 5.8). 
 
5.3.4.4 Relationship to Cytogenetic Risk Groups 
 
There were no significant differences in cell cycle parameters between the cytogenetic 
risk groups in the non-APL patients, either for the proportion of non-quiescent cells 
(median MCM2 LI for favourable-, intermediate- and adverse-risk patients, 80% vs 85% 
vs 78% respectively; P=0.06), actively cycling cells (median MIB-1 LI, 32% vs 34% 
vs 27%; P=0.1), or cells expressing geminin (median LI, 18% vs 19% vs 17%; P=0.07). 
Similarly, neither the proportion of non-quiescent cells that were actively cycling nor 
the cell cycle duration differed significantly (MIB-1/MCM2 ratio, 0.42 vs 0.46 vs 0.37; 
P=0.3; geminin/MIB-1 ratio, 0.54 vs 0.5 vs 
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Table 5.7 LI according to subtype of leukaemia: de novo, sAML, or tAML.  
AML type MCM2 LI MIB-1 LI Geminin LI MIB-1/MCM2 Geminin/MIB-1 Cleaved Caspase LI 
 
De novo 
sAML 
tAML 
 
P 
 
81.7 (42.6-99.8) 
79.3 (51.6-100) 
78.3 (40.5-94) 
 
0.74 
 
32.7 (0.1-81.7) 
26 (10.9-59.2) 
34.3 (12-66.8) 
 
0.77 
 
16.8 (0-66.1) 
18.9 (4.3-65.6) 
15.3 (5.3-32.4) 
 
0.86 
 
0.44 (0.00-0.99) 
0.34 (0.13-0.80) 
0.47 (0.11-0.91) 
 
0.57 
 
0.49 (0.00-0.97) 
0.64 (0.13-0.94) 
0.52 (0.16-0.94) 
 
0.33 
 
2.7 (0-15.4) 
3.0 (0.1-7.2) 
2.9 (0.1-7.4) 
 
0.97 
 
Values given are medians and ranges. 
Abbreviations: sAML; secondary AML, tAML; therapy related AML 
 
Table 5.8 LI according to FAB subtype.  
FAB type 
(no.) 
MCM2 MIB-1 Geminin MIB-1/MCM2 Geminin/MIB-1 Cleaved Caspase 
 
M0 (12) 
M1 (39) 
M2 (65) 
M3 (15) 
M4 (17) 
M5 (25) 
 
P (all) 
P (no M3) 
 
76.8 (42.9-95.9) 
85.7 (60.3-99.8) 
77.5 (42.6-97.0) 
67.9 (44.7-98.1) 
83 (60.9-98.9) 
84 (57.7-98.2) 
 
<0.0001 
0.07 
 
25.9 (4.7-75.3) 
30.7 (4.0 - 71.0) 
33.9 (20-80.8) 
15.7 (0.1-50) 
35.8 (25.1-75.2) 
37.3 (12-81.7) 
 
0.002 
0.12 
 
13.3 (1.2-27) 
18.3 (3.3-66.1) 
17.3 (1.9-49.9) 
5.8 (0-22) 
22.5 (7.5-65.6) 
22.9 (9.1-51.5) 
 
<0.0001 
0.07 
 
0.35 (0.07-0.96) 
0.35 (0.05-0.77) 
0.46 (0.29-0.98) 
0.27 (0.1-72.2) 
0.46 (0.35-0.8) 
0.47 (0.13-0.83) 
 
0.002 
0.1 
 
0.4 (0.04-0.91) 
0.59 (0.13-0.96) 
0.4 (0.05-0.95) 
0.36 (0-0.70) 
0.53 (0.19-0.95) 
0.55 (0.27-0.95) 
 
0.006 
0.08 
 
1.4 (0-9.7) 
2.6 (0-9.2) 
3.7 (0-17.2) 
0.9 (0.2-3.9) 
1.5 (0-9.5) 
2.2 (0-10.6) 
 
0.002 
0.1 
P values given represent a Kruskal-Wallis test across the groups with and without M3 patients. Values given are medians and ranges. 
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Figure 5.8 Difference in the LI and derived ratios between APL and non-APL patients. (A) MCM2, (B) MIB-1, (C) geminin, (D) 
MIB-1/MCM2, (E) geminin/MIB-1, (F) cleaved caspase. 
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0.53; P=0.4). However, the proportion of apoptotic cells was slightly, but significantly, 
higher in the poorer cytogenetic risk patients (median cleaved caspase LI, 1.8% vs 2.7% 
vs 3.3%, respectively; P=0.03).  
 
5.3.4.5 Relationship to molecular genotype in patients with intermediate-risk 
cytogenetics 
 
The association of NPM1 and FLT3ITD mutation status was then assessed in the 85 
patients with intermediate-risk cytogenetics whose molecular genotype was known. As 
discussed in chapter 4, these mutations were predominantly associated with this risk 
group, and it was here that their prognostic implications were most relevant.  
The proportion of non-quiescent cells was marginally higher in the NPM1MUT cases 
compared to those with NPM1WT (median MCM2 LI, 89% vs 85%; P=0.03). Although 
the proportion of actively cycling cells was also higher, the difference was not 
significant (median MIB-1 LI, 40% vs 34%; P=0.4). However, the proportion of 
cycling cells that had progressed beyond G1 was significantly higher in the NPM1MUT 
cases (median geminin LI, 24% vs 15%; P=0.002) (Figure 5.9A), as was the 
geminin/MIB-1 ratio (0.68 vs 0.40; P=0.003) (Figure 5.9B). These results indicate that 
although NPM1MUT and NPM1WT patients have a similar proportion of actively cycling 
cells, a feature of NPM1MUT cases is that cycling cells spend a smaller proportion of 
time in G1, a surrogate for the speed of cycling.  
Non-quiescent cells were slightly higher in FLT3ITD than FLT3WT patients (median 
MCM2 LI, 92% vs 84%; P=0.03) but the proportion of actively cycling cells and of 
cells in S/G2/M was similar (median MIB-1 LI, 36% vs 36%; P=0.77; median geminin 
LI, 21% vs 19%; P=0.5). The geminin/MIB-1 ratio was also not significantly different 
(0.48 vs 0.52; P=0.8). The proportion of cells positive for cleaved caspase was not 
influenced by either the NPM1 or FLT3 genotype (P=0.2 and P=0.4 respectively). 
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Figure 5.9 Comparison between intermediate-risk patients NPM1WT and NPM1MUT patients according to (A) geminin expression 
and (B) geminin/MIB-1 ratio. 
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5.3.5 Comparison between biopsies from AML patients and haematologically normal 
biopsies 
 
The results of cell cycle analysis performed using biopsies from 10 individuals with 
demonstrably normal bone marrows are shown in Table 5.9, together with the results 
from the 166 AML patients with non-APL disease. There was a trend towards a greater 
proportion of cells being licensed for replication (MCM2-positive) in the biopsies from 
the AML patients than the haematologically normal biopsies (81.8 vs 75.5, P=0.07), 
although there was no difference in the proportion of geminin-positive cells (17.9 vs 
17.1, P=0.87), implying that an equivalent proportion of cells had progressed beyond 
G1 in the histologically normal bone marrows. However, a striking feature of the 
biopsies from patients with AML as compared to the haematologically normal biopsies 
was a lower proportion of cells actively cycling, as evidenced by a lower MIB-1/MCM2 
ratio (33.8 vs 63.7, P<0.0001), although a significantly higher geminin/MIB-1 ratio 
(0.52 vs 0.27, P<0.0001) suggested that those cells that were actively cycling were 
doing so at an increased rate. Of note, the range of values was greater in the marrow 
from individuals with AML. 
 
Table 5.9 The median and overall range for the cell cycle markers and derived 
ratios for the 166 patients with non-APL disease as compared to haematologically 
normal biopsies. 
 Median (range) 
P 
 AML (non-APL) 
(n=166) 
Normal biopsy 
(n=10) 
 
MCM2 LI 81.8 (40.5 - 100) 75.5 (64.4 - 80.3) 0.07 
MIB-1 LI 33.8 (4 - 81.7) 63.7 (51.4 - 72) < 0.0001 
Geminin LI 17.9 (1.2 - 66.1) 17.1 (11.2 - 24.4) 0.87 
MIB-1/MCM2 0.45 (0.05 - 98.7) 0.86 (0.73 - 0.98) < 0.0001 
Geminin/MIB-1 0.52 (0.045 - 0.99) 0.27 (0.18 - 0.35) < 0.0001 
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5.3.6 Relationship between cell cycle status and response to therapy 
 
In the 140 non-APL patients that received intensive induction therapy, 66% achieved a 
CR after one cycle of chemotherapy, and neither the proportion of non-quiescent cells 
nor of actively cycling cells differed between those who did or did not achieve CR 
(MCM2 LI, 83% vs 75% respectively, P=0.2; MIB-1 LI, 34% vs 37%; P=0.9). 
Nevertheless, patients who achieved an early remission did have a significantly higher 
proportion of cells beyond G1 (geminin LI, 19% vs 13%; P=0.004) and a higher 
geminin/MIB-1 ratio (0.54 vs 0.41; P=0.0002). This relationship was still statistically 
significant when CR at any time was considered, which included 71% of the cohort 
(geminin LI, 19% vs 12%; P=0.02; geminin/MIB-1 ratio, 0.52 vs 0.42; P=0.02). 
However, further inspection of the response data revealed that the CR rates were 
confounded by an excess of IDs in those patients with higher geminin/MIB-1 ratios (19% 
vs 6% for above and below the median respectively, P=0.02). In multivariate analysis 
of the total cohort considering biological, cytogenetic and molecular characteristics, the 
factors predicting for ID were WCC (P=0.01) and age (P=0.02), with the impact of the 
geminin/MIB-1 ratio not achieving significance (P=0.1). However, if IDs were 
excluded, the factors significantly predicting for attainment of CR after one cycle of 
therapy were the presence of an NPM1 mutation (P=0.001), and the geminin/MIB-1 
ratio (P=0.01). Geminin could also predict for achievement of CR (P=0.01), but only if 
the geminin/MIB-1 ratio was removed from the model. Factors predicting for RD in 
this multivariate model were increasing age (P=0.01), and adverse cytogenetics P=0.01). 
When the patients were grouped according to quartiles of the geminin/MIB-1 ratio, it 
was apparent that there was an association between this ratio and the achievement of 
CR after one cycle of therapy, with the highest CR rate (74%) in the quartile with the 
highest geminin/MIB-1 ratio (Q1; median, 0.81) and the lowest CR rate (54%) in those 
with the lowest ratio (Q4; median, 0.30), although this difference did not reach 
significance (P=0.08 across all quartiles) (Table 5.10). IDs were, however, significantly 
higher in Q1 (26%) and lower in Q4 (6%; P=0.01 across all groups), and this is likely 
to relate to the fact that patients in Q1 had a much higher presenting WCC, which is a 
known risk factor for ID and an independent adverse risk factor for ID in this study. In 
fact, of the nine IDs in Q1 patients, seven had a WCC above the median value of 56 
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x109/l for this quartile. Furthermore, six of these seven patients were over the age of 60 
years, and four of the nine patients with early deaths had secondary leukaemia. When 
the induction mortality as well as the CR rate was taken into account, there was a highly 
significant relationship between RD and the geminin/MIB-1 ratio. In Q1, every patient 
who was alive after the first course of induction therapy was in CR compared to only 
58% in Q4 (P=0.0002) (Table 5.10). Considering best response at any time, the values 
for RD were 0% in Q1 and 24% in Q4 patients (P=0.02). It is notable that the incidence 
of NPM1 mutations was much higher in Q1 than in Q4, and it is not possible to clearly 
separate the impact on chemo-resistance of the cell cycle profile per se and the NPM1 
mutational status. 
 
5.3.7 Relationship between cell cycle status, cleaved caspase staining and overall 
survival 
 
The OS in the 140 intensively treated patients was then assessed according to cell cycle 
markers. For each marker or derived ratio, two groups were defined by virtue of being 
above or below the median, and the outcome compared. There was no difference in OS 
or DFS for any of the analyses (Figure 5.10). 
 
5.3.8 Relationship between geminin/MIB-1 ratio and long-term outcome 
 
The CIR and OS at 3 years in the patients who received intensive induction therapy was 
47% and 41% respectively. The CIR was significantly different between the quartiles 
of the geminin/MIB-1 ratio; it was highest (74%) in Q4 patients with the lowest 
geminin/MIB-1 ratio (P=0.01) (Figure 5.11). Although the difference in OS
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Table 5.10 Patient characteristics and outcome according to quartiles of the geminin/MIB-1 ratio in non-APL patients receiving 
intensive induction therapy. 
 Total cohort 
(n=140) 
Q1 
(n=35) 
Q2 
(n=35) 
Q3 
(n=35) 
Q4 
(n=35) 
P 
Geminin/MIB-1  
      Mean 
      Median 
      Range 
 
0.56 
0.52 
0.04-0.97 
 
0.90 
0.81 
0.82-0.97 
 
0.64 
0.61 
0.52-0.81 
 
0.43 
0.43 
0.37-0.51 
 
0.27 
0.30 
0.04-0.36 
 
Cell cycle parameters 
      Geminin, median LI 
      MIB-1, median LI 
      MCM2, LI 
      MIB-1/MCM2 ratio 
      Cleaved caspase, median LI 
 
18% 
34% 
83% 
0.45 
2.7% 
 
26% 
29% 
83% 
0.35% 
2.3% 
 
20% 
34% 
82% 
0.42 
3.0% 
 
18% 
41% 
84% 
0.54 
2.7% 
 
9% 
40% 
75% 
0.52 
2.3% 
 
0.0001 
0.01 
0.3 
0.001 
1.0 
Median age, yrs 54 54 57 47 50 0.2 
Median WCC, x109/l 22 56 8 12 15 0.0004 
Cytogenetics, n (%) 
      Favourable 
      Intermediate 
      Adverse 
      Unknown 
 
13 
80 
23 
24 
 
3 (23%) 
26 (33%) 
2 (9%) 
4 (17%) 
 
4 (31%) 
16 (20%) 
7 (30%) 
8 (33%) 
 
4 (31%) 
20 (25%) 
7 (30%) 
4 (17%) 
 
2 (15%) 
18 (23%) 
7 (30%) 
8 (33%) 
 
 
 
 
NS 
Genotype 
      NPM1MUT 
      FLT3ITD 
 
43/128 (34%) 
29/129 (22%) 
 
17/30 (57%) 
9/30 (30%) 
 
8/30 (27%) 
7/31 (23%) 
 
15/33 (45%) 
8/33 (24%) 
 
3/35 (9%) 
5/35 (14%) 
 
0.001 
0.2 
Response to therapy 
      Induction deaths 
      CR post 1 cycle 
      CR at any time 
Alive but not in CR 
      Post 1 cycle 
      At any time 
 
12% 
66% 
72% 
 
23% 
16% 
 
26% 
74% 
74% 
 
0% 
0% 
 
11% 
69% 
71% 
 
23% 
19% 
 
6% 
66% 
71% 
 
31% 
23% 
 
6% 
54% 
71% 
 
42% 
23% 
 
0.01 
0.1 
1.0 
 
0.0002 
0.02 
Long-term outcome       
      CIR at 3 yrs 
      Median time to relapse, (days) 
      OS at 3 years 
 
49% 
335 
41% 
 
48% 
304 
32% 
 
44% 
452 
46% 
 
29% 
319 
52% 
 
73% 
265.5 
34% 
 
0.01 
0.4 
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Figure 5.10 Overall survival (OS) and disease free survival (DFS) for the 140 intensively treated non-APL patients stratified 
according to the median values. (A, B) MCM2, (C, D) MIB-1, (E, F) geminin, (G, H) MIB-1/MCM2 ratio, and (I, J) geminin/MIB-1 
ratio. 
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Figure 5.10 (continued) 
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Figure 5.10 (continued) 
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Figure 5.11 Cumulative incidence of relapse stratified according to quartiles of the geminin/MIB-1 ratio. Q1, highest; Q4, lowest. 
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Figure 5.12 Overall survival stratified according to the geminin/MIB-1 ratios. (A) OS for Q1 (highest) to Q4 (lowest), (B) OS from 
the start of the second cycle of intensive chemotherapy using the geminin/MIB-1 ratio at diagnosis and comparing the highest 3 quartiles 
(Q1-3) with the lowest quartile (Q4). 
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between the quartiles was not significant (Figure 5.12A), this was again confounded by 
the higher rate of ID in the Q1 patients. In view of the high relapse rate in the Q4 
patients, an exploratory landmark analysis was performed from the time at which 
patients received their second cycle of intensive chemotherapy, comparing Q4 (n=31) 
with Q1-3 patients (n=83). The difference in survival between these groups was 
borderline significant (P=0.05) (Hazard ratio by log rank analysis, 1.65; 95% 
confidence intervals, 0.996 – 3.126). Median survival was 472 vs 1346 days in Q4 and 
Q1-3 respectively (Figure 5.12B). 
 
5.4 Discussion 
 
This chapter presents results on the association between the expression of DNA 
replication licensing proteins and the cell cycle status and outcome in a cohort of 181 
AML patients. The patients were from a single centre but, as shown in chapter 4, the 
characteristics of the cohort with regard to age, cytogenetics, mutational status and 
response to treatment were similar to other series reported in the literature, with 
particular reference to the UK MRC AML trials. An important feature of the study was 
that the cell cycle analysis of the leukaemic cells was determined solely using IHC 
analysis on cells present in BMTs, which was essential in order to avoid the issue of 
blood contamination of BMAs that was demonstrated in chapter 3 to be critical to the 
results obtained. 
Before analysis of the whole cohort, two key points were demonstrated. Firstly it was 
shown that large number of marrow cells could be assessed rapidly by using an 
automated system. This system, when trained, was shown to give results consistent with 
manual counting on multiple biopsies. Both central medullary spaces and 
paratrabecular areas were tested. It was also assessed whether the area of a biopsy gave 
a different result in any individual patient. Sampling of five different areas, again 
including paratrabecular areas, showed consistent results between different areas of the 
same patient, with generally low levels of SEM, SD, and CV%. This is important as it 
suggests that the percentage of cells expressing the different replication licensing 
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proteins is consistent throughout the sample. It also suggests that for smaller biopsies, 
where fewer cells are available or suitable areas of tissue can only be identified in 
certain areas of the biopsy, that the results will still be representative. 
Having established the automated system, the remaining samples in the cohort were 
assessed. The results highlight many important points about the expression of DNA 
replication licensing proteins and the cell cycle status in patients with AML. For 
example, they demonstrate the extensive heterogeneity seen between patients. When 
this heterogeneity was correlated with clinical features, there were a number of 
associations that could be identified. Firstly, a more proliferative profile, with fewer 
quiescent cells (MCM2 negative), more cells in S/G2/M (geminin positive), and a faster 
cycling rate (higher geminin/MIB-1 ratio), was associated with a higher presenting 
WCC, as was a lower percentage of apoptotic cells (cleaved caspase positive). Secondly, 
APL patients formed a distinct subgroup, with more cells in G0, fewer cells actively 
cycling and in S/G2/M, and a greater proportion of cells likely to be in a G1-arrested 
state than non-APL patients. They also had a lower geminin/MIB-1 ratio, implying a 
slower cell cycle time. This data is in accord with the fact that most of the cells in APL 
are differentiated to a relatively late maturational stage, by which time the proliferative 
potential is markedly reduced. No differences were observed between other FAB 
groups. There was also a significantly lower cleaved caspase LI in APL compared to 
other AML FAB types, which is in accord with the observation that high apoptosis rates 
are usually associated with the most rapidly proliferative tumours.   
Thirdly, although cytogenetic risk group did not seem to have an impact on the 
expression of DNA replication licensing proteins and the derived cell cycle status, 
molecular genotype did. Cells from NPM1MUT AML were cycling more quickly, and 
this accords with the fact that NPM1 mutations are associated with a higher presenting 
WCC (Dohner et al, 2005; Gale et al, 2008). Of note, although there was a higher 
proportion of cells licensed for replication, a similar relationship of a greater rate of cell 
cycling was not observed for cells from FLT3ITD AML, which is counterintuitive in that 
an activating mutation in a growth factor receptor would be expected to induce more 
rapid proliferation. It is possible that the major impact of a FLT3ITD is on the more 
primitive leukaemic progenitor cells and not the bulk leukaemic cells, but studies by 
Behbehani and colleagues have suggested that the more primitive AML progenitors in 
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FLT3ITD-positive AML have a lower proliferative fraction than the same phenotypic 
subpopulation in other forms of AML (Behbehani et al, 2015). 
Results were also presented showing that, compared to haematologically normal BMTs, 
the BMTs from AML patients had a similar proportion of cells licensed for replication 
but fewer actively cycling cells. However, those cells that were cycling were doing so 
at a greater speed. These results are complicated by the fact that there may be residual 
normal marrow in the AML patients, although it has been reported that this residual 
“normal marrow” does not behave normally in that it is functionally inhibited by the 
leukaemia cells (Miraki-Moud et al, 2013). 
The results indicate that there are some major similarities and differences between 
AML and other types of malignancies that have been characterised. The fact that only 
a minority of bone marrow cells in the AML patients were in G0 (median MCM2 LI for 
myeloid cells in the marrow was 81%) is similar to a number of other malignancies 
where this parameter has been assessed (Dudderidge et al, 2005a; Obermann et al, 
2005b; Kulkarni et al, 2007; Kayes et al, 2009; Loddo et al, 2009). There was also a 
relatively high proportion of actively cycling cells (approximately one-third of myeloid 
cells), similarly comparable to various other malignancies, although considerably less 
than in Burkitt’s lymphoma where nearly all the cells are actively cycling (Obermann 
et al, 2005b). However, a striking feature of the current findings is that those AML cells 
that were actively cycling were doing so rapidly (median geminin/MIB-1 ratio, 0.51). 
This is about twice the value observed in ovarian and penile cancer, and nearly three 
times that in breast cancer (Kulkarni et al, 2007; Kayes et al, 2009; Loddo et al, 2009), 
and this speed of cycling may therefore contribute to the observed sensitivity of AML 
cells to the cell cycle phase-specific agents that have been the backbone of standard 
therapy for several decades.  
The considerable heterogeneity in the cell cycle profile observed between patient 
samples also highlights a number of important factors. In spite of the general sensitivity 
of AML cells to cell cycle phase-specific agents, it was noteworthy that the proportion 
of actively cycling cells did not significantly correlate with the CR rate. Nevertheless, 
the speed of cell cycling, as assessed by the geminin/MIB-1 ratio, was inversely related 
to chemoresistance to Ara-C plus anthracycline combination chemotherapy, and 
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although it was most significant after the initial cycle of intensive induction therapy, it 
was still apparent when best response at any time was considered. The impact on CR 
rates was much less apparent than on chemoresistance, and this was largely due to the 
higher treatment-related mortality in those patients with the most rapidly proliferative 
disease. The latter have, on average, a much higher presenting WCC, and it has been 
shown previously that this is a major risk factor for treatment-related mortality (Walter 
et al, 2011; Othus et al, 2014). 
The rate of relapse was significantly higher in the quartile with the slowest cell cycling 
time than in the other quartiles, although this did not translate into a significant 
difference in survival, which was again likely to be due in part to the confounding effect 
of the increased treatment-related deaths in those with the fastest cell cycling time. This 
finding has interesting biological implications. Although the attainment of CR is a 
reflection of the properties of the bulk of the leukaemic cells, relapse is thought to 
originate from the leukaemic stem cells (LSC), which have a more primitive phenotype 
and are thought to proliferate more slowly than the bulk of cells. Nonetheless, the data 
suggests that the study of proliferation kinetics in the bulk population may be a 
surrogate for the chemosensitivity of the LSCs, probably indicating that, in those cases 
where the bulk cells are proliferating more quickly, so too are the LSCs, albeit at a 
lower level than in the bulk population. This may be testable by multi-parameter 
immunophenotypic analysis of AML progenitor cell populations using flow cytometry 
or mass cytometry on single cell suspensions made from BMTs. 
An interesting question is whether a greater proportion of cells in S/G2/M really does 
reflect an increased speed of cycling or, perhaps, may indicate a longer time to go 
through these phases of the cycle. The studies presented here cannot provide direct 
information on this question, but the fact that the derived speed of cycling correlated 
with the presenting white cell count supports this assertion and, in addition, it reflects 
the time spent by the leukaemic cells at a vulnerable point of the cell cycle and appears 
to correlate with chemosensitivity. 
A caveat to interpreting the data presented here is the heterogeneity inherent within a 
population of leukaemic cells. All studies of this kind are an attempt to average the 
behaviour of cells. In addition, since the start of this study, several new mutations have 
 222 
been discovered in AML that may have bearing on cell cycle dynamics. Although 
FLT3ITD and NPM1MUT are powerful determinants of outcome, and NPM1MUT are 
associated with distinctive features that appear to trump other lesions, it is possible that 
other coincidental mutations may have a strong influence on cell cycle dynamics, 
response to chemotherapy, and survival. For example, within the NPM1MUT cohort 
there appeared to be a bimodal distribution of values in the geminin/MIB-1 ratios 
(Figure 5.9B) that may relate to other associated mutations such as in the DNMT3A 
gene. Ultimately, it would be desirable to fully annotate the cohort in terms of genetic 
mutations and also to see if these results could be replicated in a validation cohort. 
From a clinical perspective, being able to predict the likelihood of chemo-resistance to 
the first cycle of therapy is of limited value as results based on trephine biopsies are not 
immediately available before the initial treatment is given, although it is possible that 
trephine ‘rolls’ could be used to achieve an earlier cell cycle assessment. The ability to 
predict outcome after one cycle of treatment might, however, be of therapeutic value, 
and the landmark analysis from the time patients started their second cycle of 
chemotherapy suggests that a very poor prognosis group (those with the slowest cell 
cycling time) can be identified, regardless of whether or not CR has been attained. Such 
patients might benefit from a change of therapy to agents that are not cell cycle phase-
specific. 
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
 
In addition to impaired differentiation, AML is a disease marked by dysregulation of 
the cell cycle, and at least part of the efficacy of the main chemotherapy agents used 
for intensive induction therapy in patients with the disease stems from their ability to 
target actively cycling cells. In addition, many of the new agents currently in clinical 
trials target key cell cycle proteins. As such, a full understanding of the heterogeneous 
responses to established and newer treatments requires knowledge of cell cycle 
dynamics in AML, as well as an appreciation of how this relates to established 
biological and prognostic factors, including cytogenetic and molecular lesions. Despite 
several decades of research examining the cell cycle in AML, the reports on outcome 
according to cell cycle dynamics are inconsistent, and in many cases are contradictory. 
Moreover, there are few studies that have investigated the relationship between the cell 
cycle and cytogenetics, and no published studies that have addressed the relationship 
between recurrent molecular mutations, the cell cycle, and outcome. Importantly, all 
previous studies used cells taken from BMA and/or PB for the cell cycle analysis. 
This thesis set out to investigate whether the examination of cell cycle licensing 
proteins in bone marrow biopsies might give a more accurate assessment of cell cycle 
status in diagnostic samples from patients with AML. It then sought to correlate cell 
cycle status assessed using this method with biological and clinical features of disease. 
 
6.1 Summary of results 
 
The initial studies in this thesis sought to assess whether the expression of replication 
licensing proteins in blasts from patients with AML differed according to whether the 
source of the blasts was BMT, BMA, or PB. IHC and ICC assessing MCM2, MIB-1, 
and geminin was used to compare the cell cycle status between blasts sampled in 
parallel from these tissue compartments from 8 patients with either a new diagnosis or 
relapsed disease prior to treatment. An important initial finding was that a similar 
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number of blasts from PB, BMA, and BMT samples were in a non-G0 state and “in 
cycle” (MCM2 positive), but that the number of cells actively progressing through the 
cell cycle or that had progressed beyond G1 (MIB-1 and geminin positive respectively) 
was markedly different between the blasts from each source. Although there was a 
correlation between the number of cells actively cycling or progressing beyond G1, as 
defined by the expression of these proteins in each compartment, the correlation was 
weak. Importantly, derived values such as the number of blasts that had progressed 
beyond G1 as a proportion of actively cycling cells (the geminin/MIB-1 ratio) were not 
correlated, and were likely to be particularly inaccurate where the number of MIB-1 
positive cells was low because small unit changes could result in apparently large 
changes when expressed as a percentage. The corollary of this is that the published 
studies that have used BMA or PB samples to measure the cell cycle have not, in fact, 
captured the true cell cycle dynamics within the bone marrow. This may account for 
some of the large variation in results seen in previous studies. One likely contributor to 
this inaccuracy is that, as demonstrated in the studies presented here, blasts from PB 
but not BMT samples were in an arrested G1 state and therefore the presence of PB 
cells “contaminating” BMA samples, particularly likely when large volumes of marrow 
are sampled, would influence the results obtained. Further studies from our group that 
determined the volumetric contribution of BMT and PB to BMA in matched samples 
from 13 individuals with a morphologically normal bone marrow found that a median 
53% of the BMA cells were BM-derived and 47% were PB-derived (Sellar et al, 2016). 
As these relative proportions are dependent on the absolute cell concentrations in the 
samples, the analysis also predicted that, in leukaemic samples, the contribution from 
PB cells would be greatest when the PB WCC is elevated (Sellar et al, 2016). This was 
supported by data presented in chapter 5 demonstrating that higher levels of geminin 
and geminin/MIB-1 positive cells in BMT samples correlated with a higher presenting 
WCC. Therefore analysis of BMA and PB samples may underestimate the level of 
proliferation in many of those patients in whom the proliferative drive is greatest. This 
implies that for accurate cell cycle analysis, BMT samples must be used. 
 
The discrepancies observed between the results using blasts from BMT samples and 
those from either BMA or PB samples were verified using two other methods: flow 
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cytometry and gene expression profiling using RNAseq data. Formalin fixed cells from 
the same 8 patients were permeabilised and propidium iodide used to determine the 
DNA content of individual cells and hence their cell cycle status. The summation of the 
cell cycle status of cells in these patients were both highly correlated, and showed good 
agreement with, the results obtained by IHC and ICC further demonstrating that using 
blasts from BMA or PB underestimates the number of actively cycling cells and cells 
beyond G1 within the bone marrow. In a further patient with AML and >90% blasts in 
samples from BMT, BMA, and PB RNA was extracted for comparative gene 
expression profiling by RNAseq. Many of the key DNA replication licensing genes 
previously described were shown to be downregulated in PB and BMA compared to 
BMT including geminin and members of the MCM complex. In addition, many of the 
cell cycle targets of new therapeutics were downregulated compared to BMT including 
polo-like kinases and aurora kinases. Studies also identified a number of genes that 
were differentially expressed between marrow and blood that were not primarily related 
to the cell cycle. Although this represents data from a single patient, two of these genes, 
ATF3 and FOSB, are transcription factors involved in the stress response and normal 
development that a previous study had found to be differentially expressed in blasts 
from BMA and PB samples (Cheung et al, 2009). This suggests that the transcriptional 
profile of blasts in marrow does indeed differ from that of blasts in the peripheral blood. 
Another differentially expressed transcription factor, JUN, is increasingly recognised 
as being important to fundamental aspects of disease biology, including the unfolded 
protein response (Zhou et al, 2016). It would be interesting to verify these differences 
in further patients as well as investigate their biological relevance, in particular whether 
this can be exploited therapeutically.  
These differences also have implications for the conclusions drawn in published studies 
of gene expression analysis in samples from patients with AML as they have used BMA 
or PB blasts to define gene expression signatures. An analysis assessing the prognostic 
signature described by (Bullinger et al, 2004) showed that in the matched samples 
studied here, 34% of genes in this signature had either a 2-fold lower expression or no 
expression in the PB or BMA samples as compared to the BMT sample. Indeed, many 
of the genes they identified as prognostic (e.g. COL1A1, the major component of type 
1 collagen) do not have an obvious relationship to AML blasts and would be predicted 
to be most highly expressed in stromal tissue. Thus, the gene expression profile reported 
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may, in fact, not be reporting differences between blasts but rather reflect the level of 
haemodilution, the peripheral blood WCC, or indeed the amount of stromal tissue 
aspirated. These could all be influenced by multiple factors, for example, the 
relationship between blasts and the stroma, or the level of fibrosis in the patient.  
Having identified that an accurate representation of cell cycle dynamics in the bone 
marrow of patients with AML can only be obtained using biopsy samples, chapter 4 
described the identification and characterisation of a cohort of 181 patients with 
diagnostic biopsies available for further cell cycle analysis. This cohort was defined for 
major clinical features including age, presenting WCC, and cytogenetics, as well as 
clinical outcome according to treatment received, achievement of CR, CIR, and OS. 
Another key component in defining this cohort was the identification of archived 
marrow aspirates that were used as a source of DNA for the analysis of FLT3-ITD and 
NPM1 mutations. Crucially, the incidence and clinical impact of established risk factors 
such as cytogenetic and molecular lesions were broadly in keeping with large published 
cohorts, which indicated that this AML cohort was suitable for the assessment of other 
potential prognostic factors. 
Biopsies from this cohort of 181 patients were then assessed by IHC for expression of 
the cell cycle proteins MCM2, MKI67, and geminin (chapter 5). This analysis was 
aided by an automated digital analysis system that was validated as part of the study. 
The results showed that cell cycle dynamics were highly heterogeneous between 
patients. Proliferative drive was lowest in those patients with APL, but was otherwise 
not related to the state of differentiation as denoted by the FAB category of patients. 
Increased proliferation, as assessed by the geminin LI or geminin/MIB-1 ratio, was seen 
in patients with NPM1 mutations but not those with a FLT3-ITD. Crucially, these 
values were also higher in those patients achieving CR following one cycle of intensive 
induction therapy, thereby providing a possible link between the increased remission 
rates and early responses to treatment seen in patients with NPM1 mutations (Schneider 
et al, 2009). In a multivariate analysis, the association of higher geminin LI or 
geminin/MIB-1 ratio with achievement of CR was maintained. Higher geminin and 
geminin/MIB-1 ratios were also associated with death during first induction therapy, 
although the reasons for this are unclear. It is also noteworthy that the CIR was greatest 
in those patients with the lowest geminin/MIB-1 ratio, suggesting that these patients 
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may have a greater number of cells that can escape the effects of chemotherapy and 
serve as a source of relapse. Although this study did not assess the source of relapse in 
terms of quiescent stem cells or resistant subclones, it does nevertheless suggest that 
the analysis of the bulk leukaemia cell population can inform on biology and clinically 
relevant endpoints. 
 
6.2 Future studies 
 
The results of the studies presented here indicate numerous potential areas for further 
investigation. Firstly, the relationship between cell-cycle licensing proteins, molecular 
subtype, and response to induction therapy needs to be verified in an independent cohort 
of patients. Ideally, such a cohort would have information on patients’ performance 
status that had been prospectively collected. This is key information with prognostic 
implications, for example including death from induction therapy, which is missing 
from the cohort studied here. 
A more extensive retrospective analysis of samples from patients entered into clinical 
trials might also assist in selecting patients that are more likely to respond to specific 
therapies. For example, in studies of increased anthracycline dose in induction therapy, 
might improvements be restricted to or more pronounced in particular biological 
subgroups as defined by cell cycle status? Or in trials employing G-CSF in an attempt 
to stimulate cells into cycle, might the effect only be seen in those patients with few 
cells already committed to cycle rather than in those with active and rapidly cycling 
cells where no additional benefit can be gained? This is clearly speculative but hints at 
the sort of questions that could be investigated to give further context to the results 
obtained from past clinical trials. 
A key finding from this thesis that warrants further investigation is the increased 
numbers of geminin-positive cells and increased geminin/MIB-1 ratio in the group of 
patients with NPM1 mutations. Although these values were elevated in the NPM1 
mutant cohort as a whole, they were highly variable. This suggests intriguing and 
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potentially key differences in disease biology within this group, and is important as the 
presence of an NPM1 mutation is generally considered to be a good risk factor. All 
three patients with an NPM1 mutation that failed to attain remission with one cycle of 
chemotherapy were in the group with the lowest geminin/MIB-1 ratios. However, 
because of the limited number of patients failing to achieve remission in this genotype 
group, it is not clear that this reflects a true difference in response to induction therapy, 
and expanding the number of patients investigated might help to address this issue. It 
would also be interesting to determine whether differences in cell cycle dynamics exist 
according to the type of NPM1 mutation (e.g. the most common type A mutant versus 
non-A mutants) to help discern whether the functional consequences of these mutations 
differ, especially as recently presented data suggests that their impact on outcome might 
vary (Selim et al, 2016). 
To further refine the relationship between cell cycle licensing proteins and response to 
treatment, it will be important to define the landscape of mutations and their co-
incidence beyond NPM1 and FLT3-ITD. Chapter 1 described the varied genetic 
landscape of AML, and many of these mutations have been described since this thesis 
project was first conceived. The key mutations present in an individual patient can now 
be rapidly and relatively inexpensively defined using technology that is available as 
part of routine diagnostics. For example, the “Rapid Heme Panel” employed at the 
Dana-Farber Cancer Center can identify mutations in 95 different genes within 72 hours 
of disease presentation. Given the number of mutation combinations that are possible, 
the detection of differences would require a significant expansion of the patient cohort 
studied. Another approach would be to investigate the mechanism underlying specific 
genetic lesions, their impact on cell cycle status, and the response to treatment using 
animal models of disease that can examine combinations of lesions. As an example, up 
to five genes have been modified in a single mouse haematopoietic stem cell using the 
CRISPR-Cas9 gene editing system. (Heckl et al, 2014).  
The RNA-seq data presented here was limited to matched samples from a single patient. 
It would therefore be interesting to investigate gene expression profiles using such data 
from multiple BMT samples in order to determine whether this could lead to a more 
robust prognostic scoring system. Although the modelling of the stromal signature 
would be a complicating factor, a similar issue has been overcome in solid tumours 
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where the non-malignant tissue forms a sizeable proportion of the sample. Furthermore, 
evaluation of the stromal signature in AML patients may prove useful, especially as 
there is an increasing body of knowledge supporting the role of non-haematopoietic 
cells in the bone marrow in both the maintenance and initiation of leukaemia (Kode et 
al, 2014; Krause & Scadden, 2015). Defining a combined leukaemia and stromal 
signature associated with disease resistance could lead to a major advancement in 
understanding disease biology.  
Ultimately, the aim of a better appreciation of the cell cycle dynamics is to improve 
patient therapy by defining subgroups of those who are likely, or not likely, to benefit 
from treatment targeting cell cycle proteins. In addition to the agents highlighted in 
chapter 1 that are currently being evaluated in clinical trials, there are two newer 
approaches to targeting the cell cycle in G1-S phase that are in pre-clinical development.  
One approach targets the non-redundant kinase CDC7 that phosphorylates MCM2, 
MCM4, and MCM6, and serves as a key regulator of G1-S progression (Figure 1.2). In 
theory, inhibiting CDC7 would cause normal cells to pause prior to S phase whereas 
cells with an abnormal G1-S phase checkpoint, particularly those with an abnormal 
TP53 pathway, would progress into S phase. As CDC7 is required to activate the pre-
replication complex, these abnormal cells would enter S phase with an insufficient 
number of active replication forks and progress into a catastrophic mitosis (Montagnoli 
et al, 2008; Vanotti et al, 2008; Tudzarova et al, 2010). There is some evidence from 
RNA interference experiments and inhibition using novel small molecules that this may 
indeed be selectively active against malignant cells (Kulkarni et al, 2009; Rodriguez-
Acebes et al, 2010; Huggett et al, 2016). To further understand the role of CDC7, in 
work performed since the completion of these studies, I have started to investigate the 
expression of CDC7 and association with genetic and clinical features in the defined 
cohort of patients. In addition, I have been investigating therapeutic potential and 
selectivity of CDC7 inhibition using an inducible shRNA system and a small molecule 
inhibitor XL413 (Koltun et al, 2012; Sasi et al, 2014) in cell lines, primary AML 
samples, and normal CD34+ cells. 
Another approach is targeting GSPT1 (eRF3a), a translation termination factor that 
binds eRF1 and in doing so mediates stop codon recognition and nascent protein release 
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from ribosomes. Depletion of GSPT1 has previously been shown to cause G1 arrest 
(Chauvin et al, 2007). A recently published study of a novel compound related to 
lenalidomide that is able to selectively target GSPT1 for ubiquitination and degradation 
has shown that it has potent anti-tumour activity in both established AML cell lines and 
samples from patients (Matyskiela et al, 2016). Defining the conditions through which 
AML and the cell cycle can be targeted by this approach is a major component of my 
current fellowship in the laboratory of Dr Benjamin Ebert at the Brigham and Women’s 
Hospital and the Broad Institute of Harvard/MIT in Boston MA, USA. 
 
6.3 Conclusions 
In conclusion, this thesis has described the assessment of cell cycle licensing protein 
expression in bone marrow biopsies of patients with AML. It has demonstrated that this 
method better reflects the cell cycle dynamics of the disease in marrow and is the first 
study to define the stages of the cell cycle in AML exclusively using biopsies. In 
addition these studies have described a link between the expression of geminin and the 
geminin/MIB-1 ratio and response to therapy, in particular in patients with NPM1 
mutations. As such, this work contributes to the current understanding of the biology 
of AML, and provides a rationale for the future analysis of patient cell cycle status as 
an adjunct to developing personalised therapeutic strategies. 
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SUPPLEMENTARY MATERIAL 
Supplementary table 1. Treatment regimens used for patients in the cohort 
Intensive 
Regimen  
Treatment Schedule UK trials in which used 
ADE Daunorubicin 50 mg/m2 days 1, 3, and 5 
Cytosine Arabinoside 100 mg/m2 12 hourly days 1-10 (1-8 if course 2) 
Etoposide 100 mg/m2 days 1-5 
 
AML15, AML17 
ATRA-ATO ATRA 45 mg/m2 orally in 2 equal doses per day for up to 60 days as part of course 1 or until remission, 
at the same dose on days 1-14 and days 29-42 of courses 2-4, and days 1-14 of course 5 
 
In addition to ATRA 
Course 1: Arsenic trioxide 0.3 mg/kg IV days 1-5, then 0.25 mg/kg twice weekly weeks 2-8 
Courses 2-5: Arsenic trioxide 0.3 mg/kg IV days 1-5, then 0.25 mg/kg twice weekly weeks 2-4 
 
In addition patients with presenting WCC of ≥10x109/l could receive gemtuzumab ozogamicin as a 
single infusion (6 mg/m2) within the first 4 days of course 1.  
AML17 
ATRA-Ida ATRA 45 mg/m2 orally in 2 equal doses per day for up to 60 days as part of course 1 and then on days 
1-15 of subsequent courses 
 
In addition to ATRA 
Course 1: Idarubicin 12 mg/m2 IV on days 2, 4, 6, and 8 
Course 2: Idarubicin 5 mg/m2 IV on days 1-4 
AML15, AML17 
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Course 3: Mitoxantrone 10 mg/m2 on days 1-4 
Course 4: Idarubicin 12 mg/m2 on day 1 
 
Azacytidine 75 mg/m2 per day for 5 days AML16 
Clofarabine Clofarabine 20 mg/m2 by IV infusion daily for 5 days AML16 
DA50 Daunorubicin 50 mg/m2 days 1, 3, and 5 
Cytosine Arabinoside 100 mg/m2 12 hourly days 1-10 (1-8 if course 2) 
 
AML15, AML16 
DA60 Daunorubicin 60 mg/m2 days 1, 3, and 5 
Cytosine Arabinoside 100 mg/m2 12 hourly days 1-10 
 
AML17 
DA90 Daunorubicin 90 mg/m2 days 1, 3, and 5 
Cytosine Arabinoside 100 mg/m2 12 hourly days 1-10 
 
AML17 
DAT Daunorubicin 50 or 35mg/m2 IV days 1, 2, and 3 IV push 
Cytosine Arabinoside 100 or 200mg/m2 IV push 12-hourly on days 1-10 (1-8 if course 2) 
Thioguanine 100mg/m2 oral 12-hourly days 1-10 (1-8 if course 2) 
 
AML14 
DA 2+5 Daunorubicin 50 mg/m2 days 1 and 3 
Cytosine Arabinoside 100 mg/m2 12 hourly days 1-5 
AML16 
DClo Daunorubicin 50 mg/m2 days 1, 3, and 5 
Clofarabine 20 mg/m2 days 1-5 
AML16, AML17 
FLAG-Ida G-CSF (lenograstim) 263 µg subcutaneous daily on days 1-7 
Fludarabine 30 mg/m2 IV days 2-6 
Cytosine Arabinoside 2 grams/m2 over 4 hours starting 4 hours after fludarabine on days 2-6 
AML15, AML17 
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Idarubicin 8 mg/m2 IV daily on days 4-6 
HiDAC1.5 Cytosine Arabinoside 1.5 grams/m2 IV over 4 hours, 12 hourly on days 1, 3, and 5 
 
AML15 
HiDAC3 Cytosine Arabinoside 3 grams/m2 IV over 4 hours, 12 hourly on days 1, 3, and 5 
 
AML15, AML17 
ICE Idarubicin 10mg/m2 by slow IV push on days 1 and 3 
Cytosine Arabinoside 100mg/m2 by 2-hour infusion 12-hourly, days 1, 2, and 3 
Etoposide 100mg/m2 by 1-hour infusion daily on days 1, 2, and 3 
 
AML14 
LDAC Cytosine Arabinoside 20 mg by subcutaneous injection twice daily for 10 days AML14, AML16 
MACE Amsacrine 100 mg/m2 days 1-5. 
Cytosine Arabinoside 200 mg/m2 daily continuous infusion days 1-5 
Etoposide 100 mg/m2 days 1-5 
 
AML15 
MidAC 
(older) 
 
Mitoxantrone 8mg/m2 IV on days 1, 2, and 3 
Cytosine Arabinoside 0.5 grams/m2 by 2-hour infusion 12-hourly days 1, 2, and 3 
AML14 
MidAC 
(younger) 
Mitoxantrone 10mg/m2 daily by slow IV push on days 1-5 inclusive  
Cytosine Arabinoside 1.0 grams/m2 by 2-hour IV infusion 12-hourly on days 1-3 inclusive 
AML15 
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Supplementary table 2. Additional agents used to treat patients in the cohort 
 
Additional 
Agent 
Treatment Schedule UK trials used in 
Arsenic Trioxide 0.25mg/kg days 1-5 and 9-11 AML16 
Everolimus 5-10 mg /day from 2 days post cytotoxic chemotherapy to 2 days prior to next course up to a maximum 
of 28 days 
AML17 
Gemtuzumab 
ozogamicin (GO, 
Mylotarg) 
3mg/m2  IV on day 1 of course (unless otherwise stated) AML14, AML15, AML16, AML17 
 
Lestaurtinib 
(CEP-701) 
40-80 mg oral twice daily from 2 days post cytotoxic chemotherapy to 2 days prior to next course up 
to a maximum of 28 days 
 
AML15, AML17 
PSC-833 2.0 mg/kg IV loading dose over 2 hours with simultaneous continuous infusion of 10 mg/kg/24 hours 
for 72 hours, both starting concurrently with the first daunorubicin dose of 35 mg/m2 
 
AML14 
Tipifarnib 300mg bd oral AML16 
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Supplementary Figure 1. Example flow chart of AML15 trial 
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Supplementary Figure 2. Example flow chart of AML16 trial 
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Supplementary Figure 3. Example flow chart of AML17 trial 
 
